<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><?covid-19-tdm ?><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">98593</article-id><article-id pub-id-type="doi">10.7554/eLife.98593</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.98593.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Interleukin-1 prevents SARS-CoV-2-induced membrane fusion to restrict viral transmission via induction of actin bundles</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zheng</surname><given-names>Xu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1446-1882</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund13"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Yu</surname><given-names>Shi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0651-4769</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhou</surname><given-names>Yanqiu</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Yu</surname><given-names>Kuai</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9699-4780</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Yuhui</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Mengdan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Duan</surname><given-names>Dong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yunyi</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Cui</surname><given-names>Xiaoxian</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Mou</surname><given-names>Jiabin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Yuying</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xun</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chen</surname><given-names>Min</given-names></name><email>chenmin@scdc.sh.cn</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Jiu</surname><given-names>Yaming</given-names></name><email>ymjiu@siii.cas.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhao</surname><given-names>Jincun</given-names></name><email>zhaojincun@gird.cn</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Meng</surname><given-names>Guangxun</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4634-4661</contrib-id><email>gxmeng@ips.ac.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/034t30j35</institution-id><institution>The Center for Microbes, Development and Health, National Key Laboratory of Immune Response and Immunotherapy, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, University of Chinese Academy of Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04w00xm72</institution-id><institution>Shanghai Municipal Center for Disease Control and Prevention</institution></institution-wrap><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00z0j0d77</institution-id><institution>The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health</institution></institution-wrap><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05t8y2r12</institution-id><institution>School of Life Sciences, Soochow University</institution></institution-wrap><addr-line><named-content content-type="city">Jiangsu</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cyxs230</institution-id><institution>Shanghai Blood Center</institution></institution-wrap><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Schoggins</surname><given-names>John W</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05byvp690</institution-id><institution>The University of Texas Southwestern Medical Center</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Schoggins</surname><given-names>John W</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05byvp690</institution-id><institution>The University of Texas Southwestern Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="present-address" id="pa1"><label>‡</label><p>Guangzhou National Laboratory, Guangzhou International Bio Island, Guangdong, China</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>12</day><month>02</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP98593</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-05-16"><day>16</day><month>05</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-05-17"><day>17</day><month>05</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.05.16.594569"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-07-16"><day>16</day><month>07</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.98593.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-01-21"><day>21</day><month>01</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.98593.2"/></event></pub-history><permissions><copyright-statement>© 2024, Zheng, Yu, Zhou et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Zheng, Yu, Zhou et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-98593-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-98593-figures-v1.pdf"/><abstract><p>Innate immune responses triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection play pivotal roles in the pathogenesis of COVID-19, while host factors including proinflammatory cytokines are critical for viral containment. By utilizing quantitative and qualitative models, we discovered that soluble factors secreted by human monocytes potently inhibit SARS-CoV-2-induced cell-cell fusion in viral-infected cells. Through cytokine screening, we identified that interleukin-1β (IL-1β), a key mediator of inflammation, inhibits syncytia formation mediated by various SARS-CoV-2 strains. Mechanistically, IL-1β activates RhoA/ROCK signaling through a non-canonical IL-1 receptor-dependent pathway, which drives the enrichment of actin bundles at the cell-cell junctions, thus prevents syncytia formation. Notably, in vivo infection experiments in mice confirmed that IL-1β significantly restricted SARS-CoV-2 spread in the lung epithelium. Together, by revealing the function and underlying mechanism of IL-1β on SARS-CoV-2-induced cell-cell fusion, our study highlights an unprecedented antiviral function for cytokines during viral infection.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>SARS-CoV-2, the agent responsible for COVID-19, has claimed millions of lives across the globe. To better manage this disease and develop new treatments, it is fundamental to understand how the immune system responds to this virus – and, in particular, how it can be thwarted.</p><p>Like all viruses, SARS-CoV-2 replicates within host cells and bursts out when it has made more of itself and is ready to infect more tissues. It can also cause neighbouring cells to merge, allowing the virus to replicate and spread without stepping outside. This strategy makes it harder for the immune system to access and deactivate the threat.</p><p>A group of molecules called proinflammatory cytokines (such as IL-1β and IL-1α) are released upon SARS-CoV-2 infection. People receiving immunosuppressive therapies, which can reduce proinflammatory cytokine levels to harness inflammatory damage, find it harder to tackle the virus. However, the full role of these molecules in clearing SARS-CoV-2 remains unknown.</p><p>To investigate this question, Zheng, Yu, Zhou and Yu et al. developed different experimental models that could examine how proinflammatory cytokines might protect cells from SARS-CoV-2 challenge. The results showed that IL-1β and IL-1α stop the virus from being able to fuse cells together. Further cell studies revealed the underlying mechanism: IL-1β triggers cells to increase the levels of essential components, known as actin bundles, which form the structures that prevent cells from fusing with each other. Experiments in live mice showed that IL-1β treatment significantly prevented SARS-CoV-2 from spreading within the lining of the lungs. Taken together, these findings reveal new insights into how the immune system protects hosts against SARS-CoV-2 infection; further investigation may help identify new treatments for COVID-19.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>SARS-CoV-2</kwd><kwd>innate immune cell</kwd><kwd>interlukin-1</kwd><kwd>cell-cell fusion</kwd><kwd>actin bundle</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>92269202</award-id><principal-award-recipient><name><surname>Meng</surname><given-names>Guangxun</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82825001</award-id><principal-award-recipient><name><surname>Zhao</surname><given-names>Jincun</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>92054104</award-id><principal-award-recipient><name><surname>Jiu</surname><given-names>Yaming</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82402593</award-id><principal-award-recipient><name><surname>Yu</surname><given-names>Shi</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100012166</institution-id><institution>National Key Research and Development Program of China</institution></institution-wrap></funding-source><award-id>2022YFC2303200</award-id><principal-award-recipient><name><surname>Meng</surname><given-names>Guangxun</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100012166</institution-id><institution>National Key Research and Development Program of China</institution></institution-wrap></funding-source><award-id>2022YFC2303502</award-id><principal-award-recipient><name><surname>Jiu</surname><given-names>Yaming</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002367</institution-id><institution>Chinese Academy of Sciences</institution></institution-wrap></funding-source><award-id>Strategic Priority Research Program XDB0940102</award-id><principal-award-recipient><name><surname>Meng</surname><given-names>Guangxun</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>Three-Year Initiative Plan for Strengthening Public Health System Construction in Shanghai (2023-2025) Key Discipline Project</institution></institution-wrap></funding-source><award-id>GWVI-11.1-09</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Min</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution>Shanghai Municipal Science and Technology Major Project</institution></institution-wrap></funding-source><award-id>2019SHZDZX02</award-id><principal-award-recipient><name><surname>Meng</surname><given-names>Guangxun</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100013262</institution-id><institution>State Key Laboratory of Respiratory Disease</institution></institution-wrap></funding-source><award-id>J24411029</award-id><principal-award-recipient><name><surname>Yu</surname><given-names>Shi</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100021171</institution-id><institution>Guangdong Basic and Applied Basic Research Foundation</institution></institution-wrap></funding-source><award-id>2023A1515010152</award-id><principal-award-recipient><name><surname>Yu</surname><given-names>Shi</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution>Young Scientist Fund of the Guangzhou National Laboratory</institution></institution-wrap></funding-source><award-id>QNPG23-03</award-id><principal-award-recipient><name><surname>Yu</surname><given-names>Shi</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002858</institution-id><institution>China Postdoctoral Science Foundation</institution></institution-wrap></funding-source><award-id>2024M763413</award-id><principal-award-recipient><name><surname>Zheng</surname><given-names>Xu</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Interleukin-1 activates RhoA/ROCK signaling, which drives the enrichment of actin bundles at the cell-cell junctions, preventing SARS-CoV-2 spreading via syncytia formation.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has spread globally, with at least 755 million people diagnosed and the death toll is over 6.8 million. SARS-CoV-2 variants of concern, including Alpha, Beta, Delta, and Omicron, continue to evolve and increase transmissibility and the ability to escape host immune responses. These variants have presented significant challenges to the design and development of vaccines and therapeutic agents (<xref ref-type="bibr" rid="bib50">Zhou et al., 2020</xref>). In order to discover novel strategies to control the virus, it is important to understand host responses to SARS-CoV-2 infection.</p><p>SARS-CoV-2 infection induces cell-cell fusion (also known as syncytia formation) in multiple cell types including lung epithelial cells, neurons, and glia (<xref ref-type="bibr" rid="bib24">Martínez-Mármol et al., 2023</xref>). Syncytia formation between SARS-CoV-2-infected cells with neighboring cells may contribute to increased viral transmission and pathogenicity in the infected host (<xref ref-type="bibr" rid="bib31">Rajah et al., 2022</xref>), which also makes the virus insensitive to extracellular neutralizing antibodies (<xref ref-type="bibr" rid="bib23">Li et al., 2022</xref>; <xref ref-type="bibr" rid="bib49">Yu et al., 2023</xref>). Moreover, syncytia formation among pneumocytes with long-term persistence of viral RNA has been observed in the lung autopsy of deceased COVID-19 donors, which may contribute to prolonged clearance of the virus and long COVID symptoms (<xref ref-type="bibr" rid="bib5">Bussani et al., 2020</xref>). Therefore, inhibiting syncytia formation is critical to ensure viral clearance and to control viral transmission.</p><p>It has been reported that SARS-CoV-2-mediated syncytia formation is effectively inhibited by multiple interferon (IFN)-stimulating genes (ISGs) (<xref ref-type="bibr" rid="bib28">Pfaender et al., 2020</xref>; <xref ref-type="bibr" rid="bib44">Wang et al., 2020</xref>). However, low IFN levels with impaired ISG responses were observed during early SARS-CoV-2 infection, which may have compromised the antiviral responses of IFN in severe COVID-19 patients (<xref ref-type="bibr" rid="bib4">Blanco-Melo et al., 2020</xref>; <xref ref-type="bibr" rid="bib16">Hadjadj et al., 2020</xref>). Thus, identifying other endogenous host factors that regulate syncytia formation is of great significance for harnessing the transmission of SARS-CoV-2.</p><p>Of note, a variety of cells are involved in the host responses to SARS-CoV-2 infection (<xref ref-type="bibr" rid="bib32">Ren et al., 2021</xref>). Lung epithelial cells are the primary target of SARS-CoV-2 infection and transmission, which subsequently recruit and activate innate immune cells, leading to COVID-19 pathology (<xref ref-type="bibr" rid="bib2">Barnett et al., 2023</xref>). In this process, tissue-resident macrophages and circulating monocytes contribute to local and systemic inflammation primarily by releasing inflammatory cytokines (<xref ref-type="bibr" rid="bib36">Sefik et al., 2022</xref>). Among these cytokines induced by SARS-CoV-2, the combination of TNF-α and IFN-γ induces inflammatory cell death, resulting in clear tissue damage, while other cytokines’ function remains obscure (<xref ref-type="bibr" rid="bib20">Karki et al., 2021</xref>). In addition, when corticosteroids were applied to suppress the inflammatory response in patients infected by SARS-CoV (<xref ref-type="bibr" rid="bib21">Lee et al., 2004</xref>) or MERS-CoV (<xref ref-type="bibr" rid="bib1">Arabi et al., 2018</xref>), the clearance of viral RNA was obviously delayed, suggesting the importance of innate immune factors in viral clearance.</p><p>Innate immune cells express Toll-like receptors (TLRs), and TLR-mediated signaling induces robust production of inflammatory cytokines (<xref ref-type="bibr" rid="bib25">Medzhitov, 2001</xref>). In the current work, we screened the role of soluble proinflammatory cytokines on the SARS-CoV-2 spike-induced cell-cell fusion. Notably, we identified that IL-1β, which is the key factor of inflammatory response, inhibited SARS-CoV-2 spike-induced syncytia formation in various cells by activating RhoA/ROCK pathway to initiate actin bundle formation at cell-cell interface between SARS-CoV-2-infected cells and neighboring cells. Importantly, IL-1β significantly reduced SARS-CoV-2 transmission among lung epithelia in experimental mice in vivo. Therefore, our data highlight an important role for proinflammatory cytokines against viral infection.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Host factors secreted by activated innate immune cells inhibit SARS-CoV-2-induced cell-cell fusion</title><p>We have previously established quantitative and qualitative models for SARS-CoV-2 spike-induced cell-cell fusion by bioluminescence assay, immunoblotting, and fluorescence imaging (<xref ref-type="bibr" rid="bib48">Yu et al., 2022</xref>). In order to explore the potential effect of cytokines on SARS-CoV-2-induced cell-cell fusion, human monocyte cell line THP-1 and human peripheral blood mononuclear cells (PBMCs) were used in this study. We applied several TLR ligands to stimulate such innate immune cells and collected the cell culture supernatants for subsequent experiments (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Of note, cell culture supernatants of THP-1 cells stimulated by TLR ligands significantly reduced the bioluminescence signal, while neither untreated THP-1 cell culture supernatant nor the medium control had any effect on the bioluminescence signal reflecting cell-cell fusion (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). SARS-CoV-2 spike engagement of ACE2 primed the cleavage of S2’ fragment in target cells, a key proteolytic event coupled with spike-mediated membrane fusion (<xref ref-type="bibr" rid="bib48">Yu et al., 2022</xref>). In parallel with bioluminescence assay, a large amount of enriched S2’ cleavage was detected in HEK293T-Spike and HEK293T-ACE2 co-cultured group and co-culture incubated with untreated THP-1 cell culture supernatant, while S2’ cleavage was clearly reduced upon treatment with TLR ligands-stimulated THP-1 cell culture supernatants (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Syncytia formation was also visualized using cells co-expressing spike and a ZsGreen fluorescent reporter. The area of syncytium were significantly reduced by the treatment with TLR ligands-stimulated THP-1 cell culture supernatants (<xref ref-type="fig" rid="fig1">Figure 1D</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Considering the presence of TLR ligands in such cell culture supernatants, we tested their potential direct effects. As expected, TLR ligands alone did not reduce the bioluminescence signal and S2’ cleavage compared to the control groups, as well as no effect on syncytia formation (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B–E</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Host factors secreted by activated innate immune cells inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced cell-cell fusion.</title><p>(<bold>A</bold>) Schematics of the cell-cell fusion model used to quantify spike-mediated syncytium formation upon treatment with cell culture supernatants from Toll-like receptor (TLR) ligands-stimulated innate immune cells. Cells co-expressing SARS-CoV-2 spike and Cre were co-cultured with ACE2 and <italic>Stop-luc</italic> co-expressing HEK293T cells for 16 hr, before cell lysates were collected for bioluminescence assay and immunoblotting. Cells co-expressing SARS-CoV-2 spike and ZsGreen were co-cultured with ACE2 expressing HEK293T cells for 16 hr before fluorescence imaging. (<bold>B</bold>) Luciferase activity (relative luminescence units [RLU]) measured from HEK293T cell lysates collected from THP-1 supernatants-treated HEK293T-S and HEK293T-ACE2 described in (A) for 16 hr. Fetal bovine serum (FBS)-free RPMI 1640 served as medium control. Data are representative of six individual repeats and displayed as individual points with mean ± standard error of the mean (SEM). (<bold>C</bold>) Immunoblots showing full-length spike, S2, cleaved S2’, and ACE2 collected from THP-1 supernatants-treated HEK293T-S and HEK293T-ACE2 described in (A) for 16 hr. Blots are representative of three independent experiments. Numbers below the blots indicated the intensity of S2’ versus Tubulin. (<bold>D</bold>) Representative fluorescent image captured at 488 nm from THP-1 supernatants-treated HEK293T-S-ZsGreen and HEK293T-ACE2 for 16 hr. (<bold>E</bold>) Schematic presentation of THP-1 supernatants pre-treatment on authentic SARS-CoV-2-infected cells. Pre-treatment of HEK293T-ACE2 cells with THP-1 supernatants for 1 hr, then inoculated with 0.5 multiplicity of infection (MOI) Delta or wild-type (WT) authentic SARS-CoV-2 virus. Imaging was performed at 24 hr post-infection (hpi) before cell lysates were harvested for immunoblotting. (<bold>F</bold>) Immunoblots of Delta SARS-CoV-2 S, S2, cleaved S2’, N, and ACE2 proteins collected from HEK293T-ACE2 cells 24 hpi as described in (E). Blots are representative of three individual experiments. Numbers below the blots indicated the intensity of S2’ or N versus Tubulin. (<bold>G</bold>) Immunoblots of WT SARS-CoV-2 S, S2, cleaved S2’, and N proteins collected from Caco-2 cells 24 hpi as described in (E). Blots are representative of three individual experiments. Numbers below the blots indicated the intensity of S2’ or N versus β-Actin. (<bold>H</bold>) Immunofluorescent images showing morphology of SARS-CoV-2-infected Caco-2 cells pre-treated with THP-1 supernatants. Anti-SARS-CoV-2 N was stained with Alexa Fluor 555, and nuclei were counterstained with DAPI, respectively. White arrowheads (D and H) indicate syncytia formation or infected cells, scale bars are indicative of 50 μm, and images are representative of three independent experiments. (<bold>I</bold>) Quantification of the infected area in (H).</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig1-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><caption><title>Source data of the individual points in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-98593-fig1-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Host factors secreted by activated peripheral blood mononuclear cells (PBMCs) inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-induced cell-cell fusion, but Toll-like receptors (TLR) ligands alone have no effect.</title><p>(<bold>A</bold>) Quantification of the fused area in <xref ref-type="fig" rid="fig1">Figure 1D</xref>. (<bold>B</bold>) Luciferase activity (relative luminescence units [RLU]) measured from HEK293T cell lysates collected from TLR ligands-treated HEK293T-S and HEK293T-ACE2 for 16 hr. Data are representative of four individual repeats and displayed as individual points with mean ± standard error of the mean (SEM). (<bold>C</bold>) Immunoblots showing full-length spike, S2, cleaved S2’, and ACE2 collected from TLR ligands-treated HEK293T-S and HEK293T-ACE2 for 16 hr. Blots are representative of three independent experiments. Numbers below the blots indicated the intensity of S2’ versus Tubulin. (<bold>D</bold>) Representative fluorescent image captured at 488 nm from TLR ligands-treated HEK293T-S-ZsGreen and HEK293T-ACE2 for 16 hr. (<bold>E</bold>) Quantification of the infected area in (D). (<bold>F</bold>) Luciferase activity (RLU) measured from HEK293T cell lysates collected from PBMCs supernatants-treated HEK293T-S and HEK293T-ACE2 for 16 hr. 1% fetal bovine serum (FBS) RPMI 1640 served as medium control. Data are representative of five individual repeats and displayed as individual points with mean ± SEM. (<bold>G</bold>) Immunoblots showing full-length spike, S2, cleaved S2’, and ACE2 collected from PBMCs supernatants-treated HEK293T-S and HEK293T-ACE2 for 16 hr. Blots are representative of three independent experiments. Numbers below the blots indicated the intensity of S2’ versus Tubulin. (<bold>H</bold>) Representative fluorescent image captured at 488 nm from PBMCs supernatants-treated HEK293T-S-ZsGreen and HEK293T-ACE2 for 16 hr. White arrowheads (D and H) indicate syncytia formation. Scale bars, 50 μm. Images are representative of three individual repeats. (<bold>I</bold>) Quantification of the fused area in (H).</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig1-figsupp1-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig1-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata3"><label>Figure 1—figure supplement 1—source data 3.</label><caption><title>Source data of the individual points in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-98593-fig1-figsupp1-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Host factors secreted by activated THP-1 cells inhibit authentic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced cell-cell fusion.</title><p>(<bold>A</bold>) Immunoblots of wild-type (WT) SARS-CoV-2 S, S2, cleaved S2’, and N proteins collected from HEK293T-ACE2 cells 24 hr post-infection (hpi) as described in <xref ref-type="fig" rid="fig1">Figure 1E</xref>. Blots are representative of three individual experiments. Numbers below the blots indicated the intensity of S2’ or N versus Tubulin. (<bold>B, C</bold>) Bright-field images of 0.5 multiplicity of infection (MOI) WT (B) or Delta (C) SARS-CoV-2-infected HEK293T-ACE2 cells pre-treated with THP-1 supernatants. White arrowheads indicate syncytia formation, scale bars are indicative of 50 μm, and images are representative of three independent experiments.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig1-figsupp2-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig1s2sdata2"><label>Figure 1—figure supplement 2—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig1-figsupp2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig1-figsupp2-v1.tif"/></fig></fig-group><p>Concurrently, we also tested the effect of PBMCs culture supernatants on SARS-CoV-2 spike-induced cell-cell fusion. Consistent with the results from THP-1 cells, TLR ligands-stimulated PBMCs culture supernatants treatment also strongly reduced the bioluminescence signal, S2’ cleavage, and the area of syncytium compared with the medium group (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F–I</xref>). These results thus suggested that activated innate immune cells released host factors to inhibit SARS-CoV-2 spike-induced cell-cell fusion.</p><p>To validate the effect of innate immune cell culture supernatants on cell-cell fusion in authentic SARS-CoV-2 infection, we pre-treated ACE2-expressing cells with THP-1 cell culture supernatants before inoculation with SARS-CoV-2 B.1.617.2 (Delta) or wild-type (WT) strains. Cell lysates were used for the detection of SARS-CoV-2 spike and N protein 24 hr post-infection (hpi) (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Result from this experiment showed that TLR ligands-stimulated-THP-1 cell culture supernatants reduced S2’ cleavage and N protein levels during Delta or WT SARS-CoV-2 infection in HEK293T-ACE2 cells, whereas untreated THP-1 cell culture supernatant had no effect (<xref ref-type="fig" rid="fig1">Figure 1F</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). In addition, TLR ligands-stimulated-THP-1 cell culture supernatants reduced the area of syncytium induced by Delta or WT SARS-CoV-2 infection (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B and C</xref>). Furthermore, we infected the human colon epithelial carcinoma cell line Caco-2 with WT SARS-CoV-2, and found that S2’ cleavage and N protein amounts were reduced after TLR ligands-stimulated THP-1 cell culture supernatants pre-treatment (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). Accordingly, immunofluorescent staining also showed that TLR ligands-stimulated THP-1 cell culture supernatants significantly reduced the area of syncytium during SARS-CoV-2 infection in Caco-2 cells (<xref ref-type="fig" rid="fig1">Figure 1H and I</xref>). Therefore, these data suggested that host factors secreted by activated innate immune cells inhibit authentic SARS-CoV-2-induced cell-cell fusion.</p></sec><sec id="s2-2"><title>IL-1β inhibits SARS-CoV-2-induced cell-cell fusion</title><p>To explore which host factor(s) inhibited SARS-CoV-2-induced cell-cell fusion, we first detected mRNA levels of different cytokines in THP-1 cells stimulated by TLR ligands. It was found that the expression levels of <italic>IL1A</italic>, <italic>IL1B</italic>, <italic>IL6,</italic> and <italic>IL8</italic> were significantly increased upon TLR ligands stimulation, while <italic>IL4</italic>, <italic>IL12A</italic>, <italic>IFNA1</italic>, <italic>IFNB1,</italic> and <italic>IFNG</italic> mRNA levels were not changed or undetected (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). In addition, we also detected the mRNA levels of cytokine receptors in HEK293T modeling cells, confirming that <italic>IL1R1</italic>, <italic>IL4R</italic>, <italic>IL6ST</italic>, <italic>IL8RA</italic>, <italic>IFNAR1</italic>, <italic>IFNGR1</italic> were expressed in such cells, while <italic>IL2RA</italic> and <italic>IL12RB1</italic> were undetectable (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>).</p><p>We next selected recombinant IL-1α, IL-1β, IL-6, and IL-8 to test whether individual cytokine may play a role in affecting SARS-CoV-2 spike-induced cell-cell fusion (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Interestingly, IL-1α and IL-1β significantly reduced the bioluminescence signal compared to the control group, while IL-6 and IL-8 had little or no effect (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). In addition, fluorescence images of cells expressing ZsGreen reporter also confirmed that IL-1α and IL-1β significantly inhibited SARS-CoV-2 spike-induced syncytia formation (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C and D</xref>). Furthermore, IL-1β and IL-1α both reduced the bioluminescence signal and S2’ cleavage (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>) in cell lysates in a dose-dependent manner. Moreover, the syncytia formation was inhibited with increasing concentrations of IL-1β or IL-1α (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B–E</xref>). Intriguingly, when we added both IL-1α and IL-1β, there was no synergistic inhibition on cell-cell fusion compared to either cytokine alone (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2F–H</xref>), suggesting a saturation of IL-1 receptor binding to these homologues. Since both IL-1α and IL-1β activate the downstream pathway through the same receptor IL-1R1, these data suggested that IL-1α or IL-1β may inhibit cell-cell fusion through the same pathway. Considering the higher mRNA level of <italic>IL1B</italic> than <italic>IL1A,</italic> as well as the classical release pathway of IL-1β from innate immune cells (<xref ref-type="bibr" rid="bib46">Weber et al., 2010</xref>), we applied IL-1β for further experiments.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Interleukin-1β (IL-1β) inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced cell-cell fusion.</title><p>(<bold>A</bold>) Schematics of the cell-cell fusion model used to quantify spike-mediated syncytium formation upon treatment with different cytokines. Cells co-expressing SARS-CoV-2 spike and Cre were co-cultured with ACE2 and <italic>Stop-luc</italic> co-expressing HEK293T cells for 16 hr, before cell lysates were collected for bioluminescence assay and immunoblotting. Cells co-expressing SARS-CoV-2 spike and ZsGreen were co-cultured with ACE2 expressing HEK293T cells for 16 hr before fluorescence imaging. (<bold>B</bold>) Luciferase activity (relative luminescence units [RLU]) measured from HEK293T cell lysates collected from different cytokines-treated HEK293T-S and HEK293T-ACE2 described in (A) for 16 hr. IL-1α (10 ng/mL), IL-1β (1 ng/mL), IL-6 (100 ng/mL), or IL-8 (100 ng/mL) were added into the cell-cell fusion system. Data are representative of six individual repeats and displayed as individual points with mean ± standard error of mean (SEM). (<bold>C</bold>) Luciferase activity (RLU) measured from HEK293T cell lysates collected from different concentrations of IL-1β-treated HEK293T-S and HEK293T-ACE2 for 16 hr. Data are representative of six individual repeats and displayed as individual points with mean ± SEM. (<bold>D</bold>) Immunoblots showing full-length spike, S2, cleaved S2’, and ACE2 collected from different concentrations of IL-1β-treated HEK293T-S and HEK293T-ACE2 for 16 hr. Blots are representative of three independent experiments. Numbers below the blots indicated the intensity of S2’ versus Tubulin. (<bold>E</bold>) Schematic presentation of IL-1β pre-treatment on authentic SARS-CoV-2-infected cells. Pre-treatment of HEK293T-ACE2 cells with different concentrations of IL-1β for 1 hr, then inoculated with 0.5 multiplicity of infection (MOI) Delta or wild-type (WT) authentic SARS-CoV-2 virus. Bright-field images were captured at 24 hr post-infection (hpi) before cell lysates were harvested for immunoblotting. (<bold>F</bold>) Immunoblots of Delta SARS-CoV-2 S, S2, cleaved S2’, N, and ACE2 proteins collected from HEK293T-ACE2 cells 24 hpi as described in (E). Blots are representative of three individual experiments. Numbers below the blots indicated the intensity of S2’ or N versus Tubulin. (<bold>G</bold>) Immunoblots of WT SARS-CoV-2 S, S2, cleaved S2’, and N proteins collected from Caco-2 cells 24 hpi as described in (E). Blots are representative of three individual experiments. Numbers below the blots indicated the intensity of S2’ or N versus β-Actin. (<bold>H</bold>) Immunofluorescent images showing morphology of SARS-CoV-2-infected Caco-2 cells pre-treated with or without IL-1β. Anti-SARS-CoV-2 N was stained with Alexa Fluor 555, and nuclei were counterstained with DAPI, respectively. White arrowheads indicate syncytia formation or infected cells, scale bars are indicative of 50 μm and images are representative of three independent experiments. (<bold>I</bold>) Quantification of the infected area in (H). (<bold>J</bold>) Luciferase activity (RLU) measured from THP-1 supernatants-treated HEK293T-S and HEK293T-ACE2 in the presence or absence of IL-1 receptor antagonist (IL-1RA). Data are representative of four individual repeats and displayed as individual points with mean ± SEM.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig2-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Source data of the individual points in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-98593-fig2-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>mRNA levels of different cytokine genes in THP-1 cells and selected cytokine receptor genes in HEK293T cells, as well as fluorescent images indicating cell-cell fusion in the presence of indicated cytokines.</title><p>(<bold>A</bold>) mRNA levels of different cytokine genes in THP-1 cells after Toll-like receptor (TLR) ligands stimulation for 4 hr. Data are representative of three individual repeats. (<bold>B</bold>) mRNA levels of indicated cytokine receptor genes in HEK293T cells. Data are representative of five individual repeats. (<bold>C</bold>) Representative fluorescent image captured at 488 nm from different cytokines-treated HEK293T-S-ZsGreen and HEK293T-ACE2 for 16 hr. White arrowheads indicate syncytia formation. Scale bars, 50 μm. Images are representative of three individual repeats. (<bold>D</bold>) Quantification of the fused area in (C).</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Source data of the individual points in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-98593-fig2-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>No synergistic inhibition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-induced cell-cell fusion by interleukin-1α (IL-1α) and IL-1β co-treatment.</title><p>(<bold>A</bold>) Luciferase activity (relative luminescence units [RLU]) measured from HEK293T cell lysates and immunoblots showing full-length spike, S2, cleaved S2’, and ACE2 collected from different concentrations of IL-1α-treated HEK293T-S and HEK293T-ACE2 for 16 hr. Data and blots are representative of four individual repeats. Numbers below the blots indicated the intensity of S2’ versus Tubulin. (<bold>B, C</bold>) Representative fluorescent image captured at 488 nm from different concentrations of IL-1β (B) or IL-1α (C) treated HEK293T-S-ZsGreen and HEK293T-ACE2 for 16 hr. (<bold>D</bold>) Quantification of the fused area in (B). (<bold>E</bold>) Quantification of the fused area in (C). (<bold>F</bold>) Luciferase activity (RLU) measured from HEK293T cell lysates and immunoblots showing full-length spike, S2, cleaved S2’, and ACE2 collected from IL-1α and IL-1β co-treated HEK293T-S and HEK293T-ACE2 for 16 hr. Data and blots are representative of three individual repeats. Numbers below the blots indicated the intensity of S2’ versus Tubulin. (<bold>G</bold>) Representative fluorescent image captured at 488 nm from IL-1α and IL-1β co-treated HEK293T-S-ZsGreen and HEK293T-ACE2 for 16 hr. White arrowheads (B, C, and G) indicate syncytia formation. Scale bars, 50 μm. Images are representative of three individual repeats. (<bold>H</bold>) Quantification of the fused area in (G).</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig2-figsupp2-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig2s2sdata2"><label>Figure 2—figure supplement 2—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig2-figsupp2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s2sdata3"><label>Figure 2—figure supplement 2—source data 3.</label><caption><title>Source data of the individual points in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-98593-fig2-figsupp2-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Interleukin-1β (IL-1β) inhibits authentic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced cell-cell fusion.</title><p>(<bold>A</bold>) Immunoblots of wild-type (WT) SARS-CoV-2 S, S2, cleaved S2’, and N proteins collected from HEK293T-ACE2 cells 24 hr post-infection (hpi) as described in <xref ref-type="fig" rid="fig2">Figure 2E</xref>. Blots are representative of three individual experiments. Numbers below the blots indicated the intensity of S2’ or N versus Tubulin. (<bold>B, C</bold>) Bright-field images of 0.5 multiplicity of infection (MOI) WT (B) or Delta (C) SARS-CoV-2-infected HEK293T-ACE2 cells pre-treated with different concentrations of IL-1β. White arrowheads indicate syncytia formation, scale bars are indicative of 50 μm, and images are representative of three independent experiments.</p><p><supplementary-material id="fig2s3sdata1"><label>Figure 2—figure supplement 3—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig2-figsupp3-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig2s3sdata2"><label>Figure 2—figure supplement 3—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig2-figsupp3-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig2-figsupp3-v1.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>Interleukin-1β (IL-1β) is an important host factor from innate immune cells inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-induced cell-cell fusion.</title><p>(<bold>A, B</bold>) ELISA of IL-1β concentrations in supernatants from THP-1 (A) and peripheral blood mononuclear cells (PBMCs) (B) after Toll-like receptor (TLR) ligands stimulation. Data are representative of three individual repeats. (<bold>C</bold>) Immunoblots showing full-length spike, S2, cleaved S2’, and ACE2 collected from THP-1 supernatants-treated HEK293T-S and HEK293T-ACE2 in the presence or absence of IL-1 receptor antagonist (IL-1RA). Blots are representative of three individual repeats. Numbers below the blots indicated the intensity of S2’ versus Tubulin. (<bold>D</bold>) ELISA of IL-1β concentrations in supernatants from sgControl and sg<italic>TLR2</italic> THP-1 cells after TLR ligands stimulation. Data are representative of four individual repeats. (<bold>E</bold>) Luciferase activity (relative luminescence units [RLU]) measured from HEK293T cell lysates collected from sgControl and sg<italic>TLR2</italic> THP-1 supernatants-treated HEK293T-S and HEK293T-ACE2 for 16 hr. Fetal bovine serum (FBS)-free RPMI 1640 served as medium control. Data are representative of three individual repeats and displayed as individual points with mean ± standard error of mean (SEM). (<bold>F</bold>) ELISA of IL-1β concentrations in supernatants from TAK1/IKKβ inhibitors-treated THP-1 cells after PGN stimulation. Data are representative of three individual repeats. (<bold>G</bold>) Luciferase activity (RLU) measured from HEK293T cell lysates collected from TAK1/IKKβ inhibitors pre-treated THP-1 supernatants added onto HEK293T-S and HEK293T-ACE2 cells for 16 hr. FBS-free RPMI 1640 served as medium control. Data are representative of three individual repeats and displayed as individual points with mean ± SEM. (<bold>H</bold>) ELISA of IL-1β concentrations in supernatants from TAK1/IKKβ inhibitors-treated PBMCs after PGN stimulation. Data are representative of three individual repeats. (<bold>I</bold>) Luciferase activity (RLU) measured from HEK293T cell lysates collected from TAK1/IKKβ inhibitors pre-treated PBMCs supernatants added onto HEK293T-S and HEK293T-ACE2 cells for 16 hr. 1% FBS RPMI 1640 served as medium control. Data are representative of three individual repeats and displayed as individual points with mean ± SEM.</p><p><supplementary-material id="fig2s4sdata1"><label>Figure 2—figure supplement 4—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig2-figsupp4-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig2s4sdata2"><label>Figure 2—figure supplement 4—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig2-figsupp4-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s4sdata3"><label>Figure 2—figure supplement 4—source data 3.</label><caption><title>Source data of the individual points in <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-98593-fig2-figsupp4-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig2-figsupp4-v1.tif"/></fig><fig id="fig2s5" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 5.</label><caption><title>Interleukin-1β (IL-1β) inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced cell-cell fusion through acting on both donor and acceptor cells.</title><p>(<bold>A</bold>) Schematics of the cell-cell fusion model used to determine cell types affected by IL-1β. Pre-treated HEK293T-S or HEK293T-ACE2 cells or both with 1 ng/mL IL-1β for 6 hr, then co-cultured for 16 hr after washing with phosphate buffered saline (PBS). Cells co-expressing SARS-CoV-2 spike and Cre were co-cultured with ACE2 and <italic>Stop-luc</italic> co-expressing HEK293T cells for 16 hr, before cell lysates were collected for bioluminescence assay and immunoblotting. Cells co-expressing SARS-CoV-2 spike and ZsGreen were co-cultured with ACE2 expressing HEK293T cells for 16 hr before fluorescence imaging. (<bold>B</bold>) Luciferase activity (relative luminescence units [RLU]) measured from HEK293T cell lysates and immunoblots showing full-length spike, S2, cleaved S2’, and ACE2 collected from different treatments of IL-1β described in (A) for 16 hr. Data and blots are representative of six individual repeats. Numbers below the blots indicated the intensity of S2’ versus Tubulin. (<bold>C</bold>) Immunoblots showing full-length spike, S2, cleaved S2’, and ACE2 collected from 1 ng/mL IL-1β-treated HEK293T-S and Vero E6-ACE2 for 16 hr. Blots are representative of three independent experiments. Numbers below the blots indicated the intensity of S2’ versus Tubulin. (<bold>D</bold>) Immunoblots showing full-length spike, S2, and cleaved S2’ collected from 1 ng/mL IL-1β-treated HEK293T-S and Calu-3 for 16 hr. Blots are representative of three independent experiments. Numbers below the blots indicated the intensity of S2’ versus Tubulin.</p><p><supplementary-material id="fig2s5sdata1"><label>Figure 2—figure supplement 5—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig2-figsupp5-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig2s5sdata2"><label>Figure 2—figure supplement 5—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig2-figsupp5-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s5sdata3"><label>Figure 2—figure supplement 5—source data 3.</label><caption><title>Source data of the individual points in <xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-98593-fig2-figsupp5-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig2-figsupp5-v1.tif"/></fig><fig id="fig2s6" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 6.</label><caption><title>Interleukin-1β (IL-1β) inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-induced syncytia formation in different cells.</title><p>(<bold>A</bold>) Representative fluorescent image captured at 488 nm from HEK293T-S-ZsGreen co-cultured with HEK293T-ACE2, Vero E6-ACE2, and Calu-3 for 16 hr with or without 1 ng/mL IL-1β. White arrowheads indicate syncytia formation. Scale bars, 50 μm. Images are representative of three individual repeats. (<bold>B</bold>) Quantification of the fused area in (A). (<bold>C</bold>) Luciferase activity (relative luminescence units [RLU]) measured from HEK293T cell lysates from 1 ng/mL IL-1β-treated HEK293T-S (S-Alpha, S-Beta, S-Delta, S-Omicron BA.4) and HEK293T-ACE2 for 16 hr. Data are representative of four individual repeats and displayed as individual points with mean ± standard error of mean (SEM). (<bold>D, E</bold>) Immunoblots showing full-length spike, S2, cleaved S2’, and ACE2 collected from 1 ng/mL IL-1β-treated HEK293T-S (S-Alpha, S-Beta, S-Delta (D), S-Omicron BA.4 (E)) and HEK293T-ACE2 for 16 hr. Blots are representative of three independent experiments. Numbers below the blots indicated the intensity of S2’ versus Tubulin.</p><p><supplementary-material id="fig2s6sdata1"><label>Figure 2—figure supplement 6—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig2s6">Figure 2—figure supplement 6</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig2-figsupp6-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig2s6sdata2"><label>Figure 2—figure supplement 6—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig2s6">Figure 2—figure supplement 6</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig2-figsupp6-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s6sdata3"><label>Figure 2—figure supplement 6—source data 3.</label><caption><title>Source data of the individual points in <xref ref-type="fig" rid="fig2s6">Figure 2—figure supplement 6</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-98593-fig2-figsupp6-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig2-figsupp6-v1.tif"/></fig><fig id="fig2s7" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 7.</label><caption><title>Interleukin-1β (IL-1β) inhibits severe acute respiratory syndrome coronavirus (SARS-CoV) and MERS-CoV spike-induced cell-cell fusion.</title><p>(<bold>A</bold>) Schematics of the cell-cell fusion model used to quantify SARS-CoV and MERS-CoV spike-mediated syncytia formation upon IL-1β treatment. Cells co-expressing SARS-CoV or MERS-CoV spike and Cre were co-cultured with ACE2 or DPP4 and <italic>Stop-luc</italic> co-expressing HEK293T cells for 16 hr, before cell lysates were collected for bioluminescence assay and immunoblotting. Cells co-expressing SARS-CoV or MERS-CoV spike and Cre were co-cultured with ACE2 or DPP4 and <italic>Stop-mCherry</italic> co-expressing HEK293T cells for 16 hr before fluorescence imaging. (<bold>B</bold>) Luciferase activity (relative luminescence units [RLU]) measured from HEK293T cell lysates from 1 ng/mL IL-1β-treated HEK293T-S (SARS-S) and HEK293T-ACE2 for 16 hr. Data are representative of four individual repeats and displayed as individual points with mean ± SEM. (<bold>C</bold>) Luciferase activity (RLU) measured from HEK293T cell lysates from 1 ng/mL IL-1β-treated HEK293T-S (MERS-S) and HEK293T-DPP4 for 16 hr. Data are representative of four individual repeats and displayed as individual points with mean ± SEM. (<bold>D</bold>) Immunoblots showing SARS-CoV full-length spike, cleaved S2’ and ACE2 collected from 1 ng/mL IL-1β-treated HEK293T-S (SARS-S) and HEK293T-ACE2 for 16 hr. Blots are representative of three independent experiments. Numbers below the blots indicated the intensity of S2’ versus Tubulin. (<bold>E</bold>) Immunoblots showing MERS-CoV full-length spike, cleaved S2’ collected from 1 ng/mL IL-1β-treated HEK293T-S (MERS-S) and HEK293T-DPP4 for 16 hr. Blots are representative of three independent experiments. Numbers below the blots indicated the intensity of S2’ versus Tubulin. (<bold>F</bold>) Representative fluorescent images captured at 594 nm from 1 ng/mL IL-1β-treated HEK293T-S (SARS-S) and HEK293T-ACE2 or HEK293T-S (MERS-S) and HEK293T-DPP4 for 16 hr. White arrowheads indicate syncytia formation. Scale bars, 50 μm. Images are representative of three individual experiments. (<bold>G</bold>) Quantification of the fused area in (F).</p><p><supplementary-material id="fig2s7sdata1"><label>Figure 2—figure supplement 7—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig2s7">Figure 2—figure supplement 7</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig2-figsupp7-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig2s7sdata2"><label>Figure 2—figure supplement 7—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig2s7">Figure 2—figure supplement 7</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig2-figsupp7-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s7sdata3"><label>Figure 2—figure supplement 7—source data 3.</label><caption><title>Source data of the individual points in <xref ref-type="fig" rid="fig2s7">Figure 2—figure supplement 7</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-98593-fig2-figsupp7-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig2-figsupp7-v1.tif"/></fig></fig-group><p>In order to validate the effect of IL-1β on cell-cell fusion during authentic SARS-CoV-2 infection, we pre-treated ACE2-expressing cells with IL-1β before inoculating Delta or WT authentic SARS-CoV-2. Cell lysates were used for the detection of SARS-CoV-2 spike and N protein 24 hpi (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). To this end, it was found that IL-1β reduced S2’ cleavage and N protein levels compared to the control group during such infection both in HEK293T-ACE2 (<xref ref-type="fig" rid="fig2">Figure 2F</xref> and <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A</xref>) and in Caco-2 cells (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). Meanwhile, IL-1β inhibited authentic SARS-CoV-2-induced syncytia formation (<xref ref-type="fig" rid="fig2">Figure 2H and I</xref> and <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3B and C</xref>). Thus, these results verified that IL-1β inhibits authentic SARS-CoV-2-induced cell-cell fusion in various target cells.</p><p>As expected, innate immune cells activated by TLR ligands secreted IL-1β into the cell culture supernatants (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A and B</xref>). We employed IL-1 receptor antagonist (IL-1RA) to block IL-1 receptor on target cells, and found that IL-1RA treatment reduced the inhibitory effect of PGN-stimulated-THP-1 cell culture supernatant on cell-cell fusion (<xref ref-type="fig" rid="fig2">Figure 2J</xref> and <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4C</xref>). With another note, TLR2 was essential for THP-1 cells to release IL-1β in response to TLR2 ligands (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4D</xref>). More importantly, the cell culture supernatants of TLR2-knockout THP-1 cells stimulated by TLR2 ligands had no effect on the bioluminescence signal, while the cell culture supernatants from WT THP-1 cells stimulated by the same TLR2 Ligands significantly reduced the bioluminescence signal (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4E</xref>). In addition, pre-treatment with TAK1 inhibitor (5Z-7) or IKKβ inhibitor (TPCA1) in WT THP-1 cells prevented IL-1β secretion after PGN stimulation (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4F</xref>), as well as eliminated the inhibitory effect of PGN-stimulated WT THP-1 cell culture supernatant on SARS-CoV-2 spike-induced cell-cell fusion (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4G</xref>). In parallel, pre-treatment with these inhibitors in PBMCs showed the same results (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4H and I</xref>). These data suggested that TLR-knockout or inhibitors targeting the respective TLR signaling prevented innate immune cells from releasing IL-1β into supernatants, which led to failed inhibition of SARS-CoV-2 spike-induced cell-cell fusion. These findings thus further verify that IL-1β is an important host factor inhibiting SARS-CoV-2-induced cell-cell fusion.</p><p>To investigate the effector function of IL-1 on cells expressing SARS-CoV-2 spike (donor cells) and neighboring cells expressing ACE2 (acceptor cells), we pre-treated HEK293T-S or HEK293T-ACE2 cells or both with IL-1β, then co-cultured after washing with phosphate buffered saline (PBS); cells were then analyzed by the quantitative and qualitative models (<xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5A</xref>). Notably, pre-treatment of either HEK293T-S or HEK293T-ACE2 cells with IL-1β alone reduced bioluminescence signal and S2’ cleavage; when IL-1β pre-treatment on both HEK293T-S and HEK293T-ACE2 cells was applied, bioluminescence signal and S2’ cleavage were further reduced (<xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5B</xref>). Furthermore, we also applied Vero E6-overexpressing ACE2 cell line (Vero E6-ACE2) and human Calu-3 cells as acceptor cells, and found that pre-treatment of either HEK293T-S or Vero E6-ACE2 cells with IL-1β alone reduced part of S2’ cleavage, while IL-1β pre-treatment of both HEK293T-S and Vero E6-ACE2 cells led to further reduction of S2’ cleavage (<xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5C</xref>), and the same results were observed in the case of Calu-3 as acceptor cells (<xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5D</xref>). Accordingly, fluorescence imaging also showed that IL-1β significantly reduced the area of syncytia (<xref ref-type="fig" rid="fig2s6">Figure 2—figure supplement 6A and B</xref>). Notably, IL-1β reduced the bioluminescence signal and S2’ cleavage in different SARS-CoV-2 variants (<xref ref-type="fig" rid="fig2s6">Figure 2—figure supplement 6C–E</xref>). Therefore, these results suggest that IL-1β acts on both donor and acceptor cells to inhibit SARS-CoV-2 spike-induced cell-cell fusion in various cell lines.</p><p>Of note, SARS-CoV (<xref ref-type="bibr" rid="bib3">Belouzard et al., 2009</xref>) and MERS-CoV (<xref ref-type="bibr" rid="bib38">Straus et al., 2020</xref>) spike proteins also induce cell-cell fusion in target cells. Therefore, we further explored whether IL-1β was also able to inhibit SARS-CoV and MERS-CoV spike-induced cell-cell fusion in ACE2- or dipeptidyl peptidase-4 (DPP4)-expressing cells by bioluminescence assay, immunoblotting, and a modified <italic>stop-mCherry</italic> fluorescent model, wherein mCherry reporter is only expressed when Cre excises the Stop cassette inside the fused syncytia (<xref ref-type="fig" rid="fig2s7">Figure 2—figure supplement 7A</xref>). Similar to SARS-CoV-2 spike-induced cell-cell fusion, IL-1β also reduced bioluminescence signal (<xref ref-type="fig" rid="fig2s7">Figure 2—figure supplement 7B and C</xref>), S2’ cleavage (<xref ref-type="fig" rid="fig2s7">Figure 2—figure supplement 7D and E</xref>), and the area of syncytium (<xref ref-type="fig" rid="fig2s7">Figure 2—figure supplement 7F and G</xref>) in these cell-cell fusion systems. Thus, IL-1β possesses a broad spectrum to inhibit cell-cell fusion induced by different coronaviruses.</p></sec><sec id="s2-3"><title>IL-1β inhibits SARS-CoV-2-induced cell-cell fusion through IL-1R1/MyD88/IRAK/TRAF6 pathway</title><p>To investigate the mechanism of IL-1β inhibition on SARS-CoV-2-induced cell-cell fusion, we performed gene knockout using CRISPR-Cas9 technology, in conjunction with inhibitors targeting the IL-1 receptor pathway (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). First of all, in the presence of IL-1RA, IL-1β was unable to reduce bioluminescence signal and S2’ cleavage (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Next, as MyD88 is the downstream adaptor for IL-1R1, we generated MyD88 knockout HEK293T cell line, wherein IL-1β was unable to reduce bioluminescence signal (<xref ref-type="fig" rid="fig3">Figure 3C</xref>) and S2’ cleavage (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). In addition, we found that IL-1β was unable to reduce bioluminescence signal and S2’ cleavage in the presence of IRAK1/4 inhibitor (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Furthermore, IL-1β was unable to reduce bioluminescence signal (<xref ref-type="fig" rid="fig3">Figure 3E</xref>) and S2’ cleavage (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>) in TRAF6 knockout HEK293T cell line. These results suggested that IL-1β inhibits SARS-CoV-2 spike-induced cell-cell fusion through IL-1R1-MyD88-IRAK-TRAF6 pathway.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Interleukin-1β (IL-1β) inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced cell-cell fusion through the IL-1R1/MyD88/IRAK/TRAF6 pathway.</title><p>(<bold>A</bold>) Schematics of gene knockout or inhibitor treatment in the IL-1 receptor pathway. (<bold>B</bold>) Luciferase activity (relative luminescence units [RLU]) measured from HEK293T cell lysates and immunoblots showing full-length spike, S2, cleaved S2’, and ACE2 collected from HEK293T-S and HEK293T-ACE2 pre-treated with 1000 ng/mL IL-1 receptor antagonist (IL-1RA) for 30 min, then treated with 1 ng/mL IL-1β for 16 hr. Data and blots are representative of five individual repeats. Numbers below the blots indicated the intensity of S2’ versus Tubulin. (<bold>C</bold>) Luciferase activity (RLU) measured from cell lysates collected from 10 ng/mL IL-1α or 1 ng/mL IL-1β-treated sgControl or sg<italic>MyD88</italic> HEK293T cell-cell fusion system for 16 hr. Data are representative of four individual repeats and displayed as individual points with mean ± SEM. (<bold>D</bold>) Luciferase activity (RLU) measured from HEK293T cell lysates and immunoblots showing full-length spike, S2, cleaved S2’, and ACE2 collected from HEK293T-S and HEK293T-ACE2 pre-treated with 2 μM IRAK1/4 inhibitor for 30 min, then treated with 1 ng/mL IL-1β for 16 hr. Data and blots are representative of four individual repeats. Numbers below the blots indicated the intensity of S2’ versus Tubulin. (<bold>E</bold>) Luciferase activity (RLU) measured from cell lysates collected from 10 ng/mL IL-1α- or 1 ng/mL IL-1β-treated sgControl or sg<italic>TRAF6</italic> HEK293T cell-cell fusion system for 16 hr. Data are representative of four individual repeats and displayed as individual points with mean ± SEM. (<bold>F</bold>) Immunoblots showing full-length spike, S2, cleaved S2’, and N collected from Caco-2 cells, which were pre-treated with 2 μM IRAK1/4 inhibitor and 10 ng/mL IL-1β for 1 hr, then infected with authentic SARS-CoV-2 for 24 hr. Blots are representative of three independent experiments. Numbers below the blots indicated the intensity of S2’ or N versus β-Actin. (<bold>G</bold>) Immunoblots showing full-length spike, S2, cleaved S2’, and N collected from Calu-3 cells, which were infected with authentic SARS-CoV-2 for 1 hr, then washed with phosphate buffered saline (PBS) before treated with 2 μM IRAK1/4 inhibitor and 10 ng/mL IL-1β for 24 hr. Blots are representative of three independent experiments. Numbers below the blots indicated the intensity of S2’ or N versus β-Actin.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig3-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig3-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>Source data of the individual points in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-98593-fig3-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Interleukin-1β (IL-1β) inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-induced cell-cell fusion through the IL-1R1/MyD88/IRAK/TRAF6 pathway.</title><p>(<bold>A</bold>) Immunoblots showing full-length spike, S2 and cleaved S2’, ACE2, and MyD88 collected from 10 ng/mL IL-1α- or 1 ng/mL IL-1β-treated sgControl or sg<italic>MyD88</italic> HEK293T cell-cell fusion system for 16 hr. Blots are representative of three independent experiments. Numbers below the blots indicated the intensity of S2’ versus Tubulin. (<bold>B</bold>) Immunoblots showing full-length spike, S2 and cleaved S2’, ACE2, and TRAF6 collected from 10 ng/mL IL-1α- or 1 ng/mL IL-1β-treated sgControl or sg<italic>TRAF6</italic> HEK293T cell-cell fusion system for 16 hr. Blots are representative of three independent experiments. Numbers below the blots indicated the intensity of S2’ versus Tubulin.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig3-figsupp1-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata2"><label>Figure 3—figure supplement 1—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig3-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Interleukin-1β (IL-1β) inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-induced cell-cell fusion independent from the TAK1/IKKβ/NF-κB pathway.</title><p>(<bold>A</bold>) Luciferase activity (relative luminescence units [RLU]) measured from cell lysates and immunoblots showing full-length spike, S2 and cleaved S2’, ACE2 collected from 1 ng/mL IL-1β-treated sgControl or sg<italic>MAP3K7</italic> HEK293T cell-cell fusion system for 16 hr. Data and blots are representative of five individual repeats. Numbers below the blots indicated the intensity of S2’ versus Tubulin. (<bold>B</bold>) Luciferase activity (RLU) measured from HEK293T cell lysates and immunoblots showing full-length spike, S2 and cleaved S2’, ACE2 collected from HEK293T-S and HEK293T-ACE2 pre-treated with different concentrations of TPCA1 for 30 min, then treated with 1 ng/mL IL-1β for 16 hr. Data and blots are representative of three individual repeats. Numbers below the blots indicated the intensity of S2’ versus Tubulin. (<bold>C</bold>) mRNA levels of NF-κB pathway-related genes in HEK293T cells after 1 ng/mL IL-1β for 4 hr. Data are representative of three individual repeats. (<bold>D</bold>) Luciferase activity (RLU) measured from cell lysates collected from 1 ng/mL IL-1β-treated sgControl, sg<italic>RELB</italic>, sg<italic>NFKB1,</italic> or sg<italic>NFKBIA</italic> HEK293T cell-cell fusion system for 16 hr. Data are representative of four individual repeats and displayed as individual points with mean ± standard error of mean (SEM).</p><p><supplementary-material id="fig3s2sdata1"><label>Figure 3—figure supplement 2—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig3-figsupp2-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig3s2sdata2"><label>Figure 3—figure supplement 2—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig3-figsupp2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3s2sdata3"><label>Figure 3—figure supplement 2—source data 3.</label><caption><title>Source data of the individual points in <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-98593-fig3-figsupp2-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig3-figsupp2-v1.tif"/></fig></fig-group><p>Intriguingly, when we tested TAK1, a downstream molecule of TRAF6 for the potential involvement in the signaling, it was found that IL-1β still reduced bioluminescence signal and S2’ cleavage in TAK1 knockout (<italic>sgMAP3K7</italic>) HEK293T cell line (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>). Moreover, we found that in the presence of TPCA1, an IKKβ inhibitor, IL-1β still inhibited bioluminescence signal and S2’ cleavage as well (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B</xref>). In addition, although IL-1β upregulated the mRNA transcription levels of NF-κB pathway-related genes, such as <italic>RELB</italic>, <italic>NFKBIA</italic>, and <italic>NFKB1</italic> (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C</xref>), IL-1β still reduced the bioluminescence signal after these NF-κB pathway-related genes knockout (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2D</xref>). Taken together, these results demonstrated that IL-1β inhibits SARS-CoV-2 spike-induced cell-cell fusion independent from the TAK1-IKKβ-NF-κB signaling cascade.</p><p>Furthermore, we validated these findings in authentic SARS-CoV-2-infected Caco-2 and Calu-3 cells. Consist with the results from HEK293T cells, IL-1β failed to reduce S2’ cleavage and N protein levels in the presence of IRAK1/4 inhibitor, whereas it still reduced S2’ cleavage and N protein amounts in the presence of the IKKβ inhibitor TPCA1 in Caco-2 (<xref ref-type="fig" rid="fig3">Figure 3F</xref>) and Calu-3 cells (<xref ref-type="fig" rid="fig3">Figure 3G</xref>).</p></sec><sec id="s2-4"><title>IL-1β inhibits SARS-CoV-2-induced cell-cell fusion through RhoA/ROCK-mediated actin bundle formation at the cell-cell junction</title><p>It has been reported that IL-1β activates RhoA signaling via MyD88 and IRAK, which is a pathway independent from IKKβ (<xref ref-type="bibr" rid="bib7">Chen et al., 2002</xref>). As a major downstream effector of RhoA, ROCK phosphorylates substrates that are involved in the regulation of the actin cytoskeleton, cell attachment, and cell motility (<xref ref-type="bibr" rid="bib33">Riento and Ridley, 2003</xref>). Therefore, we set out to detect the active level of RhoA through pull-down assay. To this end, we verified that IL-1β activated RhoA signaling in sgControl HEK293T cells but not in sg<italic>MyD88</italic>- or sg<italic>TRAF6</italic>-HEK293T cells (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). To directly visualize the distribution of endogenous GTP-RhoA (active RhoA), we used a location biosensor derived from the carboxy terminus of anillin (GFP-AHPH) (<xref ref-type="bibr" rid="bib30">Priya et al., 2015</xref>; <xref ref-type="bibr" rid="bib39">Sun et al., 2015</xref>). Interestingly, IL-1β significantly increased the fluorescence intensity of GFP-AHPH in sgControl HEK293T cells, but had no effect in sg<italic>MyD88</italic>- and sg<italic>TRAF6</italic>-HEK293T cells (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Interleukin-1β (IL-1β) inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced cell-cell fusion through RhoA/ROCK-mediated actin bundles assembly at cell-cell junction.</title><p>(<bold>A</bold>) GTP-RhoA pull-down assay to detect the active level of RhoA in sgControl, sg<italic>MyD88,</italic> and sg<italic>TRAF6</italic> HEK293T cells after 1 ng/mL IL-1β treatment for 30 min. Immunoblots showing activated RhoA and total RhoA. Blots are representative of three independent experiments. Numbers below the blots indicated the intensity of active RhoA versus total RhoA. (<bold>B</bold>) Representative confocal images of GFP-AHPH after 1 ng/mL IL-1β treatment for 30 min in sgControl, sg<italic>MyD88,</italic> and sg<italic>TRAF6</italic> HEK293T cells. Scale bars, 10 μm. (<bold>C</bold>) Quantification of fluorescence intensity of GFP-AHPH in (B). Data are representative of eight individual repeats. (<bold>D</bold>) Representative confocal images of GFP-AHPH localization with or without 1 ng/mL IL-1β treatment at different time points of syncytia formation in HEK293T-S-HA and HEK293T-ACE2 cells. Schematics with green dots in the white dashed line boxes representing GFP-AHPH, red cycles representing S-expressing cells, and magenta cycles representing ACE2-expressing cells. White arrowheads indicate the localization of GFP-AHPH, scale bars, 10 μm. Images are representative of three independent experiments. (<bold>E</bold>) Representative confocal images of F-actin stained with phalloidin-488 in transfected vector or 20 ng RhoA-CA HEK293T-S-HA and HEK293T-ACE2 cells. Schematics with green lines in the white dashed line boxes representing actin bundles, red cycles representing S-expressing cells, and magenta cycles representing ACE2-expressing cells. Scale bars, 10 μm. Images are representative of three independent experiments. (<bold>F</bold>) Representative confocal images of F-actin stained with phalloidin-488 in the presence or absence of 1 ng/mL IL-1β or 50 μM Y-27632 treatment at different time points of syncytia formation in HEK293T-S-HA and HEK293T-ACE2 cells. Schematics with green lines in the white dashed line boxes representing actin bundles, red cycles representing S-expressing cells, and magenta cycles representing ACE2-expressing cells. White arrowheads (E and F) indicate the enrichment or disappearance of F-actin, scale bars, 10 μm. Images are representative of three independent experiments.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig4-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig4-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Source data of the individual points in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-98593-fig4-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Single-channel confocal images.</title><p>(<bold>A</bold>) Single-channel confocal images of <xref ref-type="fig" rid="fig4">Figure 4D</xref> (top panel). (<bold>B</bold>) Single-channel confocal images of <xref ref-type="fig" rid="fig4">Figure 4D</xref> (bottom panel).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Single-channel confocal images.</title><p>(<bold>A</bold>) Single-channel confocal images of <xref ref-type="fig" rid="fig4">Figure 4E</xref>. (<bold>B</bold>) Luciferase activity (relative luminescence units [RLU]) measured from HEK293T cell lysates and immunoblots showing full-length spike, S2, cleaved S2’, ACE2, and Myc-RhoA collected from transfected vector, 10 or 20 ng constitutively active RhoA mutant (RhoA-CA) both in HEK293T-S and in HEK293T-ACE2 cells. Data and blots are representative of four individual repeats. Numbers below the blots indicated the intensity of S2’ versus Tubulin. (<bold>C</bold>) Single-channel confocal images of <xref ref-type="fig" rid="fig4">Figure 4F</xref> (top panel). (<bold>D</bold>) Single-channel confocal images of <xref ref-type="fig" rid="fig4">Figure 4F</xref> (middle panel).</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig4-figsupp2-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig4s2sdata2"><label>Figure 4—figure supplement 2—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig4-figsupp2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s2sdata3"><label>Figure 4—figure supplement 2—source data 3.</label><caption><title>Source data of the individual points in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-98593-fig4-figsupp2-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Single-channel confocal images.</title><p>(<bold>A</bold>) Single-channel confocal images of <xref ref-type="fig" rid="fig4">Figure 4F</xref> (bottom panel).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig4-figsupp3-v1.tif"/></fig></fig-group><p>To investigate whether IL-1β inhibits SARS-CoV-2 spike-induced cell-cell fusion through the RhoA/ROCK pathway, we co-transfected GFP-AHPH in ACE2-expressing cells, then co-cultured with Spike-expressing cells at different time points. In the process of syncytia formation, cell-cell contact established between S-expressing cells and ACE2-expressing cells, and GFP-AHPH localized distally from cell-cell junction in the early stage of syncytia formation. With the enlargement of syncytium, GFP-AHPH is visualized at the periphery of syncytium (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, top panel, and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). However, in IL-1β-treated group, GFP-AHPH foci is enriched to the cell-cell junction in the early stage. Over time, GFP-AHPH was recruited more to the cell-cell junction between S-expressing cells and ACE2-expressing cells, preventing further cell-cell fusion (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, bottom panel, and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). Cartoon schematics inserted in the imaging data illustrate such findings in a modeled manner.</p><p>It has been reported that RhoA initiates actin arc formation (<xref ref-type="bibr" rid="bib13">Dupraz et al., 2019</xref>; <xref ref-type="bibr" rid="bib37">Stern et al., 2021</xref>), so we further explored the changes of actin cytoskeleton during SARS-CoV-2 spike-induced cell-cell fusion. We co-transfected constitutively activated RhoA L63 (<xref ref-type="bibr" rid="bib27">Nobes and Hall, 1999</xref>) (RhoA-CA) plasmid with spike or ACE2 in HEK293T cells, and found that constitutive activation of RhoA enriches actin filaments (F-actin) at cell-cell junction (<xref ref-type="fig" rid="fig4">Figure 4E</xref> and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>) and clearly reduces the bioluminescence signal and S2’ cleavage in a dose-dependent manner (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>). Moreover, we observed that F-actin at cell-cell junction between S-expressing cells and ACE2-expressing cells was gradually disappeared along with cell-cell fusion in the early stages of syncytia formation. With the formation and enlargement of syncytium, F-actin of syncytium is preferably distributed peripherally (<xref ref-type="fig" rid="fig4">Figure 4F</xref>, top panel, and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C</xref>). However, IL-1β activated RhoA to initiate actin bundles formation at cell-cell junction, the formation of these actin bundles potentially generates barriers and prevents membrane fusion between S-expressing cells and ACE2-expressing cells. Even with the prolonged co-culture time, IL-1β-induced actin bundles formed at cell junctions consistently inhibited further syncytia formation (<xref ref-type="fig" rid="fig4">Figure 4F</xref>, middle panel, and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2D</xref>). Of note, ROCK inhibitor Y-27632 prevents the formation of actin bundles (<xref ref-type="bibr" rid="bib43">van der Heijden et al., 2008</xref>; <xref ref-type="bibr" rid="bib45">Watanabe et al., 1999</xref>). Here, we found that the ROCK inhibitor Y-27632 treatment prevented the formation of IL-1β-induced actin bundles at cell-cell junctions, thus promoted membrane fusion and cytoplasmic exchange between S-expressing cells and ACE2-expressing cells and restored syncytia formation (<xref ref-type="fig" rid="fig4">Figure 4F</xref>, bottom panel, and <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A</xref>).</p><p>Importantly, upon authentic SARS-CoV-2 infection, we observed consistent results: immunofluorescence (IF) staining showed GFP-AHPH moving to the opposite of cell-cell junction and located peripherally with syncytia formation (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, top panel, and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>), while upon IL-1β treatment, GFP-AHPH located to the cell-cell junction of infected cells and neighboring cells (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, bottom panel, and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). In parallel, staining results showed that F-actin at the cell-cell junction were disassembled during authentic SARS-CoV-2 infection; with the formation of syncytium, F-actin was mainly distributed peripherally. However, actin bundles formed at cell-cell junction upon IL-1β inhibition of membrane fusion and further syncytia formation (<xref ref-type="fig" rid="fig5">Figure 5B</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C–E</xref>). Together, these data revealed that IL-1β induced the formation of actin bundles at the cell-cell junction of SARS-CoV-2-infected cells and neighboring cells through RhoA/ROCK pathway, which inhibited SARS-CoV-2-induced cell-cell fusion.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Activation of RhoA/ROCK pathway prevents authentic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced cell-cell fusion via forming actin bundles.</title><p>(<bold>A</bold>) Representative confocal images of GFP-AHPH localization with or without 1 ng/mL interleukin-1β (IL-1β) treatment in 0.5 multiplicity of infection (MOI) wild-type (WT) authentic SARS-CoV-2-infected HEK293T-ACE2 cells at 6 and 24 hr post-infection (hpi). Schematics with green dots in the white dashed line boxes representing GFP-AHPH, red cycles representing SARS-CoV-2-infected cells, and white cycles representing neighboring cells. White arrowheads indicate the localization of GFP-AHPH, scale bars, 10 μm. Images are representative of three independent experiments. (<bold>B</bold>) Representative confocal images of F-actin stained with phalloidin-488 in the presence or absence of 1 ng/mL IL-1β treatment upon 0.5 MOI WT authentic SARS-CoV-2 infection of Caco-2 cells at 24 hpi. Schematics with green lines in the white dashed line boxes representing actin bundles, red cycles representing SARS-CoV-2-infected cells, and white cycles representing neighboring cells. Scale bars, 10 μm. Images are representative of three independent experiments. (<bold>C</bold>) Immunoblots of WT SARS-CoV-2 S, S2, cleaved S2’, N, and Myc-RhoA collected from HEK293T-ACE2 cells, which were transfected with vector, 10 or 20 ng RhoA-CA before infection with 0.5 MOI authentic SARS-CoV-2 WT strain for 24 hr. Blots are representative of three individual experiments. Numbers below the blots indicated the intensity of S2’ or N versus β-Actin. (<bold>D</bold>) Immunoblots of WT SARS-CoV-2 S, S2, cleaved S2’, N, and Myc-RhoA collected from lentivirus-transduced Calu-3 cells expressing vector or RhoA-CA, infected with WT authentic SARS-CoV-2 for 24 hr. Blots are representative of three individual experiments. Numbers below the blots indicated the intensity of S2’ or N versus β-Actin. (<bold>E</bold>) Representative confocal images of F-actin stained with phalloidin-488 from Calu-3 cells described in (D). Schematics with green lines in the white dashed line boxes representing actin bundles, red cycles representing S-expressing cells, scale bars, 10 μm. Images are representative of four independent experiments. (<bold>F, G</bold>) Immunoblots of WT SARS-CoV-2 S, S2, cleaved S2’, and N collected from Calu-3 cells (F) or primary human lung cells (G), which were infected with authentic SARS-CoV-2 for 1 hr, then washed with phosphate buffered saline (PBS) before being treated with different concentrations of Y-27632 and 10 ng/mL IL-1β for 24 hr. Blots are representative of three independent experiments. Numbers below the blots indicated the intensity of S2’ or N versus β-Actin. (<bold>H</bold>) Representative confocal images of F-actin stained with phalloidin-488 in Calu-3 cells described in (F). Schematics with green lines in the white dashed line boxes representing actin bundles, red cycles representing S-expressing cells. White arrowheads (B, E, and H) indicate the enrichment or disappearance of F-actin, scale bars, 10 μm. Images are representative of four independent experiments.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig5-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig5-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Single-channel confocal images.</title><p>(<bold>A</bold>) Single-channel confocal images of <xref ref-type="fig" rid="fig5">Figure 5A</xref> (top panel). (<bold>B</bold>) Single-channel confocal images of <xref ref-type="fig" rid="fig5">Figure 5A</xref> (bottom panel). (<bold>C</bold>) Single-channel confocal images of <xref ref-type="fig" rid="fig5">Figure 5B</xref>. (<bold>D</bold>) Representative confocal images of F-actin stained with phalloidin-488 in the presence or absence of 1 ng/mL interleukin-1β (IL-1β) treatment in 0.5 multiplicity of infection (MOI) wild-type (WT) authentic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected HEK293T-ACE2 cells at 6 or 24 hr post-infection (hpi). Schematics with green lines in the white dashed line boxes representing actin bundles, red cycles representing SARS-CoV-2-infected cells, and white cycles representing neighboring cells. White arrowheads indicate the enrichment or disappearance of F-actin, scale bars, 10 μm. Images are representative of four independent experiments. (<bold>E</bold>) Single-channel confocal images of (D).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>RhoA-CA does not affect Spike protein binding to ACE2 or ACE2 distribution on the cell surface.</title><p>(<bold>A</bold>) Immunoblots of wild-type (WT) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S, S2, cleaved S2’, N, and Myc-RhoA collected from Caco-2 cells, which were transfected with vector, 10 or 20 ng RhoA-CA before infection with 0.5 multiplicity of infection (MOI) WT authentic SARS-CoV-2 for 24 hr. Blots are representative of three individual experiments. Numbers below the blots indicated the intensity of S2’ or N versus β-Actin. (<bold>B</bold>) Representative confocal images of F-actin stained with phalloidin-488 from Caco-2 cells described in (A). Schematics with green lines in the white dashed line boxes representing actin bundles, red cycles representing S-expressing cells. White arrowheads indicate the enrichment or disappearance of F-actin, scale bars, 10 μm. Images are representative of four independent experiments. (<bold>C</bold>) Single-channel confocal images of (B). (<bold>D</bold>) Single-channel confocal images of <xref ref-type="fig" rid="fig5">Figure 5E</xref>. (<bold>E</bold>) Co-immunoprecipitation (IP) and input controls of full-length spike protein after anti-V5 or anti-IgG pull-down from cell lysates mixed between HEK293T cells expressing ACE2-V5-6his or Spike protein with vector or RhoA-CA (10 ng). Blots are representative of three individual experiments. Numbers below the blots indicated the intensity of S or S2 versus ACE2 in IP group and S, S2, or ACE2 versus Tubulin in input group. (<bold>F</bold>) Representative confocal images of wheat germ agglutinin (WGA, cell surface marker) and ACE2 from HEK293T cells co-transfected with ACE2 and vector or RhoA-CA (10 ng). Scale bars, 10 μm. Images are representative of three independent experiments. (<bold>G</bold>) Quantification of the relative ACE2 expression on the cell surface in (F).</p><p><supplementary-material id="fig5s2sdata1"><label>Figure 5—figure supplement 2—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig5-figsupp2-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig5s2sdata2"><label>Figure 5—figure supplement 2—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig5-figsupp2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s2sdata3"><label>Figure 5—figure supplement 2—source data 3.</label><caption><title>Source data of the individual points in <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-98593-fig5-figsupp2-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig5-figsupp2-v1.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Interleukin-1β (IL-1β) does not affect ACE2 and Spike distribution on the cell surface.</title><p>(<bold>A</bold>) Representative confocal images of wheat germ agglutinin (WGA) and ACE2 from HEK293T cells transfected with ACE2 and treated with phosphate buffered saline (PBS) or IL-1β. Scale bars, 10 μm. Images are representative of three independent experiments. (<bold>B</bold>) Quantification of the relative ACE2 expression on the cell surface in (A). (<bold>C</bold>) Representative confocal images of WGA and Spike from HEK293T cells transfected with Spike and treated with PBS or IL-1β. Scale bars, 10 μm. Images are representative of three independent experiments. (<bold>D</bold>) Quantification of the relative Spike expression on the cell surface in (C). (<bold>E</bold>) Luciferase activity (relative luminescence units [RLU]) measured from HEK293T cell lysates and immunoblots showing full-length spike, S2 and cleaved S2’, ACE2 collected from HEK293T-S, and HEK293T-ACE2 pre-treated with different concentrations of Y-27632 for 30 min, then treated with 1 ng/mL IL-1β for 16 hr. Data and blots are representative of three independent experiments. Numbers below the blots indicated the intensity of S2’ versus Tubulin. (<bold>F</bold>) Immunoblots of wild-type (WT) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S, S2, cleaved S2’, and N collected from Caco-2 cells, which were treated with different concentrations of Y-27632 and 10 ng/mL IL-1β for 1 hr, then infected with 0.5 multiplicity of infection (MOI) WT authentic SARS-CoV-2 for 24 hr. Blots are representative of three individual experiments. Numbers below the blots indicated the intensity of S2’ or N versus β-Actin. (<bold>G</bold>) Representative confocal images of F-actin stained with phalloidin-488 in Caco-2 cells described in (F). Schematics with green lines in the white dashed line boxes representing actin bundles, red cycles representing S-expressing cells. White arrowheads indicate the enrichment or disappearance of F-actin, scale bars, 10 μm. Images are representative of four independent experiments.</p><p><supplementary-material id="fig5s3sdata1"><label>Figure 5—figure supplement 3—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig5-figsupp3-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig5s3sdata2"><label>Figure 5—figure supplement 3—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig5-figsupp3-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s3sdata3"><label>Figure 5—figure supplement 3—source data 3.</label><caption><title>Source data of the individual points in <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-98593-fig5-figsupp3-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig5-figsupp3-v1.tif"/></fig><fig id="fig5s4" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 4.</label><caption><title>Single-channel confocal images.</title><p>(<bold>A</bold>) Single-channel confocal images of <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3G</xref>. (<bold>B</bold>) Single-channel confocal images of <xref ref-type="fig" rid="fig5">Figure 5H</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig5-figsupp4-v1.tif"/></fig></fig-group><p>To further investigate the role of RhoA/ROCK pathway in inhibiting SARS-CoV-2 induced cell-cell fusion, we found that HEK293T-ACE2 (<xref ref-type="fig" rid="fig5">Figure 5C</xref>), Caco-2 (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A</xref>), and Calu-3 cells (<xref ref-type="fig" rid="fig5">Figure 5D</xref>) expressing RhoA-CA clearly reduced S2’ cleavage and N protein levels compared to the control group during authentic SARS-CoV-2 infection. Meanwhile, we observed that constitutive activation of RhoA enriches actin bundles at cell-cell junction, thus preventing SARS-CoV-2-induced cell-cell fusion in authentic SARS-CoV-2 infected Caco-2 (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2B and C</xref>) and Calu-3 cells (<xref ref-type="fig" rid="fig5">Figure 5E</xref> and <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2D</xref>). In addition, we examined the potential effect of RhoA-CA on ACE2 and found that it did not affect Spike protein binding to ACE2 (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2E</xref>), nor ACE2 distribution on the cell surface (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2F and G</xref>). We also observed that IL-1β treatment did not change ACE2 or Spike protein distribution on the cell surface (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3A–D</xref>).</p><p>Notably, ROCK inhibitor Y-27632 treatment increased bioluminescence signal and S2’ cleavage in a dose-dependent manner, promoting syncytia formation. When treated with lower concentrations of Y-27632, IL-1β eliminated Y-27632-enhanced cell-cell fusion. However, IL-1β was unable to inhibit cell-cell fusion in the presence of higher concentrations of Y-27632 (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3E</xref>). Furthermore, we verified that IL-1β was unable to reduce S2’ cleavage and N protein levels in the presence of Y-27632 in authentic SARS-CoV-2-infected Caco-2 (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3F</xref>), Calu-3 cells (<xref ref-type="fig" rid="fig5">Figure 5F</xref>), and primary human lung cells (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). IF results also confirmed that the elimination of IL-1β induced actin bundles by Y-27632 in Caco-2 (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplements 3G</xref> and <xref ref-type="fig" rid="fig5s4">4A</xref>) and Calu-3 cells (<xref ref-type="fig" rid="fig5">Figure 5H</xref> and <xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4B</xref>). These results indicated that preventing the formation of RhoA/ROCK-mediated actin bundles at cell-cell junction promotes SARS-CoV-2-induced cell-cell fusion.</p></sec><sec id="s2-5"><title>IL-1β restricts SARS-CoV-2 transmission via induction of actin bundles in vivo</title><p>To demonstrate the role of IL-1β in controlling SARS-CoV-2 transmission in vivo, BALB/c mice were infected with authentic SARS-CoV-2 B.1.351 after IL-1β or IL-1RA+IL-1β pre-treatment (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). Interestingly, the results of this experiment showed that in mice with IL-1β treatment, the body weight loss was less than in the PBS control group, while IL-1β was unable to improve body weight in the presence of IL-1RA (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). According to hematoxylin and eosin (H&amp;E) staining, tissue histopathology analysis demonstrated that the mice with IL-1β treatment carry less pulmonary injury compared to the PBS control and IL-1RA+IL-1β groups (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>). In addition, the expression level of SARS-CoV-2 N gene in the lung from IL-1β-treated mice was significantly lower than in the PBS control and IL-1RA+IL-1β-treated mice (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). In addition, immunohistochemistry (IHC) staining showed that the infected area in the epithelial linings of lung tissue was significantly reduced by IL-1β treatment compared to the PBS control and IL-1RA+IL-1β groups (<xref ref-type="fig" rid="fig6">Figure 6D and E</xref>), indicating that IL-1β restricted the transmission of SARS-CoV-2 in the lung. Moreover, fluorescence staining showed that SARS-CoV-2-infected lung epithelial cells fused with neighboring cells, promoting viral transmission in the airway epithelial cells, while IL-1β induced the formation of actin bundles to restrict the syncytia formation and further viral transmission (<xref ref-type="fig" rid="fig6">Figure 6F</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C and D</xref>). In addition, we found that IL-1β-treated mice have no significant changes in body weight, nor liver and spleen weight compared to control mice (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A–D</xref>), indicating that this dose of IL-1β did not cause toxicity in vivo in the mice. Of note, when we isolated tissue cells from the IL-1β-treated mice and infected with authentic SARS-CoV-2, it was found that S2’ cleavage and N protein levels were strongly reduced in IL-1β-treated mice-derived lung and intestine tissue cells compared to control (<xref ref-type="fig" rid="fig6">Figure 6G</xref> and <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2E</xref>), suggesting that IL-1β may have protective effects on various tissue cells against SARS-CoV-2 infection in vivo.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Interleukin-1β (IL-1β) restricts severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission via induction of actin bundles in the lung in vivo.</title><p>(<bold>A, B</bold>) Representative images of hematoxylin and eosin (H&amp;E)-stained lung sections (A) and histopathology scores (B) from phosphate buffered saline (PBS); 1 μg/kg mIL-1β; 150 μg/kg mIL-1RA+mIL-1β pre-treated mice infected with SARS-CoV-2 at 4 days post-infection (dpi), scale bars are indicative of 500 μm and images are representative of eight samples. (<bold>C</bold>) qPCR analysis of SARS-CoV-2 N mRNA collected from infected lung tissues at 4 dpi. (<bold>D</bold>) Immunohistochemistry analysis of SARS-CoV-2 N staining in the lung tissue slices at 4 dpi, scale bars are indicative of 500 μm (top panel), 50 μm (bottom panel), and images are representative of eight samples. (<bold>E</bold>) The percentages of SARS-CoV-2-infected area in (D) were quantified. (<bold>F</bold>) Representative confocal images of F-actin stained with phalloidin-488 and SARS-CoV-2 N in the area 1 of lung tissue at 4 dpi. White arrowheads indicate syncytia formation or infected cells, scale bars are indicative of 10 μm and images are representative of three samples (top). White lines indicate SARS-CoV-2 cell-cell transmission and quantify with fluorescence intensity of F-actin and SARS-CoV-2 N (bottom). (<bold>G</bold>) Immunoblots of SARS-CoV-2 S, S2, cleaved S2’, and N proteins collected from SARS-CoV-2 B.1.351-infected lung tissue cells, which were isolated from BALB/c mice treated with or without 1 μg/kg mIL-1β at day 7. Blots are representative of three individual mouse. Numbers below the blots indicated the intensity of S2’ or N versus β-Actin.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig6-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig6-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata3"><label>Figure 6—source data 3.</label><caption><title>Source data of the individual points in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-98593-fig6-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Interleukin-1β (IL-1β) reduces the weight loss and viral transmission upon severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vivo.</title><p>(<bold>A</bold>) Schematic for a murine model of authentic SARS-CoV-2 infection, phosphate buffered saline (PBS) control (n=8); 1 μg/kg mIL-1β (n=8); 150 μg/kg mIL-1RA+1 μg/kg mIL-1β (n=8) were administered 1 hr before intranasal challenge with 5×10<sup>4</sup> FFU of SARS-CoV-2 B.1.351; mice were then intraperitoneally injected with PBS, mIL-1β and mIL-1RA+mIL-1β at 1 and 2 day post-infection (dpi), before sacrificed at 4 dpi. (<bold>B</bold>) The body weights were assessed daily for weight loss after SARS-CoV-2 infection. (<bold>C, D</bold>) Representative confocal images of F-actin stained with phalloidin-488 and SARS-CoV-2 N in the area 2 (C) and area 3 (D) of lung tissue at 4 dpi. White arrowheads indicate syncytia formation or infected cells, scale bars are indicative of 10 μm and images are representative of three samples (top). White lines indicate SARS-CoV-2 cell-cell transmission and quantify with fluorescence intensity of F-actin and SARS-CoV-2 N (bottom).</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Source data of the individual points in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-98593-fig6-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Treatment with 1 μg/kg mIL-1β protects mouse lung and intestinal tissue cells against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection without toxicity in vivo.</title><p>(<bold>A</bold>) Schematic of phosphate buffered saline (PBS) (n=5) and mIL-1β (n=5) treated BALB/c mice. (<bold>B</bold>) The body weights were assessed daily for weight loss. Liver (<bold>C</bold>) and spleen (<bold>D</bold>) weights were assessed at day 7. (<bold>E</bold>) Immunoblots of SARS-CoV-2 S, S2, cleaved S2’, and N proteins collected from SARS-CoV-2 B.1.351-infected intestine tissue cells, which isolated from BALB/c mice treated with or without 1 μg/kg mIL-1β at day 7. Blots are representative of three individual mouse. Numbers below the blots indicated the intensity of S2’ or N versus β-Actin.</p><p><supplementary-material id="fig6s2sdata1"><label>Figure 6—figure supplement 2—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig6-figsupp2-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig6s2sdata2"><label>Figure 6—figure supplement 2—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig6-figsupp2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6s2sdata3"><label>Figure 6—figure supplement 2—source data 3.</label><caption><title>Source data of the individual points in <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-98593-fig6-figsupp2-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig6-figsupp2-v1.tif"/></fig></fig-group><p>To further verify the function and mechanism of IL-1β in controlling SARS-CoV-2 transmission in vivo, BALB/c mice were infected with authentic SARS-CoV-2 B.1.351 after IL-1β or ROCK inhibitor Y-27632+IL-1β pre-treatment (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>). Similar to IL-1RA, Y-27632 compromised the effect of IL-1β in preventing weight loss (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>). In addition, H&amp;E staining showed that Y-27632 treatment aggravated lung injury in IL-1β-treated mice upon SARS-CoV-2 infection (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>), although Y-27632+IL-1β did not cause weight loss or lung injury in uninfected mice (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1C and D</xref>). Moreover, Y-27632 treatment increased the expression level of SARS-CoV-2 N gene (<xref ref-type="fig" rid="fig7">Figure 7C</xref>) and infected area (<xref ref-type="fig" rid="fig7">Figure 7D and E</xref>) in the lungs of IL-1β-treated mice. Importantly, Y-27632 treatment prevented the formation of IL-1β-induced actin bundles at cell-cell junctions, thus promoted syncytia formation and further viral transmission (<xref ref-type="fig" rid="fig7">Figure 7F</xref> and <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A and B</xref>). Furthermore, we treated BALB/c mice with PBS, IL-1β, or Y-27632+IL-1β (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2C</xref>), then isolated the lung tissue cells for authentic SARS-CoV-2 infection. Here, it was found that S2’ cleavage and N protein levels were clearly reduced in IL-1β-treated mice compared to control at day 2, while Y-27632 treatment abolished the inhibitory effect of IL-1β (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2D</xref>). Of note, the lung tissue cells in IL-1β-treated mice remained resistant to SARS-CoV-2 infection at day 7, while the protective effect of IL-1β was abolished by Y-27632 treatment (<xref ref-type="fig" rid="fig7">Figure 7G</xref>). Taken together, IL-1β prevents the transmission of SARS-CoV-2 through inducing the formation of actin bundles via the RhoA/ROCK pathway in vivo.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Prevention of interleukin-1β (IL-1β)-induced actin bundles by ROCK inhibitor Y-27632 promotes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission in vivo.</title><p>(<bold>A, B</bold>) Representative images of hematoxylin and eosin (H&amp;E)-stained lung sections (A) and histopathology scores (B) from phosphate buffered saline (PBS); 1 μg/kg mIL-1β; 1 mg/kg Y-27632+mIL-1β pre-treated mice infected with SARS-CoV-2 at 4 days post-infection (dpi), scale bars are indicative of 500 μm and images are representative of eight samples. (<bold>C</bold>) qPCR analysis of SARS-CoV-2 N mRNA collected from infected lung tissues at 4 dpi. (<bold>D</bold>) Immunohistochemistry analysis of SARS-CoV-2 N staining in the lung tissue slices at 4 dpi, scale bars are indicative of 500 μm (top panel), 50 μm (bottom panel) and images are representative of eight samples. (<bold>E</bold>) The percentages of SARS-CoV-2-infected area in (D) were quantified. (<bold>F</bold>) Representative confocal images of F-actin stained with phalloidin-488 and SARS-CoV-2 N in the area 1 of lung tissue at 4 dpi. White arrowheads indicate syncytia formation or infected cells, scale bars are indicative of 10 μm and images are representative of three samples (top). White lines indicate SARS-CoV-2 cell-cell transmission and quantify with fluorescence intensity of F-actin and SARS-CoV-2 N (bottom). (<bold>G</bold>) Immunoblots of SARS-CoV-2 S, S2, cleaved S2’, and N proteins collected from authentic SARS-CoV-2 BF.7-infected lung tissue cells, which were isolated from BALB/c mice treated with PBS, 1 μg/kg mIL-1β or 1 mg/kg Y-27632+1 μg/kg mIL-1β at day 7. Blots are representative of three individual mouse. Numbers below the blots indicated the intensity of S2’ or N versus β-Actin.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig7">Figure 7</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig7-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig7sdata2"><label>Figure 7—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig7">Figure 7</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig7-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata3"><label>Figure 7—source data 3.</label><caption><title>Source data of the individual points in <xref ref-type="fig" rid="fig7">Figure 7</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-98593-fig7-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Y-27632+IL-1β do not cause weight loss and lung injury in uninfected BALB/c mice.</title><p>(<bold>A</bold>) Schematic for a murine model of authentic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, phosphate buffered saline (PBS) control (n=8); 1 μg/kg mIL-1β (n=8); 1mg/kg Y-27632+1 μg/kg mIL-1β (n=8) were administered 1 hr before intranasal challenge with 5×10<sup>4</sup> FFU of SARS-CoV-2 B.1.351; mice were then intraperitoneally injected with PBS, mIL-1β, and Y-27632+mIL-1β at 1 and 2 day post-infection (dpi), before sacrificed at 4 dpi. (<bold>B</bold>) The body weights were assessed daily for weight loss after SARS-CoV-2 infection. (<bold>C</bold>) The body weights were assessed daily from PBS or Y-27632+mIL-1β-treated uninfected mice. (<bold>D</bold>) Representative images of hematoxylin and eosin (H&amp;E)-stained lung sections from PBS or Y-27632+mIL-1β-treated uninfected mice at day 7, scale bars are indicative of 500 μm and images are representative of four samples.</p><p><supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>Source data of the individual points in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-98593-fig7-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig7-figsupp1-v1.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Y-27632 treatment prevents the formation of interleukin-1β (IL-1β)-induced actin bundles at cell-cell junctions in vivo.</title><p>(<bold>A, B</bold>) Representative confocal images of F-actin stained with phalloidin-488 and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) N in the area 2 (A) and area 3 (B) of lung tissue at 4 days post-infection (dpi). White arrowheads indicate syncytia formation or infected cells, scale bars are indicative of 10 μm and images are representative of three samples (top). White lines indicate SARS-CoV-2 cell-cell transmission and quantify with fluorescence intensity of F-actin and SARS-CoV-2 N (bottom). (<bold>C</bold>) Schematic of phosphate buffered saline (PBS) mIL-1β and Y-27632+mIL-1β-treated BALB/c mice. (<bold>D</bold>) Immunoblots of SARS-CoV-2 S, S2, cleaved S2’, and N proteins collected from authentic SARS-CoV-2 BF.7-infected lung tissue cells, which were isolated from BALB/c mice treated with PBS, 1 μg/kg mIL-1β or 1mg/kg Y-27632+1 μg/kg mIL-1β at day 2. Blots are representative of three individual mouse. Numbers below the blots indicated the intensity of S2’ or N versus β-Actin.</p><p><supplementary-material id="fig7s2sdata1"><label>Figure 7—figure supplement 2—source data 1.</label><caption><title>Annotated, uncropped blots in <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98593-fig7-figsupp2-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig7s2sdata2"><label>Figure 7—figure supplement 2—source data 2.</label><caption><title>Raw, uncropped blots in <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98593-fig7-figsupp2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7s2sdata3"><label>Figure 7—figure supplement 2—source data 3.</label><caption><title>Source data of the individual points in <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-98593-fig7-figsupp2-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig7-figsupp2-v1.tif"/></fig><fig id="fig7s3" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 3.</label><caption><title>Graphical abstract.</title><p>Host factors secreted from innate immune cells upon Toll-like receptor (TLR) ligands stimulation, including interleukin-1β (IL-1β) and IL-1α, act on both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected cells expressing spike protein and neighboring cells expressing ACE2 receptor via IL-1R1-MyD88-IRAK-TRAF6 signaling pathway, which leads to strong enrichment of activated RhoA at cell-cell junction, resulting in the formation of ROCK-mediated actin bundle to prevent SARS-CoV-2-induced cell-cell fusion and further viral transmission through syncytia formation.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-fig7-figsupp3-v1.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In the present study, we explored the function of innate immune factors against SARS-CoV-2 infection. Notably, IL-1β inhibited various SARS-CoV-2 variants and other beta-coronaviruses spike-induced cell-cell fusion. Mechanistically, IL-1β activates and enriches RhoA to the cell-cell junction between SARS-CoV-2-infected cells and neighboring cells via the IL-1R-mediated signal to initiate actin bundle formation, preventing cell-cell fusion and viral spreading (<xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3</xref>). These findings revealed a critical function for proinflammatory cytokines to control viral infection.</p><p>Elevated IL-1β levels in severe COVID-19 patients is central to innate immune response as it induces the expression of other proinflammatory cytokines (<xref ref-type="bibr" rid="bib40">Tahtinen et al., 2022</xref>). In addition, IL-1α is also secreted during SARS-CoV-2 infection (<xref ref-type="bibr" rid="bib47">Xiao et al., 2021</xref>). Of note, several therapeutic strategies have employed the inhibition of IL-1 signal in an attempt to treat SARS-CoV-2 infection (<xref ref-type="bibr" rid="bib19">Huet et al., 2020</xref>; <xref ref-type="bibr" rid="bib42">Ucciferri et al., 2020</xref>). Intriguingly, although anakinra, a recombinant human IL-1RA, improved clinical outcomes and reduced mortality in severe COVID-19 patients (<xref ref-type="bibr" rid="bib6">Cavalli et al., 2020</xref>), it did not reduce mortality in mild-to-moderate COVID-19 patients, and even increased the probability of serious adverse events (<xref ref-type="bibr" rid="bib41">Tharaux et al., 2021</xref>). With another note, IL-1 blockade significantly decreased the neutralizing activity of serous anti-SARS-CoV-2 antibodies in severe COVID-19 patients (<xref ref-type="bibr" rid="bib10">Della-Torre et al., 2021</xref>). According to our finding that both IL-1β and IL-1α are able to inhibit SARS-CoV-2-induced cell-cell fusion, inhibition of IL-1 signaling may have abolished the antiviral function of IL-1, thus failing to restrict virus-induced syncytia formation and transmission.</p><p>Notably, IL-1β plays a key role in triggering vaccine-induced innate immunity, suggesting that innate immune responses play important roles in the antiviral defense by enhancing the protective efficacy of vaccines (<xref ref-type="bibr" rid="bib14">Eisenbarth et al., 2008</xref>; <xref ref-type="bibr" rid="bib40">Tahtinen et al., 2022</xref>). In addition, vaccination with Bacillus Calmette-Guérin (BCG) has been reported to confer nonspecific protection against heterologous pathogens, including protection against SARS-CoV-2 infection in humans and mice (<xref ref-type="bibr" rid="bib18">Hilligan et al., 2022</xref>; <xref ref-type="bibr" rid="bib22">Lee et al., 2024</xref>; <xref ref-type="bibr" rid="bib34">Rivas et al., 2021</xref>). Moreover, lipid nanoparticle in mRNA vaccine (<xref ref-type="bibr" rid="bib17">Han et al., 2023</xref>) and penton base in adenovirus vaccine (<xref ref-type="bibr" rid="bib11">Di Paolo et al., 2009</xref>) can both activate innate immune cells to amplify the protective effect of vaccines, which may also be attributed to IL-1β-mediated inhibition of SARS-CoV-2-induced cell-cell fusion on top of adaptive immune responses induced by the vaccines.</p><p>With another note, patients with inherited MyD88 or IRAK4 deficiency have been reported to be selectively vulnerable to COVID-19 pneumonia. It was found that these patients’ susceptibility to SARS-CoV-2 can be attributed to impaired type I IFN production, which do not sense the virus correctly in the absence of MyD88 or IRAK4 (<xref ref-type="bibr" rid="bib15">García-García et al., 2023</xref>). In our study, MyD88 or IRAK4 deficiency abolished the inhibitory effect of IL-1β on SARS-CoV-2-induced cell-cell fusion, suggesting that these innate immune molecules are critical to contain SARS-CoV-2 infection, and this may be another mechanism accounting for the disease of those patients. Moreover, MyD88 signaling was essential for BCG-induced innate and type 1 helper T cell (TH1 cell) responses and protection against SARS-CoV-2, which is consistent with our fundings.</p><p>Of note, cell-cell fusion is not limited to the process of viral infection, both normal and cancerous cells can utilize this physiological process in tissue regeneration or tumor evolution (<xref ref-type="bibr" rid="bib9">Delespaul et al., 2020</xref>; <xref ref-type="bibr" rid="bib29">Powell et al., 2011</xref>). For example, myoblast fusion is the key process of skeletal muscle terminal differentiation, inactivation of RhoA/ROCK signaling is crucial for myoblast fusion (<xref ref-type="bibr" rid="bib26">Nishiyama et al., 2004</xref>). Our current work revealed that inhibition of RhoA/ROCK signaling promoted virus-induced cell-cell fusion, possibly due to the virus hijacking of such biological process. In turn, activated RhoA/ROCK signaling inhibits virus-induced cell-cell fusion, so it can be targeted for future therapeutic development to control viral transmission. Cell-cell fusion is mediated by actin cytoskeletal rearrangements, the dissolution of F-actin focus is essential for cell-cell fusion; in contrast, syncytia formation cannot proceed if disassembly of actin filaments or bundles is prevented (<xref ref-type="bibr" rid="bib12">Doherty et al., 2011</xref>; <xref ref-type="bibr" rid="bib35">Rodríguez-Pérez et al., 2021</xref>). We uncovered that preventing actin bundles dissolution inhibited virus-induced cell-cell fusion, and IL-1β-induced RhoA/ROCK signal promotes actin bundle formation at cell-cell junctions. As RhoA is ubiquitously expressed by all cell types, it is currently unclear whether IL-1-mediated RhoA activation is specific toward viral infection-associated cytoskeleton modification, or may regulate other RhoA-related processes, which is a limitation of the current work and remains to be investigated in future.</p><p>In summary, this study demonstrated the function and mechanism of IL-1β in inhibiting SARS-CoV-2-induced syncytia formation, and highlighted the function of innate immune factors including cytokines against coronaviruses transmission, thus provide potential therapeutic targets for viral control.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit polyclonal antibody (pAb) to SARS-CoV-2 S2</td><td align="left" valign="bottom">Sino Biological</td><td align="char" char="hyphen" valign="bottom">Cat#:40590-T62, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_3073714">AB_3073714</ext-link></td><td align="left" valign="bottom">WB (1:2000), IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal antibody (mAb) to SARS-CoV-2 Nucleocapsid</td><td align="left" valign="bottom">Sino Biological</td><td align="char" char="hyphen" valign="bottom">Cat#:40143-MM05, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2827977">AB_2827977</ext-link></td><td align="left" valign="bottom">WB (1:1000), IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit polyclonal antibody (pAb) to ACE2</td><td align="left" valign="bottom">Proteintech</td><td align="char" char="ndash" valign="bottom">Cat#:21115-1-AP, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_10732845">AB_10732845</ext-link></td><td align="left" valign="bottom">WB (1:2000), IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit polyclonal antibody (pAb) to MERS-CoV S2 antibody</td><td align="left" valign="bottom">Sino Biological</td><td align="char" char="hyphen" valign="bottom">Cat#:40070-T62</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit monoclonal antibody (mAb) to MyD88</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">Cat#:4283, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_10547882">AB_10547882</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit monoclonal antibody (mAb) to TRAF6</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat#:ab33915, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_778572">AB_778572</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit polyclonal antibody (pAb) to TAK1</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">Cat#:4505, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_490858">AB_490858</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal antibody (mAb) to Myc-Tag</td><td align="left" valign="bottom">Abclonal</td><td align="left" valign="bottom">Cat#:AE010, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2770408">AB_2770408</ext-link></td><td align="left" valign="bottom">WB (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal antibody (mAb) to HA-Tag</td><td align="left" valign="bottom">Abclonal</td><td align="left" valign="bottom">Cat#:AE008, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2770404">AB_2770404</ext-link></td><td align="left" valign="bottom">IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal antibody (mAb) to HRP-conjugated β-tubulin</td><td align="left" valign="bottom">Abclonal</td><td align="left" valign="bottom">Cat#:AC030, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2769870">AB_2769870</ext-link></td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal antibody (mAb) to β-actin</td><td align="left" valign="bottom">Proteintech</td><td align="char" char="ndash" valign="bottom">Cat#:66009-1-Ig, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2687938">AB_2687938</ext-link></td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 555</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat#:A-21424, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_141780">AB_141780</ext-link></td><td align="left" valign="bottom">IF (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 647</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat#:A-21236, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2535805">AB_2535805</ext-link></td><td align="left" valign="bottom">IF (1:400)</td></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Actin-Tracker Green-488</td><td align="left" valign="bottom">Beyotime</td><td align="left" valign="bottom">C2201S</td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">DAPI</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab228549</td><td align="left" valign="bottom">IF (1:2000)</td></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Antifade mounting medium</td><td align="left" valign="bottom">Vectorlabs</td><td align="left" valign="bottom">H-1400-10</td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Purified LTA from <italic>S. aureus</italic></td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">tlrl-pslta</td><td align="left" valign="bottom">10 μg/mL</td></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Pam3CSK4</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">tlrl-pms</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Peptidoglycan from <italic>S. aureus</italic></td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="char" char="." valign="bottom">77140</td><td align="left" valign="bottom">2 μg/mL</td></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">LPS</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">tlrl-eklps</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">TPCA1</td><td align="left" valign="bottom">Selleck</td><td align="left" valign="bottom">S2824</td><td align="left" valign="bottom">0.5 μM, 1 μM</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">5Z-7-Oxozeaenol</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">O9890</td><td align="left" valign="bottom">1 μM</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">IRAK1/4 inhibitor</td><td align="left" valign="bottom">Selleck</td><td align="left" valign="bottom">S6598</td><td align="left" valign="bottom">2 μM</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Y-27632</td><td align="left" valign="bottom">Selleck</td><td align="left" valign="bottom">S6390</td><td align="left" valign="bottom">In vitro: 1 μM, 10 μM, 50 μM; In vivo: 1 mg/kg</td></tr><tr><td align="left" valign="bottom">Recombinant protein</td><td align="left" valign="bottom">Recombinant human IL-1α</td><td align="left" valign="bottom">Peprotech</td><td align="char" char="ndash" valign="bottom">200-01A</td><td align="char" char="." valign="bottom">10 ng/mL</td></tr><tr><td align="left" valign="bottom">Recombinant protein</td><td align="left" valign="bottom">Recombinant human IL-1β</td><td align="left" valign="bottom">Peprotech</td><td align="char" char="hyphen" valign="bottom">200-01B</td><td align="char" char="." valign="bottom">1 ng/mL</td></tr><tr><td align="left" valign="bottom">Recombinant protein</td><td align="left" valign="bottom">Recombinant mouse IL-1β</td><td align="left" valign="bottom">Peprotech</td><td align="char" char="hyphen" valign="bottom">211-11B</td><td align="left" valign="bottom">In vivo: 1 μg/kg</td></tr><tr><td align="left" valign="bottom">Recombinant protein</td><td align="left" valign="bottom">Recombinant human IL-1RA</td><td align="left" valign="bottom">Peprotech</td><td align="char" char="hyphen" valign="bottom">200-01RA</td><td align="char" char="." valign="bottom">1000 ng/mL</td></tr><tr><td align="left" valign="bottom">Recombinant protein</td><td align="left" valign="bottom">Recombinant human IL-6</td><td align="left" valign="bottom">Peprotech</td><td align="char" char="ndash" valign="bottom">200-06</td><td align="char" char="." valign="bottom">100 ng/mL</td></tr><tr><td align="left" valign="bottom">Recombinant protein</td><td align="left" valign="bottom">Recombinant human IL-8</td><td align="left" valign="bottom">Peprotech</td><td align="char" char="ndash" valign="bottom">200-08M</td><td align="char" char="." valign="bottom">100 ng/mL</td></tr><tr><td align="left" valign="bottom">Recombinant protein</td><td align="left" valign="bottom">Recombinant mouse IL-1RA</td><td align="left" valign="bottom">BioLegend</td><td align="char" char="." valign="bottom">769706</td><td align="left" valign="bottom">In vivo: 150 μg/kg</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Human IL-1β ELISA kit</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">DY201</td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RhoA pull-down activation assay Biochem kit</td><td align="left" valign="bottom">Cytoskeleton</td><td align="left" valign="bottom">BK036-S</td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pVAX1 SARS-CoV-2 spike (Wild type) plasmid</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">GenBank: QHD43419.1</td><td align="left" valign="bottom"><italic>Homo sapiens</italic> codon-optimized, HA-tag at the C-terminal</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pVAX1 SARS-CoV-2 spike (Alpha) plasmid</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Truncated 19 amino acids at the C-terminal</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pVAX1 SARS-CoV-2 spike (Beta) plasmid</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Truncated 19 amino acids at the C-terminal</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pVAX1 SARS-CoV-2 spike (Delta) plasmid</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Truncated 19 amino acids at the C-terminal</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pVAX1 SARS-CoV-2 spike (Omicron) plasmid</td><td align="left" valign="bottom">GeneScript</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Truncated 19 amino acids at the C-terminal</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA4.0 human ACE2 plasmid</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">V5-tag at the C-terminal</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">GFP-AHPH plasmid</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Cat#:71368, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_71368">Addgene_71368</ext-link></td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pRK5myc RhoA L63 plasmid</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Cat#:15900, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_15900">Addgene_15900</ext-link></td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> for primers used in this study</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">sgRNA primers</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">sgRNA primers</td><td align="left" valign="bottom">See <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref> for sgRNA primers used in this study</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell culture and stimulation</title><p>HEK293T cells (4201HUM-CCTCC00187) were purchased from the National Science &amp; Technology Infrastructure (NSTI) cell bank (<ext-link ext-link-type="uri" xlink:href="https://www.cellbank.org.cn/">https://www.cellbank.org.cn/</ext-link>). Human colon epithelial carcinoma cell line Caco-2 (catalog no. SCSP-5027) cells were obtained from Cell Bank/Stem Cell Bank, Chinese Academy of Sciences. Human lung cancer cell line Calu-3 and Vero E6-ACE2 cells were gifted from Prof. Dimitri Lavillette (Applied Molecular Virology Laboratory, Discovery Biology Department, Institut Pasteur Korea). Human monocytic cell line THP-1 (TIB-202; ATCC) was authenticated at Genetic Testing Biotechnology Corporation (Suzhou, China) using short tandem repeat analysis as described in 2012 in ANSI Standard (ASN-0002) by the ATCC Standards Development Organization. Their identity has been authenticated by the supplier and regular mycoplasma checks were performed. HEK293T and Vero E6-ACE2 cells were cultured in Gibco Dulbecco’s Modified Eagle Medium (DMEM) (GE Healthcare) supplemented with 10% fetal bovine serum (FBS) (Sigma) and 1% penicillin/streptomycin (P/S) (Life Technologies) at 37°C with 5% CO<sub>2</sub> in a humidified incubator. Caco-2 and Calu-3 cells were cultured in Minimum Essential Medium supplemented with 10% FBS, 1% non-essential amino acids, and 1% P/S at 37°C with 5% CO<sub>2</sub> in a humidified incubator. THP-1 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 supplemented with 10% FBS, 1% P/S, and 50 μM 2-ME at 37°C with 5% CO<sub>2</sub> in a humidified incubator. All cells were routinely tested for mycoplasma contamination; passages between 4th and 25th were used. Human PBMCs were isolated from the peripheral blood of healthy doners (Shanghai Blood Center). This study was performed in accordance with the International Ethical Guidelines for Biomedical Research Involving Human Subjects and the principles expressed in the Declaration of Helsinki. Briefly, fresh human PBMCs were separated using Ficoll-Paque PLUS reagent (cytiva, 17144003) at 1200×<italic>g</italic> for 10 min at room temperature with SepMateTM-50 (SepMate, 86450). PBMCs were washed three times with filtered PBS containing 0.5% bovine serum albumin (BSA) and 2 mM EDTA. PBMCs were counted and resuspended in RPMI 1640 medium supplemented with 1% FBS and 1% P/S.</p><p>For stimulation, THP-1 cells were seeded at 2×10<sup>6</sup> cells/mL in FBS-free RPMI 1640 and PBMCs were seeded at 1×10<sup>7</sup> cells/mL in 1% FBS RPMI 1640, then stimulated with LTA (10 μg/mL), Pam3CSK4 (1 μg/mL), PGN (2 μg/mL), LPS (1 μg/mL) for 24 hr, cell culture supernatants were collected after centrifugation at 2000×<italic>g</italic> for 5 min for subsequent experiments.</p></sec><sec id="s4-2"><title>Transient transfection and cell-cell fusion assays</title><p>For transient transfections, HEK293T cells were seeded in 24-well plates at 0.5×10<sup>6</sup> cells/mL overnight. 250 ng plasmids encoding SARS-CoV-2 spike mutants or ACE2 variants were packaged in Lipofectamine 2000 (Life Technologies) and transfected for 24 hr. For luciferase assays, Spike-mediated membrane fusion, a <italic>Cre-loxp</italic> Firefly luciferase (<italic>Stop-Luc</italic>) co-expression system was introduced to enable the detection of DNA recombination events during cell-cell fusion. 200 ng Cre plasmids were co-transfected into HEK293T-S cells and 200 ng <italic>Stop-Luc</italic> plasmid were co-transfected into HEK293T±ACE2 cells, respectively. For visualization of syncytia formation, 100 ng ZsGreen plasmid was co-transfected with spike variants. HEK293T cells in the 24-well plates were then detached using ice-cold calcium-free PBS in the absence of trypsin and centrifuged at 600×<italic>g</italic> for 4 min.</p><p>For cell-cell fusion assays, cell pellets were resuspended into complete DMEM and mixed with control HEK293T cells, or HEK293T-ACE2, Vero E6-ACE2, or Calu-3 cells at 1:1 ratio before adhesion to the 48-well or 96-well plates, cell mixes were incubated for 16 hr at 37°C. Quantification of cell-cell fusion was performed by measuring luciferase expression as relative luminescence units (RLU) 1 min by mixing cell lysates with the Bright-Glo luciferase substrate (E2610, Promega) on a Synergy H1 plate reader (Biotek). Fluorescent images showing syncytia formation were captured at endpoint using a 10× objective and 12-bit monochrome CMOS camera installed on the IX73 inverted microscope (Olympus). Attached cells and syncytia were lysed in an NP40 lysis buffer containing 0.5% (vol/vol) NP40, 25 mM Tris pH 7.3, 150 mM NaCl, 5% glycerol, and 1× EDTA-free protease inhibitor cocktail (PIC) (Roche).</p></sec><sec id="s4-3"><title>Immunoblotting</title><p>Tissue culture plates containing adherent syncytia and cell mixes were directly lysed on ice in 2× reducing Laemmli loading buffer before boiled at 95°C for 5 min. Protein samples were separated by standard Tris-glycine SDS-PAGE on 7.5% or 9.5% Tris-glycine polyacrylamide gels. Proteins were then transferred onto 0.45 μm PVDF membranes (Millipore) for wet transfer using Towbin transfer buffer. All membranes were blocked in PBS supplemented with 0.1% Tween 20 (PBST) and 2.5% BSA or 5% non-fat dry milk, before overnight incubation in primary antibodies at 4°C. Blots were labeled with HRP-tagged secondary antibodies (Jackson ImmnuoResearch) and visualized with PicoLight substrate enhanced chemiluminescence solution (Epizyme Scientific). Immunoblot images were captured digitally using a 5200 chemiluminescent imaging system (Tanon) with molecular weight markers indicated.</p></sec><sec id="s4-4"><title>Real-time PCR</title><p>0.5×10<sup>6</sup> cells/mL HEK293T cells were seeded in 24-well plates overnight. After the cells were about 80% covered, specified stimulant was added. Upon harvesting, cells were washed with PBS for three times, and 1 mL TRIzol Reagent (15596018; Thermo Fisher Scientific) was added for full lysis at room temperature for 5 min. 250 μL chloroform was added, fully mixed at room temperature for 5 min, centrifuged at 10,000 r/min, 4°C for 10 min. After carefully removing the aqueous phase using a pipette into another 1.5 mL Eppendorf tube, some of the aqueous phase (about 1 mm above DNA layer to prevent DNA contamination) was remained. 550 µL isopropanol was added in the aqueous phase and mixed gently, then placed at –20°C for 30 min. The tubes were centrifuged at 14,000 r/min, 4°C for 20 min, and washed with 75% ethanol twice before dissolved in 30 µL DEPC water. RNA was reverse-transcribed to cDNA using a GoSript Reverse Transcription Kit (Promega). Real-time PCR was performed using SYBR Green Realtime PCR Master Mix (TOYOBO) on ABI QuantStudio 6 flex Real-time PCR System (Thermo Fisher Scientific). The RT-qPCR primer sequences for targeting genes are displayed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. Target genes’ relative quantification was normalized to <italic>GAPDH</italic> as relative unit (RU).</p></sec><sec id="s4-5"><title>CRISPR/Cas9-mediated gene targeting</title><p>Gene-deficient THP-1 or HEK293T cells were generated using CRISPR/Cas9-mediated gene targeting technology. Briefly, LentiCRISPR v2 (52961; Addgene) containing sgRNA specifically targeting indicated genes were constructed. The sgRNA sequences for targeting respective genes are displayed in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. The lentiviral particles were produced in HEK293T cells by transfection with LentiCRISPR v2-sg gene, psPAX2, VSV-G at 2:1.5:1 ratio using Lipofectamine 2000. The lentiviral particles were employed to infect THP-1 or HEK293T cells. One day post-infection (dpi), the cells were subjected to puromycin selection at a concentration of 2 μg/mL for 72 hr. Survived cells were subjected to limiting dilution in 96-well plates to obtain single clones stably knocking-out respective genes.</p></sec><sec id="s4-6"><title>RhoA pull-down assay</title><p>RhoA pull-down activation assay Biochem kit was applied for this experiment. In brief, after 1 ng/mL IL-1β treatment for 30 min, HEK293T cells were placed on ice and the culture media was aspirated off before washing cells with ice-cold PBS, then washed cells were transferred into 1.5 mL Eppendorf tubes followed with a centrifugation 600×<italic>g</italic>, 4°C for 5 min. Then, the cell lysis buffer with PIC was added. The tubes were immediately centrifuged at 10,000×<italic>g</italic>, 4°C for 1 min, then 20 µL of the lysate was saved for total RhoA, and the remaining lysate was used for pull-down assay. For pull-down assay, 10 μL rhotekin-RBD beads were mixed with 600 µg total protein, then the tubes were incubated at 4°C on a rotator for 1 hr before centrifuged at 5000×<italic>g</italic>, 4°C for 1 min. Next, 90% of the supernatants were carefully removed before washing beads with 500 μL wash buffer. Then, the tubes were centrifuged at 5000×<italic>g</italic>, 4°C for 3 min, and supernatant was carefully removed before adding 20 μL of 2× Laemmli sample buffer, then the beads were thoroughly resuspended and boiled for 2 min and analyzed through immunoblotting.</p></sec><sec id="s4-7"><title>Immunostaining and confocal microscopy</title><p>HEK293T-ACE2 cells were seeded onto sterilized poly-D-lysine (100 µg/mL) (Beyotime, ST508) treated 12 mm coverslips (Fisher Scientific, 1254580) in 24-well plates. After co-culture with HEK293T-S, cells were washed with PBS once before fixing with 4% (wt/vol) paraformaldehyde (PFA) for 20 min. Then, cells were washed twice with PBS and permeabilized with 0.1% Triton at room temperature for 10 min (for wheat germ agglutinin [WGA] staining, cells were not treated with Triton). Next, cells were washed twice with PBS and blocked with Immunol Staining Blocking Buffer (Beyotime, P0102) at room temperature for 1 hr. Primary antibodies were incubated at room temperature for 1 hr. Coverslips were then washed twice with PBS before incubation with Actin-Tracker Green-488 or secondary antibodies for 1 hr at room temperature. Coverslips were washed twice with PBS before DAPI staining for 10 min or being mounted in antifade mounting medium. Fluorescent images covering various areas on the coverslips were captured at 12-bit depth in monochrome using a 100× oil immersion objective on the Olympus SpinSR10 confocal microscope and subsequently processed using ImageJ software (NIH) with scale bars labeled.</p></sec><sec id="s4-8"><title>Authentic SARS-CoV-2 infection of cells</title><p>All experiments involving authentic SARS-CoV-2 virus in vitro were conducted in the biosafety level 3 laboratory of the Shanghai Municipal Center for Disease Control and Prevention (CDC). The experiments and protocols in this study were approved by the Ethical Review Committee of the Shanghai CDC (Permit Number: 2022-51). Briefly, HEK293T-ACE2 or Caco-2 cells were seeded into 24-well or 96-well plates at a density of 4×10<sup>5</sup> cells/mL overnight, then pre-treated with different reagents for 1 hr before infection with 0.5 multiplicity of infection (MOI) Delta or WT authentic SARS-CoV-2 (B.1.617.2 and WT) for 24 hr. Calu-3 cells were seeded into 24-well or 96-well plates at a density of 4×10<sup>5</sup> cells/mL overnight, infected with 0.5 MOI WT authentic SARS-CoV-2 for 1 hr, then washed with PBS before treating with different reagents for 24 hr. Bright-field images were captured to indicate the syncytia formation, cell lysates were collected for spike S2’ cleavage and N protein immunoblots.</p><p>For primary mouse tissue cells, specific pathogen-free 6-week-old female BALB/c mice were lightly anesthetized with isoflurane and intranasal treated with PBS, mIL-1β (1 μg/kg) or Y-27632 (1 mg/kg)+mIL-1β (1 μg/kg) at day 0, then mice were intraperitoneally injected with PBS, mIL-1β (1 μg/kg) or Y-27632 (1 mg/kg)+mIL-1β (1 μg/kg) at days 1 and 2. At day 7, mice were anesthetized by intraperitoneal injection of Avertin (2,2,2-tribromoethanol, Sigma-Aldrich), the thoracic cavity and abdominal cavity were opened, an outlet was cut in the left ventricle of the mice, and then the right ventricle was perfused with PBS through the pulmonary artery to remove blood cells in the lung. Next, the lung digestive solution with HBSS 1 mL, 1 mg/mL collagenase IA, DNaseI (200 mg/mL; Roche), DispaseII (4 U/mL; Gibco), and 5% FBS was injected into the lung cavity, then the lungs were peeled off and digested for 30 min with shaking at 37°C. For the intestinal cell isolation, the intestines are peeled off and put into the intestine digestive solution containing DMEM 10 mL, 1 μM DTT, 0.25 μM EDTA, and 5% FBS, then digested for 30 min with shaking at 37°C. After digestion, the lung and intestinal cells were resuspended in DMEM supplemented with 10% FBS and 1% P/S, subsequently, the cells were infected with 1 MOI authentic SARS-CoV-2 B.1.351 or BF.7 for 24 hr. All procedures were conducted in compliance with a protocol approved by the Institutional Animal Care and Use Committee (IACUC) at Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences.</p><p>For primary human lung cells, the human lung tissues were cut into small pieces of about 2 mm<sup>3</sup> and washed three times with HBSS solution containing 1% PS, digested with collagenase type I (100 mg+50 mL PBS) in an incubator at 37°C for 4 hr. Then filtered through a 70 μm filter and centrifuged at 500×<italic>g</italic> for 5 min at room temperature. Lysed with 3 mL Red Blood Cell Lysis Buffer for 5 min at room temperature, and then centrifuged at 500×<italic>g</italic> for 5 min at room temperature, washed twice with HBSS solution containing 1% PS. Human lung cells were resuspended in B-ALI Growth Media and seeded into 96-well plates at a density of 4×10<sup>5</sup> cells/mL overnight, infected with 0.5 MOI WT authentic SARS-CoV-2 for 1 hr, then washed with PBS before treating cells with different reagents for 24 hr. The experiments and protocols were approved by the Ethical Review Committee of the Shanghai CDC.</p></sec><sec id="s4-9"><title>Authentic SARS-CoV-2 infection of BALB/c mice</title><p>Specific pathogen-free 6-week-old female BALB/c mice were lightly anesthetized with isoflurane and intranasal treated with PBS, mIL-1β (1 μg/kg), mIL-1RA (150 μg/kg)+mIL-1β (1 μg/kg); or PBS, mIL-1β (1 μg/kg), Y-27632 (1 mg/kg)+mIL-1β (1 μg/kg) for 1 hr, then intranasally challenged with 5×10<sup>4</sup> FFU of SARS-CoV-2 B.1.351. For booster injection, mice were intraperitoneally injected with PBS, mIL-1β (1 μg/kg), mIL-1RA (150 μg/kg)+mIL-1β (1 μg/kg); or PBS, mIL-1β (1 μg/kg), Y-27632 (1 mg/kg)+mIL-1β (1 μg/kg) at 1 and 2 dpi. Mice were monitored daily for weight loss. Lungs were removed into TRIzol or 4% PFA at 4 dpi. Animal experiments related to authentic SARS-CoV-2 were conducted in Guangzhou Customs District Technology Center BSL-3 Laboratory (Permit Number: IQTC202302).</p></sec><sec id="s4-10"><title>Pulmonary histopathology</title><p>Lungs were collected from mice infected with SARS-CoV-2 at 4 dpi and fixed in 4% PFA (Bioss) for 12 hr followed by dehydrating, embedded in paraffin for sectioning, then stained with H&amp;E, IHC, or IF. H&amp;E and IHC data were analyzed by PerkinElmer Vectra 3, IF results were analyzed by Olympus SpinSR10 confocal microscope. The pathological scores were judged according to previous work (<xref ref-type="bibr" rid="bib8">Curtis et al., 1990</xref>).</p></sec><sec id="s4-11"><title>Statistics analysis</title><p>Bar graphs were presented as mean values ± standard error of mean (SEM) with individual data points. All statistical analyses were carried out with the Prism software v8.0.2 (GraphPad). Data with multiple groups were analyzed using matched one-way ANOVA followed by Sidak’s post hoc comparisons. Statistical significance p values were indicated between compared groups and shown on figures.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Funding acquisition, Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Investigation</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Investigation</p></fn><fn fn-type="con" id="con11"><p>Investigation</p></fn><fn fn-type="con" id="con12"><p>Investigation</p></fn><fn fn-type="con" id="con13"><p>Resources, Funding acquisition</p></fn><fn fn-type="con" id="con14"><p>Resources, Funding acquisition, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Resources, Funding acquisition, Investigation</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Resources, Supervision, Funding acquisition, Methodology, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experiments related to authentic SARS-CoV-2 were conducted in Guangzhou Customs District Technology Center BSL-3 Laboratory (Permit Number: IQTC202302).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Primer sequences for RT-qPCR.</title></caption><media xlink:href="elife-98593-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Primer sequences for sgRNA.</title></caption><media xlink:href="elife-98593-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-98593-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files; source data files have been provided for figures and figure supplements.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Qiuhong Guo, Prof. Dimitri Lavillette, and Prof. Gary Wong for their experimental supports and reagents used in this work. This study is supported by grants from Natural Science Foundation of China (92269202, 82825001, 92054104, 82402593), National Key R&amp;D Program of China (2022YFC2303200, 2022YFC2303502), Strategic Priority Research Program of the Chinese Academy of Sciences (XDB0940102),Three-Year Initiative Plan for Strengthening Public Health System Construction in Shanghai (2023–2025) Key Discipline Project (GWVI-11.1-09), Shanghai Municipal Science and Technology Major Project (2019SHZDZX02), State Key Laboratory of Respiratory Disease Project (J24411029), Guangdong Basic and Applied Basic Research Foundation (2023A1515010152), Young Scientists Fund of the Guangzhou National Laboratory (QNPG23-03), and China Postdoctoral Science Foundation (2024M763413).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>YM</given-names></name><name><surname>Mandourah</surname><given-names>Y</given-names></name><name><surname>Al-Hameed</surname><given-names>F</given-names></name><name><surname>Sindi</surname><given-names>AA</given-names></name><name><surname>Almekhlafi</surname><given-names>GA</given-names></name><name><surname>Hussein</surname><given-names>MA</given-names></name><name><surname>Jose</surname><given-names>J</given-names></name><name><surname>Pinto</surname><given-names>R</given-names></name><name><surname>Al-Omari</surname><given-names>A</given-names></name><name><surname>Kharaba</surname><given-names>A</given-names></name><name><surname>Almotairi</surname><given-names>A</given-names></name><name><surname>Al Khatib</surname><given-names>K</given-names></name><name><surname>Alraddadi</surname><given-names>B</given-names></name><name><surname>Shalhoub</surname><given-names>S</given-names></name><name><surname>Abdulmomen</surname><given-names>A</given-names></name><name><surname>Qushmaq</surname><given-names>I</given-names></name><name><surname>Mady</surname><given-names>A</given-names></name><name><surname>Solaiman</surname><given-names>O</given-names></name><name><surname>Al-Aithan</surname><given-names>AM</given-names></name><name><surname>Al-Raddadi</surname><given-names>R</given-names></name><name><surname>Ragab</surname><given-names>A</given-names></name><name><surname>Balkhy</surname><given-names>HH</given-names></name><name><surname>Al Harthy</surname><given-names>A</given-names></name><name><surname>Deeb</surname><given-names>AM</given-names></name><name><surname>Al Mutairi</surname><given-names>H</given-names></name><name><surname>Al-Dawood</surname><given-names>A</given-names></name><name><surname>Merson</surname><given-names>L</given-names></name><name><surname>Hayden</surname><given-names>FG</given-names></name><name><surname>Fowler</surname><given-names>RA</given-names></name><collab>Saudi Critical Care Trial Group</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Corticosteroid therapy for critically ill patients with middle east respiratory syndrome</article-title><source>American Journal of Respiratory and Critical Care Medicine</source><volume>197</volume><fpage>757</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1164/rccm.201706-1172OC</pub-id><pub-id pub-id-type="pmid">29161116</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnett</surname><given-names>KC</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Asakura</surname><given-names>T</given-names></name><name><surname>Song</surname><given-names>D</given-names></name><name><surname>Liang</surname><given-names>K</given-names></name><name><surname>Taft-Benz</surname><given-names>SA</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Okuda</surname><given-names>K</given-names></name><name><surname>Gilmore</surname><given-names>RC</given-names></name><name><surname>Loome</surname><given-names>JF</given-names></name><name><surname>Oguin Iii</surname><given-names>TH</given-names></name><name><surname>Sempowski</surname><given-names>GD</given-names></name><name><surname>Randell</surname><given-names>SH</given-names></name><name><surname>Heise</surname><given-names>MT</given-names></name><name><surname>Lei</surname><given-names>YL</given-names></name><name><surname>Boucher</surname><given-names>RC</given-names></name><name><surname>Ting</surname><given-names>JP-Y</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>An epithelial-immune circuit amplifies inflammasome and IL-6 responses to SARS-CoV-2</article-title><source>Cell Host &amp; Microbe</source><volume>31</volume><fpage>243</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2022.12.005</pub-id><pub-id pub-id-type="pmid">36563691</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belouzard</surname><given-names>S</given-names></name><name><surname>Chu</surname><given-names>VC</given-names></name><name><surname>Whittaker</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites</article-title><source>PNAS</source><volume>106</volume><fpage>5871</fpage><lpage>5876</lpage><pub-id pub-id-type="doi">10.1073/pnas.0809524106</pub-id><pub-id pub-id-type="pmid">19321428</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanco-Melo</surname><given-names>D</given-names></name><name><surname>Nilsson-Payant</surname><given-names>BE</given-names></name><name><surname>Liu</surname><given-names>WC</given-names></name><name><surname>Uhl</surname><given-names>S</given-names></name><name><surname>Hoagland</surname><given-names>D</given-names></name><name><surname>Møller</surname><given-names>R</given-names></name><name><surname>Jordan</surname><given-names>TX</given-names></name><name><surname>Oishi</surname><given-names>K</given-names></name><name><surname>Panis</surname><given-names>M</given-names></name><name><surname>Sachs</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>TT</given-names></name><name><surname>Schwartz</surname><given-names>RE</given-names></name><name><surname>Lim</surname><given-names>JK</given-names></name><name><surname>Albrecht</surname><given-names>RA</given-names></name><name><surname>tenOever</surname><given-names>BR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Imbalanced host response to SARS-CoV-2 drives development of COVID-19</article-title><source>Cell</source><volume>181</volume><fpage>1036</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.04.026</pub-id><pub-id pub-id-type="pmid">32416070</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bussani</surname><given-names>R</given-names></name><name><surname>Schneider</surname><given-names>E</given-names></name><name><surname>Zentilin</surname><given-names>L</given-names></name><name><surname>Collesi</surname><given-names>C</given-names></name><name><surname>Ali</surname><given-names>H</given-names></name><name><surname>Braga</surname><given-names>L</given-names></name><name><surname>Volpe</surname><given-names>MC</given-names></name><name><surname>Colliva</surname><given-names>A</given-names></name><name><surname>Zanconati</surname><given-names>F</given-names></name><name><surname>Berlot</surname><given-names>G</given-names></name><name><surname>Silvestri</surname><given-names>F</given-names></name><name><surname>Zacchigna</surname><given-names>S</given-names></name><name><surname>Giacca</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology</article-title><source>EBioMedicine</source><volume>61</volume><elocation-id>103104</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2020.103104</pub-id><pub-id pub-id-type="pmid">33158808</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalli</surname><given-names>G</given-names></name><name><surname>De Luca</surname><given-names>G</given-names></name><name><surname>Campochiaro</surname><given-names>C</given-names></name><name><surname>Della-Torre</surname><given-names>E</given-names></name><name><surname>Ripa</surname><given-names>M</given-names></name><name><surname>Canetti</surname><given-names>D</given-names></name><name><surname>Oltolini</surname><given-names>C</given-names></name><name><surname>Castiglioni</surname><given-names>B</given-names></name><name><surname>Tassan Din</surname><given-names>C</given-names></name><name><surname>Boffini</surname><given-names>N</given-names></name><name><surname>Tomelleri</surname><given-names>A</given-names></name><name><surname>Farina</surname><given-names>N</given-names></name><name><surname>Ruggeri</surname><given-names>A</given-names></name><name><surname>Rovere-Querini</surname><given-names>P</given-names></name><name><surname>Di Lucca</surname><given-names>G</given-names></name><name><surname>Martinenghi</surname><given-names>S</given-names></name><name><surname>Scotti</surname><given-names>R</given-names></name><name><surname>Tresoldi</surname><given-names>M</given-names></name><name><surname>Ciceri</surname><given-names>F</given-names></name><name><surname>Landoni</surname><given-names>G</given-names></name><name><surname>Zangrillo</surname><given-names>A</given-names></name><name><surname>Scarpellini</surname><given-names>P</given-names></name><name><surname>Dagna</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study</article-title><source>The Lancet. Rheumatology</source><volume>2</volume><fpage>e325</fpage><lpage>e331</lpage><pub-id pub-id-type="doi">10.1016/S2665-9913(20)30127-2</pub-id><pub-id pub-id-type="pmid">32501454</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>LY</given-names></name><name><surname>Zuraw</surname><given-names>BL</given-names></name><name><surname>Liu</surname><given-names>FT</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Pan</surname><given-names>ZK</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>IL-1 receptor-associated kinase and low molecular weight GTPase RhoA signal molecules are required for bacterial lipopolysaccharide-induced cytokine gene transcription</article-title><source>Journal of Immunology</source><volume>169</volume><fpage>3934</fpage><lpage>3939</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.169.7.3934</pub-id><pub-id pub-id-type="pmid">12244193</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curtis</surname><given-names>JL</given-names></name><name><surname>Warnock</surname><given-names>ML</given-names></name><name><surname>Arraj</surname><given-names>SM</given-names></name><name><surname>Kaltreider</surname><given-names>HB</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Histologic analysis of an immune response in the lung parenchyma of mice. Angiopathy accompanies inflammatory cell influx</article-title><source>The American Journal of Pathology</source><volume>137</volume><fpage>689</fpage><lpage>699</lpage><pub-id pub-id-type="pmid">2399937</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delespaul</surname><given-names>L</given-names></name><name><surname>Gélabert</surname><given-names>C</given-names></name><name><surname>Lesluyes</surname><given-names>T</given-names></name><name><surname>Le Guellec</surname><given-names>S</given-names></name><name><surname>Pérot</surname><given-names>G</given-names></name><name><surname>Leroy</surname><given-names>L</given-names></name><name><surname>Baud</surname><given-names>J</given-names></name><name><surname>Merle</surname><given-names>C</given-names></name><name><surname>Lartigue</surname><given-names>L</given-names></name><name><surname>Chibon</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cell-cell fusion of mesenchymal cells with distinct differentiations triggers genomic and transcriptomic remodelling toward tumour aggressiveness</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>21634</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-78502-z</pub-id><pub-id pub-id-type="pmid">33303824</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Della-Torre</surname><given-names>E</given-names></name><name><surname>Criscuolo</surname><given-names>E</given-names></name><name><surname>Lanzillotta</surname><given-names>M</given-names></name><name><surname>Locatelli</surname><given-names>M</given-names></name><name><surname>Clementi</surname><given-names>N</given-names></name><name><surname>Mancini</surname><given-names>N</given-names></name><name><surname>Dagna</surname><given-names>L</given-names></name><collab>COVID-BioB study group</collab></person-group><year iso-8601-date="2021">2021</year><article-title>IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19</article-title><source>The Lancet. Rheumatology</source><volume>3</volume><fpage>e829</fpage><lpage>e831</lpage><pub-id pub-id-type="doi">10.1016/S2665-9913(21)00321-0</pub-id><pub-id pub-id-type="pmid">34746843</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Paolo</surname><given-names>NC</given-names></name><name><surname>Miao</surname><given-names>EA</given-names></name><name><surname>Iwakura</surname><given-names>Y</given-names></name><name><surname>Murali-Krishna</surname><given-names>K</given-names></name><name><surname>Aderem</surname><given-names>A</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name><name><surname>Papayannopoulou</surname><given-names>T</given-names></name><name><surname>Shayakhmetov</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo</article-title><source>Immunity</source><volume>31</volume><fpage>110</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.04.015</pub-id><pub-id pub-id-type="pmid">19576795</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doherty</surname><given-names>JT</given-names></name><name><surname>Lenhart</surname><given-names>KC</given-names></name><name><surname>Cameron</surname><given-names>MV</given-names></name><name><surname>Mack</surname><given-names>CP</given-names></name><name><surname>Conlon</surname><given-names>FL</given-names></name><name><surname>Taylor</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Skeletal muscle differentiation and fusion are regulated by the BAR-containing Rho-GTPase-activating protein (Rho-GAP), GRAF1</article-title><source>The Journal of Biological Chemistry</source><volume>286</volume><fpage>25903</fpage><lpage>25921</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.243030</pub-id><pub-id pub-id-type="pmid">21622574</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dupraz</surname><given-names>S</given-names></name><name><surname>Hilton</surname><given-names>BJ</given-names></name><name><surname>Husch</surname><given-names>A</given-names></name><name><surname>Santos</surname><given-names>TE</given-names></name><name><surname>Coles</surname><given-names>CH</given-names></name><name><surname>Stern</surname><given-names>S</given-names></name><name><surname>Brakebusch</surname><given-names>C</given-names></name><name><surname>Bradke</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>RhoA controls axon extension independent of specification in the developing brain</article-title><source>Current Biology</source><volume>29</volume><fpage>3874</fpage><lpage>3886</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2019.09.040</pub-id><pub-id pub-id-type="pmid">31679934</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenbarth</surname><given-names>SC</given-names></name><name><surname>Colegio</surname><given-names>OR</given-names></name><name><surname>O’Connor</surname><given-names>W</given-names></name><name><surname>Sutterwala</surname><given-names>FS</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants</article-title><source>Nature</source><volume>453</volume><fpage>1122</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1038/nature06939</pub-id><pub-id pub-id-type="pmid">18496530</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García-García</surname><given-names>A</given-names></name><name><surname>Pérez de Diego</surname><given-names>R</given-names></name><name><surname>Flores</surname><given-names>C</given-names></name><name><surname>Rinchai</surname><given-names>D</given-names></name><name><surname>Solé-Violán</surname><given-names>J</given-names></name><name><surname>Deyà-Martínez</surname><given-names>À</given-names></name><name><surname>García-Solis</surname><given-names>B</given-names></name><name><surname>Lorenzo-Salazar</surname><given-names>JM</given-names></name><name><surname>Hernández-Brito</surname><given-names>E</given-names></name><name><surname>Lanz</surname><given-names>A-L</given-names></name><name><surname>Moens</surname><given-names>L</given-names></name><name><surname>Bucciol</surname><given-names>G</given-names></name><name><surname>Almuqamam</surname><given-names>M</given-names></name><name><surname>Domachowske</surname><given-names>JB</given-names></name><name><surname>Colino</surname><given-names>E</given-names></name><name><surname>Santos-Perez</surname><given-names>JL</given-names></name><name><surname>Marco</surname><given-names>FM</given-names></name><name><surname>Pignata</surname><given-names>C</given-names></name><name><surname>Bousfiha</surname><given-names>A</given-names></name><name><surname>Turvey</surname><given-names>SE</given-names></name><name><surname>Bauer</surname><given-names>S</given-names></name><name><surname>Haerynck</surname><given-names>F</given-names></name><name><surname>Ocejo-Vinyals</surname><given-names>JG</given-names></name><name><surname>Lendinez</surname><given-names>F</given-names></name><name><surname>Prader</surname><given-names>S</given-names></name><name><surname>Naumann-Bartsch</surname><given-names>N</given-names></name><name><surname>Pachlopnik Schmid</surname><given-names>J</given-names></name><name><surname>Biggs</surname><given-names>CM</given-names></name><name><surname>Hildebrand</surname><given-names>K</given-names></name><name><surname>Dreesman</surname><given-names>A</given-names></name><name><surname>Cárdenes</surname><given-names>MÁ</given-names></name><name><surname>Ailal</surname><given-names>F</given-names></name><name><surname>Benhsaien</surname><given-names>I</given-names></name><name><surname>Giardino</surname><given-names>G</given-names></name><name><surname>Molina-Fuentes</surname><given-names>A</given-names></name><name><surname>Fortuny</surname><given-names>C</given-names></name><name><surname>Madhavarapu</surname><given-names>S</given-names></name><name><surname>Conway</surname><given-names>DH</given-names></name><name><surname>Prando</surname><given-names>C</given-names></name><name><surname>Schidlowski</surname><given-names>L</given-names></name><name><surname>Martínez de Saavedra Álvarez</surname><given-names>MT</given-names></name><name><surname>Alfaro</surname><given-names>R</given-names></name><name><surname>Rodríguez de Castro</surname><given-names>F</given-names></name><collab>ESID Registry Working Party</collab><collab>COVID Human Genetic Effort</collab><name><surname>Meyts</surname><given-names>I</given-names></name><name><surname>Hauck</surname><given-names>F</given-names></name><name><surname>Puel</surname><given-names>A</given-names></name><name><surname>Bastard</surname><given-names>P</given-names></name><name><surname>Boisson</surname><given-names>B</given-names></name><name><surname>Jouanguy</surname><given-names>E</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name><name><surname>Cobat</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Casanova</surname><given-names>J-L</given-names></name><name><surname>Alsina</surname><given-names>L</given-names></name><name><surname>Rodríguez-Gallego</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Humans with inherited MyD88 and IRAK-4 deficiencies are predisposed to hypoxemic COVID-19 pneumonia</article-title><source>The Journal of Experimental Medicine</source><volume>220</volume><elocation-id>e20220170</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20220170</pub-id><pub-id pub-id-type="pmid">36880831</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadjadj</surname><given-names>J</given-names></name><name><surname>Yatim</surname><given-names>N</given-names></name><name><surname>Barnabei</surname><given-names>L</given-names></name><name><surname>Corneau</surname><given-names>A</given-names></name><name><surname>Boussier</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>N</given-names></name><name><surname>Péré</surname><given-names>H</given-names></name><name><surname>Charbit</surname><given-names>B</given-names></name><name><surname>Bondet</surname><given-names>V</given-names></name><name><surname>Chenevier-Gobeaux</surname><given-names>C</given-names></name><name><surname>Breillat</surname><given-names>P</given-names></name><name><surname>Carlier</surname><given-names>N</given-names></name><name><surname>Gauzit</surname><given-names>R</given-names></name><name><surname>Morbieu</surname><given-names>C</given-names></name><name><surname>Pène</surname><given-names>F</given-names></name><name><surname>Marin</surname><given-names>N</given-names></name><name><surname>Roche</surname><given-names>N</given-names></name><name><surname>Szwebel</surname><given-names>T-A</given-names></name><name><surname>Merkling</surname><given-names>SH</given-names></name><name><surname>Treluyer</surname><given-names>J-M</given-names></name><name><surname>Veyer</surname><given-names>D</given-names></name><name><surname>Mouthon</surname><given-names>L</given-names></name><name><surname>Blanc</surname><given-names>C</given-names></name><name><surname>Tharaux</surname><given-names>P-L</given-names></name><name><surname>Rozenberg</surname><given-names>F</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Duffy</surname><given-names>D</given-names></name><name><surname>Rieux-Laucat</surname><given-names>F</given-names></name><name><surname>Kernéis</surname><given-names>S</given-names></name><name><surname>Terrier</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients</article-title><source>Science</source><volume>369</volume><fpage>718</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1126/science.abc6027</pub-id><pub-id pub-id-type="pmid">32661059</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Alameh</surname><given-names>M-G</given-names></name><name><surname>Butowska</surname><given-names>K</given-names></name><name><surname>Knox</surname><given-names>JJ</given-names></name><name><surname>Lundgreen</surname><given-names>K</given-names></name><name><surname>Ghattas</surname><given-names>M</given-names></name><name><surname>Gong</surname><given-names>N</given-names></name><name><surname>Xue</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Lavertu</surname><given-names>M</given-names></name><name><surname>Bates</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Nie</surname><given-names>G</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Weissman</surname><given-names>D</given-names></name><name><surname>Mitchell</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines</article-title><source>Nature Nanotechnology</source><volume>18</volume><fpage>1105</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.1038/s41565-023-01404-4</pub-id><pub-id pub-id-type="pmid">37365276</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilligan</surname><given-names>KL</given-names></name><name><surname>Namasivayam</surname><given-names>S</given-names></name><name><surname>Clancy</surname><given-names>CS</given-names></name><name><surname>O’Mard</surname><given-names>D</given-names></name><name><surname>Oland</surname><given-names>SD</given-names></name><name><surname>Robertson</surname><given-names>SJ</given-names></name><name><surname>Baker</surname><given-names>PJ</given-names></name><name><surname>Castro</surname><given-names>E</given-names></name><name><surname>Garza</surname><given-names>NL</given-names></name><name><surname>Lafont</surname><given-names>BAP</given-names></name><name><surname>Johnson</surname><given-names>R</given-names></name><name><surname>Ronchese</surname><given-names>F</given-names></name><name><surname>Mayer-Barber</surname><given-names>KD</given-names></name><name><surname>Best</surname><given-names>SM</given-names></name><name><surname>Sher</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Intravenous administration of BCG protects mice against lethal SARS-CoV-2 challenge</article-title><source>The Journal of Experimental Medicine</source><volume>219</volume><elocation-id>e20211862</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20211862</pub-id><pub-id pub-id-type="pmid">34889942</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huet</surname><given-names>T</given-names></name><name><surname>Beaussier</surname><given-names>H</given-names></name><name><surname>Voisin</surname><given-names>O</given-names></name><name><surname>Jouveshomme</surname><given-names>S</given-names></name><name><surname>Dauriat</surname><given-names>G</given-names></name><name><surname>Lazareth</surname><given-names>I</given-names></name><name><surname>Sacco</surname><given-names>E</given-names></name><name><surname>Naccache</surname><given-names>J-M</given-names></name><name><surname>Bézie</surname><given-names>Y</given-names></name><name><surname>Laplanche</surname><given-names>S</given-names></name><name><surname>Le Berre</surname><given-names>A</given-names></name><name><surname>Le Pavec</surname><given-names>J</given-names></name><name><surname>Salmeron</surname><given-names>S</given-names></name><name><surname>Emmerich</surname><given-names>J</given-names></name><name><surname>Mourad</surname><given-names>J-J</given-names></name><name><surname>Chatellier</surname><given-names>G</given-names></name><name><surname>Hayem</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Anakinra for severe forms of COVID-19: a cohort study</article-title><source>The Lancet. Rheumatology</source><volume>2</volume><fpage>e393</fpage><lpage>e400</lpage><pub-id pub-id-type="doi">10.1016/S2665-9913(20)30164-8</pub-id><pub-id pub-id-type="pmid">32835245</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karki</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>BR</given-names></name><name><surname>Tuladhar</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>EP</given-names></name><name><surname>Zalduondo</surname><given-names>L</given-names></name><name><surname>Samir</surname><given-names>P</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Sundaram</surname><given-names>B</given-names></name><name><surname>Banoth</surname><given-names>B</given-names></name><name><surname>Malireddi</surname><given-names>RKS</given-names></name><name><surname>Schreiner</surname><given-names>P</given-names></name><name><surname>Neale</surname><given-names>G</given-names></name><name><surname>Vogel</surname><given-names>P</given-names></name><name><surname>Webby</surname><given-names>R</given-names></name><name><surname>Jonsson</surname><given-names>CB</given-names></name><name><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes</article-title><source>Cell</source><volume>184</volume><fpage>149</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.11.025</pub-id><pub-id pub-id-type="pmid">33278357</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N</given-names></name><name><surname>Allen Chan</surname><given-names>KC</given-names></name><name><surname>Hui</surname><given-names>DS</given-names></name><name><surname>Ng</surname><given-names>EKO</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name><name><surname>Chiu</surname><given-names>RWK</given-names></name><name><surname>Wong</surname><given-names>VWS</given-names></name><name><surname>Chan</surname><given-names>PKS</given-names></name><name><surname>Wong</surname><given-names>KT</given-names></name><name><surname>Wong</surname><given-names>E</given-names></name><name><surname>Cockram</surname><given-names>CS</given-names></name><name><surname>Tam</surname><given-names>JS</given-names></name><name><surname>Sung</surname><given-names>JJY</given-names></name><name><surname>Lo</surname><given-names>YMD</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients</article-title><source>Journal of Clinical Virology</source><volume>31</volume><fpage>304</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2004.07.006</pub-id><pub-id pub-id-type="pmid">15494274</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Floyd</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>Tan</surname><given-names>TK</given-names></name><name><surname>Froggatt</surname><given-names>HM</given-names></name><name><surname>Powers</surname><given-names>JM</given-names></name><name><surname>Leist</surname><given-names>SR</given-names></name><name><surname>Gully</surname><given-names>KL</given-names></name><name><surname>Hubbard</surname><given-names>ML</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Hui</surname><given-names>H</given-names></name><name><surname>Scoville</surname><given-names>D</given-names></name><name><surname>Ruggiero</surname><given-names>AD</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Pavenko</surname><given-names>A</given-names></name><name><surname>Lujan</surname><given-names>V</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name><name><surname>Nolan</surname><given-names>GP</given-names></name><name><surname>Arunachalam</surname><given-names>PS</given-names></name><name><surname>Suthar</surname><given-names>MS</given-names></name><name><surname>Pulendran</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>BCG vaccination stimulates integrated organ immunity by feedback of the adaptive immune response to imprint prolonged innate antiviral resistance</article-title><source>Nature Immunology</source><volume>25</volume><fpage>41</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1038/s41590-023-01700-0</pub-id><pub-id pub-id-type="pmid">38036767</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Peng</surname><given-names>W</given-names></name><name><surname>Chang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Fan</surname><given-names>Z</given-names></name><name><surname>Chai</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Lei</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Hao</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Tan</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>GF</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>An engineered bispecific human monoclonal antibody against SARS-CoV-2</article-title><source>Nature Immunology</source><volume>23</volume><fpage>423</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1038/s41590-022-01138-w</pub-id><pub-id pub-id-type="pmid">35228696</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martínez-Mármol</surname><given-names>R</given-names></name><name><surname>Giordano-Santini</surname><given-names>R</given-names></name><name><surname>Kaulich</surname><given-names>E</given-names></name><name><surname>Cho</surname><given-names>A-N</given-names></name><name><surname>Przybyla</surname><given-names>M</given-names></name><name><surname>Riyadh</surname><given-names>MA</given-names></name><name><surname>Robinson</surname><given-names>E</given-names></name><name><surname>Chew</surname><given-names>KY</given-names></name><name><surname>Amor</surname><given-names>R</given-names></name><name><surname>Meunier</surname><given-names>FA</given-names></name><name><surname>Balistreri</surname><given-names>G</given-names></name><name><surname>Short</surname><given-names>KR</given-names></name><name><surname>Ke</surname><given-names>YD</given-names></name><name><surname>Ittner</surname><given-names>LM</given-names></name><name><surname>Hilliard</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>SARS-CoV-2 infection and viral fusogens cause neuronal and glial fusion that compromises neuronal activity</article-title><source>Science Advances</source><volume>9</volume><elocation-id>eadg2248</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.adg2248</pub-id><pub-id pub-id-type="pmid">37285437</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Toll-like receptors and innate immunity</article-title><source>Nature Reviews. Immunology</source><volume>1</volume><fpage>135</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1038/35100529</pub-id><pub-id pub-id-type="pmid">11905821</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishiyama</surname><given-names>T</given-names></name><name><surname>Kii</surname><given-names>I</given-names></name><name><surname>Kudo</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Inactivation of Rho/ROCK signaling is crucial for the nuclear accumulation of FKHR and myoblast fusion</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>47311</fpage><lpage>47319</lpage><pub-id pub-id-type="doi">10.1074/jbc.M403546200</pub-id><pub-id pub-id-type="pmid">15322110</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nobes</surname><given-names>CD</given-names></name><name><surname>Hall</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Rho GTPases control polarity, protrusion, and adhesion during cell movement</article-title><source>The Journal of Cell Biology</source><volume>144</volume><fpage>1235</fpage><lpage>1244</lpage><pub-id pub-id-type="doi">10.1083/jcb.144.6.1235</pub-id><pub-id pub-id-type="pmid">10087266</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfaender</surname><given-names>S</given-names></name><name><surname>Mar</surname><given-names>KB</given-names></name><name><surname>Michailidis</surname><given-names>E</given-names></name><name><surname>Kratzel</surname><given-names>A</given-names></name><name><surname>Boys</surname><given-names>IN</given-names></name><name><surname>V’kovski</surname><given-names>P</given-names></name><name><surname>Fan</surname><given-names>W</given-names></name><name><surname>Kelly</surname><given-names>JN</given-names></name><name><surname>Hirt</surname><given-names>D</given-names></name><name><surname>Ebert</surname><given-names>N</given-names></name><name><surname>Stalder</surname><given-names>H</given-names></name><name><surname>Kleine-Weber</surname><given-names>H</given-names></name><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Hoffmann</surname><given-names>H-H</given-names></name><name><surname>Saeed</surname><given-names>M</given-names></name><name><surname>Dijkman</surname><given-names>R</given-names></name><name><surname>Steinmann</surname><given-names>E</given-names></name><name><surname>Wight-Carter</surname><given-names>M</given-names></name><name><surname>McDougal</surname><given-names>MB</given-names></name><name><surname>Hanners</surname><given-names>NW</given-names></name><name><surname>Pöhlmann</surname><given-names>S</given-names></name><name><surname>Gallagher</surname><given-names>T</given-names></name><name><surname>Todt</surname><given-names>D</given-names></name><name><surname>Zimmer</surname><given-names>G</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name><name><surname>Schoggins</surname><given-names>JW</given-names></name><name><surname>Thiel</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>LY6E impairs coronavirus fusion and confers immune control of viral disease</article-title><source>Nature Microbiology</source><volume>5</volume><fpage>1330</fpage><lpage>1339</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0769-y</pub-id><pub-id pub-id-type="pmid">32704094</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>AE</given-names></name><name><surname>Anderson</surname><given-names>EC</given-names></name><name><surname>Davies</surname><given-names>PS</given-names></name><name><surname>Silk</surname><given-names>AD</given-names></name><name><surname>Pelz</surname><given-names>C</given-names></name><name><surname>Impey</surname><given-names>S</given-names></name><name><surname>Wong</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Fusion between Intestinal epithelial cells and macrophages in a cancer context results in nuclear reprogramming</article-title><source>Cancer Research</source><volume>71</volume><fpage>1497</fpage><lpage>1505</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-3223</pub-id><pub-id pub-id-type="pmid">21303980</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Priya</surname><given-names>R</given-names></name><name><surname>Gomez</surname><given-names>GA</given-names></name><name><surname>Budnar</surname><given-names>S</given-names></name><name><surname>Verma</surname><given-names>S</given-names></name><name><surname>Cox</surname><given-names>HL</given-names></name><name><surname>Hamilton</surname><given-names>NA</given-names></name><name><surname>Yap</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Feedback regulation through myosin II confers robustness on RhoA signalling at E-cadherin junctions</article-title><source>Nature Cell Biology</source><volume>17</volume><fpage>1282</fpage><lpage>1293</lpage><pub-id pub-id-type="doi">10.1038/ncb3239</pub-id><pub-id pub-id-type="pmid">26368311</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajah</surname><given-names>MM</given-names></name><name><surname>Bernier</surname><given-names>A</given-names></name><name><surname>Buchrieser</surname><given-names>J</given-names></name><name><surname>Schwartz</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The mechanism and consequences of SARS-CoV-2 spike-mediated fusion and syncytia formation</article-title><source>Journal of Molecular Biology</source><volume>434</volume><elocation-id>e167280</elocation-id><pub-id pub-id-type="doi">10.1016/j.jmb.2021.167280</pub-id><pub-id pub-id-type="pmid">34606831</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>X</given-names></name><name><surname>Wen</surname><given-names>W</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Hou</surname><given-names>W</given-names></name><name><surname>Su</surname><given-names>B</given-names></name><name><surname>Cai</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Cao</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>G</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>W</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Gan</surname><given-names>R</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y-M</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Ling</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>S-Q</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Song</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>Xing</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Yin</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Zhong</surname><given-names>S</given-names></name><name><surname>Zhong</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>P</given-names></name><name><surname>Zou</surname><given-names>B</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Zuo</surname><given-names>Z</given-names></name><name><surname>Bai</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Jiang</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Bei</surname><given-names>J-X</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Bian</surname><given-names>X-W</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>F-S</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Su</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Qu</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas</article-title><source>Cell</source><volume>184</volume><fpage>1895</fpage><lpage>1913</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.01.053</pub-id><pub-id pub-id-type="pmid">33657410</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riento</surname><given-names>K</given-names></name><name><surname>Ridley</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Rocks: multifunctional kinases in cell behaviour</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>4</volume><fpage>446</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1038/nrm1128</pub-id><pub-id pub-id-type="pmid">12778124</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivas</surname><given-names>MN</given-names></name><name><surname>Ebinger</surname><given-names>JE</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>N</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name><name><surname>Sobhani</surname><given-names>K</given-names></name><name><surname>Van Eyk</surname><given-names>JE</given-names></name><name><surname>Cheng</surname><given-names>S</given-names></name><name><surname>Arditi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers</article-title><source>The Journal of Clinical Investigation</source><volume>131</volume><elocation-id>e145157</elocation-id><pub-id pub-id-type="doi">10.1172/JCI145157</pub-id><pub-id pub-id-type="pmid">33211672</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodríguez-Pérez</surname><given-names>F</given-names></name><name><surname>Manford</surname><given-names>AG</given-names></name><name><surname>Pogson</surname><given-names>A</given-names></name><name><surname>Ingersoll</surname><given-names>AJ</given-names></name><name><surname>Martínez-González</surname><given-names>B</given-names></name><name><surname>Rape</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Ubiquitin-dependent remodeling of the actin cytoskeleton drives cell fusion</article-title><source>Developmental Cell</source><volume>56</volume><fpage>588</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2021.01.016</pub-id><pub-id pub-id-type="pmid">33609460</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sefik</surname><given-names>E</given-names></name><name><surname>Qu</surname><given-names>R</given-names></name><name><surname>Junqueira</surname><given-names>C</given-names></name><name><surname>Kaffe</surname><given-names>E</given-names></name><name><surname>Mirza</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Brewer</surname><given-names>JR</given-names></name><name><surname>Han</surname><given-names>A</given-names></name><name><surname>Steach</surname><given-names>HR</given-names></name><name><surname>Israelow</surname><given-names>B</given-names></name><name><surname>Blackburn</surname><given-names>HN</given-names></name><name><surname>Velazquez</surname><given-names>SE</given-names></name><name><surname>Chen</surname><given-names>YG</given-names></name><name><surname>Halene</surname><given-names>S</given-names></name><name><surname>Iwasaki</surname><given-names>A</given-names></name><name><surname>Meffre</surname><given-names>E</given-names></name><name><surname>Nussenzweig</surname><given-names>M</given-names></name><name><surname>Lieberman</surname><given-names>J</given-names></name><name><surname>Wilen</surname><given-names>CB</given-names></name><name><surname>Kluger</surname><given-names>Y</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Inflammasome activation in infected macrophages drives COVID-19 pathology</article-title><source>Nature</source><volume>606</volume><fpage>585</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04802-1</pub-id><pub-id pub-id-type="pmid">35483404</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stern</surname><given-names>S</given-names></name><name><surname>Hilton</surname><given-names>BJ</given-names></name><name><surname>Burnside</surname><given-names>ER</given-names></name><name><surname>Dupraz</surname><given-names>S</given-names></name><name><surname>Handley</surname><given-names>EE</given-names></name><name><surname>Gonyer</surname><given-names>JM</given-names></name><name><surname>Brakebusch</surname><given-names>C</given-names></name><name><surname>Bradke</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>RhoA drives actin compaction to restrict axon regeneration and astrocyte reactivity after CNS injury</article-title><source>Neuron</source><volume>109</volume><fpage>3436</fpage><lpage>3455</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2021.08.014</pub-id><pub-id pub-id-type="pmid">34508667</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Straus</surname><given-names>MR</given-names></name><name><surname>Tang</surname><given-names>T</given-names></name><name><surname>Lai</surname><given-names>AL</given-names></name><name><surname>Flegel</surname><given-names>A</given-names></name><name><surname>Bidon</surname><given-names>M</given-names></name><name><surname>Freed</surname><given-names>JH</given-names></name><name><surname>Daniel</surname><given-names>S</given-names></name><name><surname>Whittaker</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Ca<sup>2+</sup> ions promote fusion of middle east respiratory syndrome coronavirus with host cells and increase infectivity</article-title><source>Journal of Virology</source><volume>94</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.00426-20</pub-id><pub-id pub-id-type="pmid">32295925</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Guan</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>I-J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>J-Q</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mechanistic insights into the anchorage of the contractile ring by anillin and Mid1</article-title><source>Developmental Cell</source><volume>33</volume><fpage>413</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2015.03.003</pub-id><pub-id pub-id-type="pmid">25959226</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahtinen</surname><given-names>S</given-names></name><name><surname>Tong</surname><given-names>A-J</given-names></name><name><surname>Himmels</surname><given-names>P</given-names></name><name><surname>Oh</surname><given-names>J</given-names></name><name><surname>Paler-Martinez</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>L</given-names></name><name><surname>Wichner</surname><given-names>S</given-names></name><name><surname>Oei</surname><given-names>Y</given-names></name><name><surname>McCarron</surname><given-names>MJ</given-names></name><name><surname>Freund</surname><given-names>EC</given-names></name><name><surname>Amir</surname><given-names>ZA</given-names></name><name><surname>de la Cruz</surname><given-names>CC</given-names></name><name><surname>Haley</surname><given-names>B</given-names></name><name><surname>Blanchette</surname><given-names>C</given-names></name><name><surname>Schartner</surname><given-names>JM</given-names></name><name><surname>Ye</surname><given-names>W</given-names></name><name><surname>Yadav</surname><given-names>M</given-names></name><name><surname>Sahin</surname><given-names>U</given-names></name><name><surname>Delamarre</surname><given-names>L</given-names></name><name><surname>Mellman</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines</article-title><source>Nature Immunology</source><volume>23</volume><fpage>532</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1038/s41590-022-01160-y</pub-id><pub-id pub-id-type="pmid">35332327</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tharaux</surname><given-names>PL</given-names></name><name><surname>Pialoux</surname><given-names>G</given-names></name><name><surname>Pavot</surname><given-names>A</given-names></name><name><surname>Mariette</surname><given-names>X</given-names></name><name><surname>Hermine</surname><given-names>O</given-names></name><name><surname>Resche-Rigon</surname><given-names>M</given-names></name><name><surname>Porcher</surname><given-names>R</given-names></name><name><surname>Ravaud</surname><given-names>P</given-names></name><name><surname>Bureau</surname><given-names>S</given-names></name><name><surname>Dougados</surname><given-names>M</given-names></name><name><surname>Tibi</surname><given-names>A</given-names></name><name><surname>Azoulay</surname><given-names>E</given-names></name><name><surname>Cadranel</surname><given-names>J</given-names></name><name><surname>Emmerich</surname><given-names>J</given-names></name><name><surname>Fartoukh</surname><given-names>M</given-names></name><name><surname>Guidet</surname><given-names>B</given-names></name><name><surname>Humbert</surname><given-names>M</given-names></name><name><surname>Lacombe</surname><given-names>K</given-names></name><name><surname>Mahevas</surname><given-names>M</given-names></name><name><surname>Pene</surname><given-names>F</given-names></name><name><surname>Pourchet-Martinez</surname><given-names>V</given-names></name><name><surname>Schlemmer</surname><given-names>F</given-names></name><name><surname>Yazdanpanah</surname><given-names>Y</given-names></name><name><surname>Baron</surname><given-names>G</given-names></name><name><surname>Perrodeau</surname><given-names>E</given-names></name><name><surname>Vanhoye</surname><given-names>D</given-names></name><name><surname>Kedzia</surname><given-names>C</given-names></name><name><surname>Demerville</surname><given-names>L</given-names></name><name><surname>Gysembergh-Houal</surname><given-names>A</given-names></name><name><surname>Bourgoin</surname><given-names>A</given-names></name><name><surname>Dalibey</surname><given-names>S</given-names></name><name><surname>Raked</surname><given-names>N</given-names></name><name><surname>Mameri</surname><given-names>L</given-names></name><name><surname>Alary</surname><given-names>S</given-names></name><name><surname>Hamiria</surname><given-names>S</given-names></name><name><surname>Bariz</surname><given-names>T</given-names></name><name><surname>Semri</surname><given-names>H</given-names></name><name><surname>Hai</surname><given-names>DM</given-names></name><name><surname>Benafla</surname><given-names>M</given-names></name><name><surname>Belloul</surname><given-names>M</given-names></name><name><surname>Vauboin</surname><given-names>P</given-names></name><name><surname>Flamand</surname><given-names>S</given-names></name><name><surname>Pacheco</surname><given-names>C</given-names></name><name><surname>Walter-Petrich</surname><given-names>A</given-names></name><name><surname>Stan</surname><given-names>E</given-names></name><name><surname>Benarab</surname><given-names>S</given-names></name><name><surname>Nyanou</surname><given-names>C</given-names></name><name><surname>Montlahuc</surname><given-names>C</given-names></name><name><surname>Biard</surname><given-names>L</given-names></name><name><surname>Charreteur</surname><given-names>R</given-names></name><name><surname>Dupré</surname><given-names>C</given-names></name><name><surname>Cardet</surname><given-names>K</given-names></name><name><surname>Lehmann</surname><given-names>B</given-names></name><name><surname>Baghli</surname><given-names>K</given-names></name><name><surname>Madelaine</surname><given-names>C</given-names></name><name><surname>D’Ortenzio</surname><given-names>E</given-names></name><name><surname>Puéchal</surname><given-names>O</given-names></name><name><surname>Semaille</surname><given-names>C</given-names></name><name><surname>Savale</surname><given-names>L</given-names></name><name><surname>Harrois</surname><given-names>A</given-names></name><name><surname>Figueiredo</surname><given-names>S</given-names></name><name><surname>Duranteau</surname><given-names>J</given-names></name><name><surname>Anguel</surname><given-names>N</given-names></name><name><surname>Monnet</surname><given-names>X</given-names></name><name><surname>Richard</surname><given-names>C</given-names></name><name><surname>Teboul</surname><given-names>JL</given-names></name><name><surname>Durand</surname><given-names>P</given-names></name><name><surname>Tissieres</surname><given-names>P</given-names></name><name><surname>Jevnikar</surname><given-names>M</given-names></name><name><surname>Montani</surname><given-names>D</given-names></name><name><surname>Bulifon</surname><given-names>S</given-names></name><name><surname>Jaïs</surname><given-names>X</given-names></name><name><surname>Sitbon</surname><given-names>O</given-names></name><name><surname>Pavy</surname><given-names>S</given-names></name><name><surname>Noel</surname><given-names>N</given-names></name><name><surname>Lambotte</surname><given-names>O</given-names></name><name><surname>Escaut</surname><given-names>L</given-names></name><name><surname>Jauréguiberry</surname><given-names>S</given-names></name><name><surname>Baudry</surname><given-names>E</given-names></name><name><surname>Verny</surname><given-names>C</given-names></name><name><surname>Noaillon</surname><given-names>M</given-names></name><name><surname>Lefèvre</surname><given-names>E</given-names></name><name><surname>Zaidan</surname><given-names>M</given-names></name><name><surname>Le Tiec</surname><given-names>CLT</given-names></name><name><surname>Verstuyft</surname><given-names>CV</given-names></name><name><surname>Roques</surname><given-names>AM</given-names></name><name><surname>Grimaldi</surname><given-names>L</given-names></name><name><surname>Molinari</surname><given-names>D</given-names></name><name><surname>Leprun</surname><given-names>G</given-names></name><name><surname>Fourreau</surname><given-names>A</given-names></name><name><surname>Cylly</surname><given-names>L</given-names></name><name><surname>Virlouvet</surname><given-names>M</given-names></name><name><surname>Meftali</surname><given-names>R</given-names></name><name><surname>Fabre</surname><given-names>S</given-names></name><name><surname>Licois</surname><given-names>M</given-names></name><name><surname>Mamoune</surname><given-names>A</given-names></name><name><surname>Boudali</surname><given-names>Y</given-names></name><name><surname>Georgin-Lavialle</surname><given-names>S</given-names></name><name><surname>Senet</surname><given-names>P</given-names></name><name><surname>Soria</surname><given-names>A</given-names></name><name><surname>Parrot</surname><given-names>A</given-names></name><name><surname>François</surname><given-names>H</given-names></name><name><surname>Rozensztajn</surname><given-names>N</given-names></name><name><surname>Blin</surname><given-names>E</given-names></name><name><surname>Choinier</surname><given-names>P</given-names></name><name><surname>Camuset</surname><given-names>J</given-names></name><name><surname>Rech</surname><given-names>JS</given-names></name><name><surname>Canellas</surname><given-names>A</given-names></name><name><surname>Rolland-Debord</surname><given-names>C</given-names></name><name><surname>Lemarié</surname><given-names>N</given-names></name><name><surname>Belaube</surname><given-names>N</given-names></name><name><surname>Nadal</surname><given-names>M</given-names></name><name><surname>Siguier</surname><given-names>M</given-names></name><name><surname>Petit-Hoang</surname><given-names>C</given-names></name><name><surname>Chas</surname><given-names>J</given-names></name><name><surname>Drouet</surname><given-names>E</given-names></name><name><surname>Lemoine</surname><given-names>M</given-names></name><name><surname>Phibel</surname><given-names>A</given-names></name><name><surname>Aunay</surname><given-names>L</given-names></name><name><surname>Bertrand</surname><given-names>E</given-names></name><name><surname>Ravato</surname><given-names>S</given-names></name><name><surname>Vayssettes</surname><given-names>M</given-names></name><name><surname>Adda</surname><given-names>A</given-names></name><name><surname>Wilpotte</surname><given-names>C</given-names></name><name><surname>Thibaut</surname><given-names>P</given-names></name><name><surname>Fillon</surname><given-names>J</given-names></name><name><surname>Debrix</surname><given-names>I</given-names></name><name><surname>Fellahi</surname><given-names>S</given-names></name><name><surname>Bastard</surname><given-names>JP</given-names></name><name><surname>Lefèvre</surname><given-names>G</given-names></name><name><surname>Fallet</surname><given-names>V</given-names></name><name><surname>Gottenberg</surname><given-names>JE</given-names></name><name><surname>Hansmann</surname><given-names>Y</given-names></name><name><surname>Andres</surname><given-names>E</given-names></name><name><surname>Bayer</surname><given-names>S</given-names></name><name><surname>Becker</surname><given-names>G</given-names></name><name><surname>Blanc</surname><given-names>F</given-names></name><name><surname>Brin</surname><given-names>S</given-names></name><name><surname>Castelain</surname><given-names>V</given-names></name><name><surname>Chatelus</surname><given-names>E</given-names></name><name><surname>Chatron</surname><given-names>E</given-names></name><name><surname>Collange</surname><given-names>O</given-names></name><name><surname>Danion</surname><given-names>F</given-names></name><name><surname>De Blay</surname><given-names>F</given-names></name><name><surname>Demonsant</surname><given-names>E</given-names></name><name><surname>Diemunsch</surname><given-names>P</given-names></name><name><surname>Diemunsch</surname><given-names>S</given-names></name><name><surname>Felten</surname><given-names>R</given-names></name><name><surname>Goichot</surname><given-names>B</given-names></name><name><surname>Greigert</surname><given-names>V</given-names></name><name><surname>Guffroy</surname><given-names>A</given-names></name><name><surname>Heger</surname><given-names>B</given-names></name><name><surname>Hutt</surname><given-names>A</given-names></name><name><surname>Kaeuffer</surname><given-names>C</given-names></name><name><surname>Kassegne</surname><given-names>L</given-names></name><name><surname>Korganow</surname><given-names>AS</given-names></name><name><surname>Le Borgne</surname><given-names>P</given-names></name><name><surname>Lefebvre</surname><given-names>N</given-names></name><name><surname>Martin</surname><given-names>T</given-names></name><name><surname>Mertes</surname><given-names>PM</given-names></name><name><surname>Metzger</surname><given-names>C</given-names></name><name><surname>Meyer</surname><given-names>N</given-names></name><name><surname>Nisand</surname><given-names>G</given-names></name><name><surname>Noll</surname><given-names>E</given-names></name><name><surname>Oberlin</surname><given-names>M</given-names></name><name><surname>Ohlmann-Caillard</surname><given-names>S</given-names></name><name><surname>Poindron</surname><given-names>V</given-names></name><name><surname>Pottecher</surname><given-names>J</given-names></name><name><surname>Ruch</surname><given-names>Y</given-names></name><name><surname>Sublon</surname><given-names>C</given-names></name><name><surname>Tayebi</surname><given-names>H</given-names></name><name><surname>Weill</surname><given-names>F</given-names></name><name><surname>Mekinian</surname><given-names>A</given-names></name><name><surname>Chopin</surname><given-names>D</given-names></name><name><surname>Fain</surname><given-names>O</given-names></name><name><surname>Garnier</surname><given-names>M</given-names></name><name><surname>Krause le Garrec</surname><given-names>J</given-names></name><name><surname>Morgand</surname><given-names>M</given-names></name><name><surname>Pacanowski</surname><given-names>J</given-names></name><name><surname>Urbina</surname><given-names>T</given-names></name><name><surname>McAvoy</surname><given-names>C</given-names></name><name><surname>Pereira</surname><given-names>M</given-names></name><name><surname>Aratus</surname><given-names>G</given-names></name><name><surname>Berard</surname><given-names>L</given-names></name><name><surname>Simon</surname><given-names>T</given-names></name><name><surname>Daguenel-Nguyen</surname><given-names>A</given-names></name><name><surname>Antignac</surname><given-names>M</given-names></name><name><surname>Leplay</surname><given-names>C</given-names></name><name><surname>Arlet</surname><given-names>JB</given-names></name><name><surname>Diehl</surname><given-names>JL</given-names></name><name><surname>Bellenfant</surname><given-names>F</given-names></name><name><surname>Blanchard</surname><given-names>A</given-names></name><name><surname>Buffet</surname><given-names>A</given-names></name><name><surname>Cholley</surname><given-names>B</given-names></name><name><surname>Fayol</surname><given-names>A</given-names></name><name><surname>Flamarion</surname><given-names>E</given-names></name><name><surname>Godier</surname><given-names>A</given-names></name><name><surname>Gorget</surname><given-names>T</given-names></name><name><surname>Hamada</surname><given-names>SR</given-names></name><name><surname>Hauw-Berlemont</surname><given-names>C</given-names></name><name><surname>Hulot</surname><given-names>JS</given-names></name><name><surname>Lebeaux</surname><given-names>D</given-names></name><name><surname>Livrozet</surname><given-names>M</given-names></name><name><surname>Michon</surname><given-names>A</given-names></name><name><surname>Neuschwander</surname><given-names>A</given-names></name><name><surname>Penet</surname><given-names>MA</given-names></name><name><surname>Planquette</surname><given-names>B</given-names></name><name><surname>Ranque</surname><given-names>B</given-names></name><name><surname>Sanchez</surname><given-names>O</given-names></name><name><surname>Volle</surname><given-names>G</given-names></name><name><surname>Briois</surname><given-names>S</given-names></name><name><surname>Cornic</surname><given-names>M</given-names></name><name><surname>Elisee</surname><given-names>V</given-names></name><name><surname>Jesuthasan</surname><given-names>D</given-names></name><name><surname>Djadi-Prat</surname><given-names>J</given-names></name><name><surname>Jouany</surname><given-names>P</given-names></name><name><surname>Junquera</surname><given-names>R</given-names></name><name><surname>Henriques</surname><given-names>M</given-names></name><name><surname>Kebir</surname><given-names>A</given-names></name><name><surname>Lehir</surname><given-names>I</given-names></name><name><surname>Meunier</surname><given-names>J</given-names></name><name><surname>Patin</surname><given-names>F</given-names></name><name><surname>Paquet</surname><given-names>V</given-names></name><name><surname>Tréhan</surname><given-names>A</given-names></name><name><surname>Vigna</surname><given-names>V</given-names></name><name><surname>Sabatier</surname><given-names>B</given-names></name><name><surname>Bergerot</surname><given-names>D</given-names></name><name><surname>Jouve</surname><given-names>C</given-names></name><name><surname>Knosp</surname><given-names>C</given-names></name><name><surname>Lenoir</surname><given-names>O</given-names></name><name><surname>Mahtal</surname><given-names>N</given-names></name><name><surname>Resmini</surname><given-names>L</given-names></name><name><surname>Lescure</surname><given-names>FX</given-names></name><name><surname>Ghosn</surname><given-names>J</given-names></name><name><surname>Bachelard</surname><given-names>A</given-names></name><name><surname>Bironne</surname><given-names>T</given-names></name><name><surname>Borie</surname><given-names>R</given-names></name><name><surname>Bounhiol</surname><given-names>A</given-names></name><name><surname>Boussard</surname><given-names>C</given-names></name><name><surname>CHAUFFiER</surname><given-names>J</given-names></name><name><surname>Chalal</surname><given-names>S</given-names></name><name><surname>Chalal</surname><given-names>L</given-names></name><name><surname>Chansombat</surname><given-names>M</given-names></name><name><surname>Crespin</surname><given-names>P</given-names></name><name><surname>Crestani</surname><given-names>B</given-names></name><name><surname>Daconceicao</surname><given-names>O</given-names></name><name><surname>Deconinck</surname><given-names>L</given-names></name><name><surname>Dieude</surname><given-names>P</given-names></name><name><surname>Dossier</surname><given-names>A</given-names></name><name><surname>Dubert</surname><given-names>M</given-names></name><name><surname>Ducrocq</surname><given-names>G</given-names></name><name><surname>Fuentes</surname><given-names>A</given-names></name><name><surname>Gervais</surname><given-names>A</given-names></name><name><surname>Gilbert</surname><given-names>M</given-names></name><name><surname>Isernia</surname><given-names>V</given-names></name><name><surname>Ismael</surname><given-names>S</given-names></name><name><surname>Joly</surname><given-names>V</given-names></name><name><surname>Julia</surname><given-names>Z</given-names></name><name><surname>Lariven</surname><given-names>S</given-names></name><name><surname>Le Gac</surname><given-names>S</given-names></name><name><surname>Le Pluart</surname><given-names>D</given-names></name><name><surname>Louni</surname><given-names>F</given-names></name><name><surname>Ndiaye</surname><given-names>A</given-names></name><name><surname>Papo</surname><given-names>T</given-names></name><name><surname>Parisey</surname><given-names>M</given-names></name><name><surname>Phung</surname><given-names>B</given-names></name><name><surname>Pourbaix</surname><given-names>A</given-names></name><name><surname>Rachline</surname><given-names>A</given-names></name><name><surname>Rioux</surname><given-names>C</given-names></name><name><surname>Sautereau</surname><given-names>A</given-names></name><name><surname>Steg</surname><given-names>G</given-names></name><name><surname>Tarhini</surname><given-names>H</given-names></name><name><surname>Valayer</surname><given-names>S</given-names></name><name><surname>Vallois</surname><given-names>D</given-names></name><name><surname>Vermes</surname><given-names>P</given-names></name><name><surname>Volpe</surname><given-names>T</given-names></name><name><surname>Nguyen</surname><given-names>Y</given-names></name><name><surname>Honsel</surname><given-names>V</given-names></name><name><surname>Weiss</surname><given-names>E</given-names></name><name><surname>Codorniu</surname><given-names>A</given-names></name><name><surname>Zarrouk</surname><given-names>V</given-names></name><name><surname>De Lastours</surname><given-names>V</given-names></name><name><surname>Uzzan</surname><given-names>M</given-names></name><name><surname>Olivier</surname><given-names>O</given-names></name><name><surname>Rossi</surname><given-names>G</given-names></name><name><surname>Gamany</surname><given-names>N</given-names></name><name><surname>Rahli</surname><given-names>R</given-names></name><name><surname>Louis</surname><given-names>Z</given-names></name><name><surname>Boutboul</surname><given-names>D</given-names></name><name><surname>Galicier</surname><given-names>L</given-names></name><name><surname>Amara</surname><given-names>Y</given-names></name><name><surname>Archer</surname><given-names>G</given-names></name><name><surname>Benattia</surname><given-names>A</given-names></name><name><surname>Bergeron</surname><given-names>A</given-names></name><name><surname>Bondeelle</surname><given-names>L</given-names></name><name><surname>De Castro</surname><given-names>N</given-names></name><name><surname>Clément</surname><given-names>M</given-names></name><name><surname>Darmont</surname><given-names>M</given-names></name><name><surname>Denis</surname><given-names>B</given-names></name><name><surname>Dupin</surname><given-names>C</given-names></name><name><surname>Feredj</surname><given-names>E</given-names></name><name><surname>Feyeux</surname><given-names>D</given-names></name><name><surname>Joseph</surname><given-names>A</given-names></name><name><surname>Lengliné</surname><given-names>E</given-names></name><name><surname>Le Guen</surname><given-names>P</given-names></name><name><surname>Liégeon</surname><given-names>G</given-names></name><name><surname>Lorillon</surname><given-names>G</given-names></name><name><surname>Mabrouki</surname><given-names>A</given-names></name><name><surname>Mariotte</surname><given-names>E</given-names></name><name><surname>Martin de Frémont</surname><given-names>G</given-names></name><name><surname>Mirouse</surname><given-names>A</given-names></name><name><surname>Molina</surname><given-names>JM</given-names></name><name><surname>Peffault de Latour</surname><given-names>R</given-names></name><name><surname>Oksenhendler</surname><given-names>E</given-names></name><name><surname>Saussereau</surname><given-names>J</given-names></name><name><surname>Tazi</surname><given-names>A</given-names></name><name><surname>Tudesq</surname><given-names>JJ</given-names></name><name><surname>Zafrani</surname><given-names>L</given-names></name><name><surname>Brindele</surname><given-names>I</given-names></name><name><surname>Bugnet</surname><given-names>E</given-names></name><name><surname>Celli Lebras</surname><given-names>K</given-names></name><name><surname>Chabert</surname><given-names>J</given-names></name><name><surname>Djaghout</surname><given-names>L</given-names></name><name><surname>Fauvaux</surname><given-names>C</given-names></name><name><surname>Jegu</surname><given-names>AL</given-names></name><name><surname>Kozaliewicz</surname><given-names>E</given-names></name><name><surname>Meunier</surname><given-names>M</given-names></name><name><surname>Tremorin</surname><given-names>MT</given-names></name><name><surname>Davoine</surname><given-names>C</given-names></name><name><surname>Madeleine</surname><given-names>I</given-names></name><name><surname>Caillat-Zucman</surname><given-names>S</given-names></name><name><surname>Delaugerre</surname><given-names>C</given-names></name><name><surname>Morin</surname><given-names>F</given-names></name><name><surname>Sene</surname><given-names>D</given-names></name><name><surname>Burlacu</surname><given-names>R</given-names></name><name><surname>Chousterman</surname><given-names>B</given-names></name><name><surname>Megarbane</surname><given-names>B</given-names></name><name><surname>Richette</surname><given-names>P</given-names></name><name><surname>Riveline</surname><given-names>JP</given-names></name><name><surname>Frazier</surname><given-names>A</given-names></name><name><surname>Vicaut</surname><given-names>E</given-names></name><name><surname>Berton</surname><given-names>L</given-names></name><name><surname>Hadjam</surname><given-names>T</given-names></name><name><surname>Vasquez-ibarra</surname><given-names>MA</given-names></name><name><surname>Jourdaine</surname><given-names>C</given-names></name><name><surname>Jacob</surname><given-names>A</given-names></name><name><surname>Smati</surname><given-names>J</given-names></name><name><surname>Renaud</surname><given-names>S</given-names></name><name><surname>Manivet</surname><given-names>P</given-names></name><name><surname>Pernin</surname><given-names>C</given-names></name><name><surname>Suarez</surname><given-names>L</given-names></name><name><surname>Semerano</surname><given-names>L</given-names></name><name><surname>Abad</surname><given-names>S</given-names></name><name><surname>Benainous</surname><given-names>R</given-names></name><name><surname>Bloch Queyrat</surname><given-names>C</given-names></name><name><surname>Bonnet</surname><given-names>N</given-names></name><name><surname>Brahmi</surname><given-names>S</given-names></name><name><surname>Cailhol</surname><given-names>J</given-names></name><name><surname>Cohen</surname><given-names>Y</given-names></name><name><surname>Comparon</surname><given-names>C</given-names></name><name><surname>Cordel</surname><given-names>H</given-names></name><name><surname>Dhote</surname><given-names>R</given-names></name><name><surname>Dournon</surname><given-names>N</given-names></name><name><surname>Duchemann</surname><given-names>B</given-names></name><name><surname>Ebstein</surname><given-names>N</given-names></name><name><surname>Giroux-Leprieur</surname><given-names>B</given-names></name><name><surname>Goupil de Bouille</surname><given-names>J</given-names></name><name><surname>Jacolot</surname><given-names>A</given-names></name><name><surname>Nunes</surname><given-names>H</given-names></name><name><surname>Oziel</surname><given-names>J</given-names></name><name><surname>Rathouin</surname><given-names>V</given-names></name><name><surname>Rigal</surname><given-names>M</given-names></name><name><surname>Roulot</surname><given-names>D</given-names></name><name><surname>Tantet</surname><given-names>C</given-names></name><name><surname>Uzunhan</surname><given-names>Y</given-names></name><name><surname>Costedoat-chalumeau</surname><given-names>N</given-names></name><name><surname>Ait Hamou</surname><given-names>Z</given-names></name><name><surname>Benghanem</surname><given-names>S</given-names></name><name><surname>Blanche</surname><given-names>P</given-names></name><name><surname>Canoui</surname><given-names>E</given-names></name><name><surname>Carlier</surname><given-names>N</given-names></name><name><surname>Chaigne</surname><given-names>B</given-names></name><name><surname>Contejean</surname><given-names>A</given-names></name><name><surname>Dunogue</surname><given-names>B</given-names></name><name><surname>Dupland</surname><given-names>P</given-names></name><name><surname>Durel - Maurisse</surname><given-names>A</given-names></name><name><surname>Gauzit</surname><given-names>R</given-names></name><name><surname>Jaubert</surname><given-names>P</given-names></name><name><surname>Joumaa</surname><given-names>H</given-names></name><name><surname>Jozwiak</surname><given-names>M</given-names></name><name><surname>Kerneis</surname><given-names>S</given-names></name><name><surname>Lachatre</surname><given-names>M</given-names></name><name><surname>Lafoeste</surname><given-names>H</given-names></name><name><surname>Legendre</surname><given-names>P</given-names></name><name><surname>Luong Nguyen</surname><given-names>LB</given-names></name><name><surname>Marey</surname><given-names>J</given-names></name><name><surname>Morbieu</surname><given-names>C</given-names></name><name><surname>Mouthon</surname><given-names>L</given-names></name><name><surname>Nguyen</surname><given-names>L</given-names></name><name><surname>Palmieri</surname><given-names>LJ</given-names></name><name><surname>Regent</surname><given-names>A</given-names></name><name><surname>Szwebel</surname><given-names>TA</given-names></name><name><surname>Terrier</surname><given-names>B</given-names></name><name><surname>Guerin</surname><given-names>C</given-names></name><name><surname>Zerbit</surname><given-names>J</given-names></name><name><surname>Cheref</surname><given-names>K</given-names></name><name><surname>Chitour</surname><given-names>K</given-names></name><name><surname>Cisse</surname><given-names>MS</given-names></name><name><surname>Clarke</surname><given-names>A</given-names></name><name><surname>Clavere</surname><given-names>G</given-names></name><name><surname>Dusanter</surname><given-names>I</given-names></name><name><surname>Gaudefroy</surname><given-names>C</given-names></name><name><surname>Jallouli</surname><given-names>M</given-names></name><name><surname>Kolta</surname><given-names>S</given-names></name><name><surname>Le Bourlout</surname><given-names>C</given-names></name><name><surname>Marin</surname><given-names>N</given-names></name><name><surname>Menage</surname><given-names>N</given-names></name><name><surname>Moores</surname><given-names>A</given-names></name><name><surname>Peigney</surname><given-names>I</given-names></name><name><surname>Pierron</surname><given-names>C</given-names></name><name><surname>Saleh-mghir</surname><given-names>S</given-names></name><name><surname>Vallet</surname><given-names>M</given-names></name><name><surname>Michel</surname><given-names>M</given-names></name><name><surname>Melica</surname><given-names>G</given-names></name><name><surname>Lelievre</surname><given-names>JD</given-names></name><name><surname>Fois</surname><given-names>E</given-names></name><name><surname>Lim</surname><given-names>P</given-names></name><name><surname>Matignon</surname><given-names>M</given-names></name><name><surname>Guillaud</surname><given-names>C</given-names></name><name><surname>Thiemele</surname><given-names>A</given-names></name><name><surname>Schmitz</surname><given-names>D</given-names></name><name><surname>Bouhris</surname><given-names>M</given-names></name><name><surname>Belazouz</surname><given-names>S</given-names></name><name><surname>Languille</surname><given-names>L</given-names></name><name><surname>Mekontso-dessaps</surname><given-names>A</given-names></name><name><surname>Sadaoui</surname><given-names>T</given-names></name><name><surname>Mayaux</surname><given-names>J</given-names></name><name><surname>Cacoub</surname><given-names>P</given-names></name><name><surname>Corvol</surname><given-names>JC</given-names></name><name><surname>Louapre</surname><given-names>C</given-names></name><name><surname>Sambin</surname><given-names>S</given-names></name><name><surname>Mariani</surname><given-names>LL</given-names></name><name><surname>Karachi</surname><given-names>C</given-names></name><name><surname>Tubach</surname><given-names>F</given-names></name><name><surname>Estellat</surname><given-names>C</given-names></name><name><surname>Gimeno</surname><given-names>L</given-names></name><name><surname>Martin</surname><given-names>K</given-names></name><name><surname>Bah</surname><given-names>A</given-names></name><name><surname>Keo</surname><given-names>V</given-names></name><name><surname>Ouamri</surname><given-names>S</given-names></name><name><surname>Messaoudi</surname><given-names>Y</given-names></name><name><surname>Yelles</surname><given-names>N</given-names></name><name><surname>Faye</surname><given-names>P</given-names></name><name><surname>Cavelot</surname><given-names>S</given-names></name><name><surname>Larcheveque</surname><given-names>C</given-names></name><name><surname>Annonay</surname><given-names>L</given-names></name><name><surname>Benhida</surname><given-names>J</given-names></name><name><surname>Zahrate-Ghoul</surname><given-names>A</given-names></name><name><surname>Hammal</surname><given-names>S</given-names></name><name><surname>Belilita</surname><given-names>R</given-names></name><name><surname>Lecronier</surname><given-names>M</given-names></name><name><surname>Beurton</surname><given-names>A</given-names></name><name><surname>Haudebourg</surname><given-names>L</given-names></name><name><surname>Deleris</surname><given-names>R</given-names></name><name><surname>Le Marec</surname><given-names>J</given-names></name><name><surname>Virolle</surname><given-names>S</given-names></name><name><surname>Nemlaghi</surname><given-names>S</given-names></name><name><surname>Bureau</surname><given-names>C</given-names></name><name><surname>Mora</surname><given-names>P</given-names></name><name><surname>De Sarcus</surname><given-names>M</given-names></name><name><surname>Clovet</surname><given-names>O</given-names></name><name><surname>Duceau</surname><given-names>B</given-names></name><name><surname>Grisot</surname><given-names>PH</given-names></name><name><surname>Pari</surname><given-names>M</given-names></name><name><surname>Arzoine</surname><given-names>J</given-names></name><name><surname>Clarac</surname><given-names>U</given-names></name><name><surname>Faure</surname><given-names>M</given-names></name><name><surname>Delemazure</surname><given-names>J</given-names></name><name><surname>Decavele</surname><given-names>M</given-names></name><name><surname>Morawiec</surname><given-names>E</given-names></name><name><surname>Demoule</surname><given-names>A</given-names></name><name><surname>Dres</surname><given-names>M</given-names></name><name><surname>Vautier</surname><given-names>M</given-names></name><name><surname>Allenbach</surname><given-names>Y</given-names></name><name><surname>Benveniste</surname><given-names>O</given-names></name><name><surname>Leroux</surname><given-names>G</given-names></name><name><surname>Rigolet</surname><given-names>A</given-names></name><name><surname>Guillaume-Jugnot</surname><given-names>P</given-names></name><name><surname>Domont</surname><given-names>F</given-names></name><name><surname>Desbois</surname><given-names>AC</given-names></name><name><surname>Comarmond</surname><given-names>C</given-names></name><name><surname>Champtiaux</surname><given-names>N</given-names></name><name><surname>Toquet</surname><given-names>S</given-names></name><name><surname>Ghembaza</surname><given-names>A</given-names></name><name><surname>Vieira</surname><given-names>M</given-names></name><name><surname>Maalouf</surname><given-names>G</given-names></name><name><surname>Boleto</surname><given-names>G</given-names></name><name><surname>Ferfar</surname><given-names>Y</given-names></name><name><surname>Charbonnier</surname><given-names>F</given-names></name><name><surname>Aguilar</surname><given-names>C</given-names></name><name><surname>Alby-laurent</surname><given-names>F</given-names></name><name><surname>Alyanakian</surname><given-names>MA</given-names></name><name><surname>Bakouboula</surname><given-names>P</given-names></name><name><surname>Broissand</surname><given-names>C</given-names></name><name><surname>Burger</surname><given-names>C</given-names></name><name><surname>Campos-vega</surname><given-names>C</given-names></name><name><surname>Chavarot</surname><given-names>N</given-names></name><name><surname>Choupeaux</surname><given-names>L</given-names></name><name><surname>Fournier</surname><given-names>B</given-names></name><name><surname>Granville</surname><given-names>S</given-names></name><name><surname>Issorat</surname><given-names>E</given-names></name><name><surname>Rouzaud</surname><given-names>C</given-names></name><name><surname>Vimpere</surname><given-names>D</given-names></name><name><surname>Geri</surname><given-names>G</given-names></name><name><surname>Derridj</surname><given-names>N</given-names></name><name><surname>Sguiouar</surname><given-names>N</given-names></name><name><surname>Meddah</surname><given-names>H</given-names></name><name><surname>Djadel</surname><given-names>M</given-names></name><name><surname>Chambrin-Lauvray</surname><given-names>H</given-names></name><name><surname>Duclos-Vallée</surname><given-names>JC</given-names></name><name><surname>Saliba</surname><given-names>F</given-names></name><name><surname>Sacleux</surname><given-names>SC</given-names></name><name><surname>Koumis</surname><given-names>I</given-names></name><name><surname>Michot</surname><given-names>JM</given-names></name><name><surname>Stoclin</surname><given-names>A</given-names></name><name><surname>Colomba</surname><given-names>E</given-names></name><name><surname>Pommeret</surname><given-names>F</given-names></name><name><surname>Willekens</surname><given-names>C</given-names></name><name><surname>Sakkal</surname><given-names>M</given-names></name><name><surname>Da Silva</surname><given-names>R</given-names></name><name><surname>Dejean</surname><given-names>V</given-names></name><name><surname>Mekid</surname><given-names>Y</given-names></name><name><surname>Ben-Mabrouk</surname><given-names>I</given-names></name><name><surname>Pradon</surname><given-names>C</given-names></name><name><surname>Drouard</surname><given-names>L</given-names></name><name><surname>Camara-Clayette</surname><given-names>V</given-names></name><name><surname>Morel</surname><given-names>A</given-names></name><name><surname>Garcia</surname><given-names>G</given-names></name><name><surname>Mohebbi</surname><given-names>A</given-names></name><name><surname>Berbour</surname><given-names>F</given-names></name><name><surname>Dehais</surname><given-names>M</given-names></name><name><surname>Pouliquen</surname><given-names>AL</given-names></name><name><surname>Klasen</surname><given-names>A</given-names></name><name><surname>Soyez-Herkert</surname><given-names>L</given-names></name><name><surname>London</surname><given-names>J</given-names></name><name><surname>Keroumi</surname><given-names>Y</given-names></name><name><surname>Guillot</surname><given-names>E</given-names></name><name><surname>Grailles</surname><given-names>G</given-names></name><name><surname>El Amine</surname><given-names>Y</given-names></name><name><surname>Defrancq</surname><given-names>F</given-names></name><name><surname>Fodil</surname><given-names>H</given-names></name><name><surname>Bouras</surname><given-names>C</given-names></name><name><surname>Dautel</surname><given-names>D</given-names></name><name><surname>Gambier</surname><given-names>N</given-names></name><name><surname>Dieye</surname><given-names>T</given-names></name><name><surname>Razurel</surname><given-names>A</given-names></name><name><surname>Bienvenu</surname><given-names>B</given-names></name><name><surname>Lancon</surname><given-names>V</given-names></name><name><surname>Lecomte</surname><given-names>L</given-names></name><name><surname>Beziriganyan</surname><given-names>K</given-names></name><name><surname>Asselate</surname><given-names>B</given-names></name><name><surname>Allanic</surname><given-names>L</given-names></name><name><surname>Kiouris</surname><given-names>E</given-names></name><name><surname>Legros</surname><given-names>MH</given-names></name><name><surname>Lemagner</surname><given-names>C</given-names></name><name><surname>Martel</surname><given-names>P</given-names></name><name><surname>Provitolo</surname><given-names>V</given-names></name><name><surname>Ackermann</surname><given-names>F</given-names></name><name><surname>Le Marchand</surname><given-names>M</given-names></name><name><surname>Clan Hew Wai</surname><given-names>A</given-names></name><name><surname>Fremont</surname><given-names>D</given-names></name><name><surname>Coupez</surname><given-names>E</given-names></name><name><surname>Adda</surname><given-names>M</given-names></name><name><surname>Duée</surname><given-names>F</given-names></name><name><surname>Bernard</surname><given-names>L</given-names></name><name><surname>Gros</surname><given-names>A</given-names></name><name><surname>Henry</surname><given-names>E</given-names></name><name><surname>Courtin</surname><given-names>C</given-names></name><name><surname>Pattyn</surname><given-names>A</given-names></name><name><surname>Guinot</surname><given-names>PG</given-names></name><name><surname>Bardou</surname><given-names>M</given-names></name><name><surname>Maurer</surname><given-names>A</given-names></name><name><surname>Jambon</surname><given-names>J</given-names></name><name><surname>Cransac</surname><given-names>A</given-names></name><name><surname>Pernot</surname><given-names>C</given-names></name><name><surname>Mourvillier</surname><given-names>B</given-names></name><name><surname>Servettaz</surname><given-names>A</given-names></name><name><surname>Deslée</surname><given-names>G</given-names></name><name><surname>Wynckel</surname><given-names>A</given-names></name><name><surname>Benoit</surname><given-names>P</given-names></name><name><surname>Marquis</surname><given-names>E</given-names></name><name><surname>Roux</surname><given-names>D</given-names></name><name><surname>Gernez</surname><given-names>C</given-names></name><name><surname>Yelnik</surname><given-names>C</given-names></name><name><surname>Poissy</surname><given-names>J</given-names></name><name><surname>Nizard</surname><given-names>M</given-names></name><name><surname>Denies</surname><given-names>F</given-names></name><name><surname>Gros</surname><given-names>H</given-names></name><name><surname>Mourad</surname><given-names>JJ</given-names></name><name><surname>Sacco</surname><given-names>E</given-names></name><name><surname>Renet</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial</article-title><source>The Lancet. Respiratory Medicine</source><volume>9</volume><fpage>295</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30556-7</pub-id><pub-id pub-id-type="pmid">33493450</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ucciferri</surname><given-names>C</given-names></name><name><surname>Auricchio</surname><given-names>A</given-names></name><name><surname>Di Nicola</surname><given-names>M</given-names></name><name><surname>Potere</surname><given-names>N</given-names></name><name><surname>Abbate</surname><given-names>A</given-names></name><name><surname>Cipollone</surname><given-names>F</given-names></name><name><surname>Vecchiet</surname><given-names>J</given-names></name><name><surname>Falasca</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Canakinumab in a subgroup of patients with COVID-19</article-title><source>The Lancet. Rheumatology</source><volume>2</volume><fpage>e457</fpage><lpage>ee458</lpage><pub-id pub-id-type="doi">10.1016/S2665-9913(20)30167-3</pub-id><pub-id pub-id-type="pmid">32835251</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Heijden</surname><given-names>M</given-names></name><name><surname>Versteilen</surname><given-names>AMG</given-names></name><name><surname>Sipkema</surname><given-names>P</given-names></name><name><surname>van Nieuw Amerongen</surname><given-names>GP</given-names></name><name><surname>Musters</surname><given-names>RJP</given-names></name><name><surname>Groeneveld</surname><given-names>ABJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Rho-kinase-dependent F-actin rearrangement is involved in the inhibition of PI3-kinase/Akt during ischemia-reperfusion-induced endothelial cell apoptosis</article-title><source>Apoptosis</source><volume>13</volume><fpage>404</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1007/s10495-007-0173-6</pub-id><pub-id pub-id-type="pmid">18165899</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Hui</surname><given-names>H</given-names></name><name><surname>Tiwari</surname><given-names>SK</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Croker</surname><given-names>BA</given-names></name><name><surname>Rawlings</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Carlin</surname><given-names>AF</given-names></name><name><surname>Rana</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol</article-title><source>The EMBO Journal</source><volume>39</volume><elocation-id>e106057</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2020106057</pub-id><pub-id pub-id-type="pmid">32944968</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>N</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Fujita</surname><given-names>A</given-names></name><name><surname>Ishizaki</surname><given-names>T</given-names></name><name><surname>Narumiya</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Cooperation between mDia1 and ROCK in Rho-induced actin reorganization</article-title><source>Nature Cell Biology</source><volume>1</volume><fpage>136</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1038/11056</pub-id><pub-id pub-id-type="pmid">10559899</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>A</given-names></name><name><surname>Wasiliew</surname><given-names>P</given-names></name><name><surname>Kracht</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Interleukin-1beta (IL-1beta) processing pathway</article-title><source>Science Signaling</source><volume>3</volume><elocation-id>cm2</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.3105cm2</pub-id><pub-id pub-id-type="pmid">20086236</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>N</given-names></name><name><surname>Nie</surname><given-names>M</given-names></name><name><surname>Pang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Ran</surname><given-names>X</given-names></name><name><surname>Long</surname><given-names>Q</given-names></name><name><surname>Deng</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>N</given-names></name><name><surname>Huang</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>1618</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-21907-9</pub-id><pub-id pub-id-type="pmid">33712622</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Deng</surname><given-names>R</given-names></name><name><surname>Wong</surname><given-names>G</given-names></name><name><surname>Lavillette</surname><given-names>D</given-names></name><name><surname>Meng</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SARS-CoV-2 spike engagement of ACE2 primes S2’ site cleavage and fusion initiation</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2111199119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2111199119</pub-id><pub-id pub-id-type="pmid">34930824</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Mou</surname><given-names>J</given-names></name><name><surname>Cui</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Lavillette</surname><given-names>D</given-names></name><name><surname>Meng</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Antibody-mediated spike activation promotes cell-cell transmission of SARS-CoV-2</article-title><source>PLOS Pathogens</source><volume>19</volume><elocation-id>e1011789</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1011789</pub-id><pub-id pub-id-type="pmid">37948454</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>X-L</given-names></name><name><surname>Wang</surname><given-names>X-G</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Si</surname><given-names>H-R</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>C-L</given-names></name><name><surname>Chen</surname><given-names>H-D</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>R-D</given-names></name><name><surname>Liu</surname><given-names>M-Q</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>X-R</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>X-S</given-names></name><name><surname>Zhao</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>Q-J</given-names></name><name><surname>Deng</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>L-L</given-names></name><name><surname>Yan</surname><given-names>B</given-names></name><name><surname>Zhan</surname><given-names>F-X</given-names></name><name><surname>Wang</surname><given-names>Y-Y</given-names></name><name><surname>Xiao</surname><given-names>G-F</given-names></name><name><surname>Shi</surname><given-names>Z-L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A pneumonia outbreak associated with A new coronavirus of probable bat origin</article-title><source>Nature</source><volume>579</volume><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id><pub-id pub-id-type="pmid">32015507</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.98593.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Schoggins</surname><given-names>John W</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>The University of Texas Southwestern Medical Center</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This study provides <bold>important</bold> insights into how IL-1 cytokines protect cells against SARS-CoV-2 infection. By inducing a non-canonical RhoA/ROCK signaling pathway, IL-1beta inhibits the ability of SARS-CoV-2 infected cells to fuse with uninfected cells and produce syncytia. <bold>Convincing</bold> evidence underlies the identification of the key signaling components required for this inhibitory phenotype, and suggests that this process may also function to inhibit SARS-CoV-2 infection in vivo.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.98593.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>SARS-CoV-2 infection induces syncytia formation, which promotes viral transmission. In this paper, the authors aimed to understand how host-derived inflammatory cytokines IL-1α/β combat SARS-CoV-2 infection.</p><p>Strengths:</p><p>First, they used a cell-cell fusion assay developed previously to identify IL-1α/β as the cytokines that inhibit syncytia formation. They co-cultured cells expressing the spike protein and cells expressing ACE2 and found that IL-1β treatment decreased syncytia formation and S2 cleavage.</p><p>Second, they investigated the IL-1 signaling pathway in detail, using knockouts or pharmacological perturbation to understand the signaling proteins responsible for blocking cell fusion. They found that IL-1 prevents cell-cell fusion through MyD88/IRAK/TRAF6 but not TAK1/IKK/NF-κB, as only knocking out MyD88/IRAK/TRAF6 eliminates the inhibitory effect on cell-cell fusion in response to IL-1β. This revealed that the inhibition of cell fusion did not require a transcriptional response and was mediated by IL-1R proximal signaling effectors.</p><p>Third, the authors identified RhoA/ROCK activation by IL-1 as the basis for this inhibition of cell fusion. By visualizing a RhoA biosensor and actin, they found a redistribution of RhoA to the cell periphery and cell-cell junctions after IL-1 stimulation. This triggered the formation of actin bundles at cell-cell junctions, preventing fusion and syncytia formation. The authors confirmed this molecular mechanism by using constitutively active RhoA and an inhibitor of ROCK.</p><p>Diverse Cell types and in vivo models were used, and consistent results were shown across diverse models. These results were convincing and well-presented.</p><p>In summary, the authors have provided compelling evidence regarding how IL-1 signaling induces a prophylactic response to viral infection. While the mechanistic details of how IL-1R and MyD88 induce RhoA/Rock pathway to mediate actin remodeling remain unclear, this manuscript serves as the basis for future studies.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.98593.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>In this study, Zheng et al investigated the role of inflammatory cytokines in protecting cells against SARS-CoV-2 infection. They demonstrate that soluble factors in the supernatants of TLR stimulated THP1 cells reduce fusion events between HEK293 cells expressing SARS-CoV-2 S protein and the ACE2 receptor. Using qRT-PCR and ELISA, they demonstrate that IL-1 cytokines are (not surprisingly) upregulated by TLR treatment in THP1 cells. Further, they convincingly demonstrate that recombinant IL-1 cytokines are sufficient to reduce cell-to-cell fusion mediated by the S protein. Using chemical inhibitors and CRISPR knock-out of key IL-1 receptor signaling components in HEK293 cells, they demonstrate that components of the myddosome (MYD88, IRAK1/4, and TRAF6) are required for fusion inhibition, but that downstream canonical signaling (i.e., TAK1 and NFKB activation) is not required. Instead, they provide evidence that IL-1-dependent non-canonical activation of RhoA/Rock is important for this phenotype. Importantly, the authors demonstrate that expression of a constitutively active RhoA alone is sufficient to inhibit fusion and that chemical inhibition of Rock could reverse this inhibition. The authors followed up these in vitro experiments by examining the effects of IL-1 on SARS-COV-2 infection in vivo and they demonstrate that recombinant IL-1 can reduce viral burden and lung pathogenesis in a mouse model of infection. Use of a ROCK inhibitor in IL-1 treated mice restored the ability of SARS-CoV-2 to spread in the lung, suggesting that this inhibitory process functions in vivo.</p><p>Strengths:</p><p>(1) The bioluminescence cell-cell fusion assay provides a robust quantitative method to examine cytokine effects on viral glycoprotein-mediated fusion.</p><p>(2) The study identifies a new mechanism by which IL-1 cytokines can limit virus infection.</p><p>(3) The authors tested IL-1 mediated inhibition of fusion induced by many different coronavirus S proteins and several SARS-CoV-2 strains.</p><p>(4) The authors demonstrate that recombinant IL-1 mediated inhibition of SARS-CoV-2 infection in mice is dependent on the RhoA/Rock pathway.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.98593.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Xu</given-names></name><role specific-use="author">Author</role><aff><institution>The Center for Microbes, Development and Health, National Key Laboratory of Immune Response and Immunotherapy, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, University of Chinese Academy of Sciences</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Shi</given-names></name><role specific-use="author">Author</role><aff><institution>The Center for Microbes, Development and Health, National Key Laboratory of Immune Response and Immunotherapy, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, University of Chinese Academy of Sciences</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Yanqiu</given-names></name><role specific-use="author">Author</role><aff><institution>Shanghai Municipal Center for Disease Control and Prevention</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Kuai</given-names></name><role specific-use="author">Author</role><aff><institution>The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China</institution><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Yuhui</given-names></name><role specific-use="author">Author</role><aff><institution>The Center for Microbes, Development and Health, National Key Laboratory of Immune Response and Immunotherapy, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, University of Chinese Academy of Sciences</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Mengdan</given-names></name><role specific-use="author">Author</role><aff><institution>The Center for Microbes, Development and Health, National Key Laboratory of Immune Response and Immunotherapy, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, University of Chinese Academy of Sciences</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Duan</surname><given-names>Dong</given-names></name><role specific-use="author">Author</role><aff><institution>The Center for Microbes, Development and Health, National Key Laboratory of Immune Response and Immunotherapy, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, University of Chinese Academy of Sciences</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff><institution>School of life sciences, Soochow University</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yunyi</given-names></name><role specific-use="author">Author</role><aff><institution>Shanghai Municipal Center for Disease Control and Prevention</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Cui</surname><given-names>Xiaoxian</given-names></name><role specific-use="author">Author</role><aff><institution>Shanghai Municipal Center for Disease Control and Prevention</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Mou</surname><given-names>Jiabin</given-names></name><role specific-use="author">Author</role><aff><institution>Shanghai Municipal Center for Disease Control and Prevention</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Yuying</given-names></name><role specific-use="author">Author</role><aff><institution>Shanghai Municipal Center for Disease Control and Prevention</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xun</given-names></name><role specific-use="author">Author</role><aff><institution>Shanghai Blood Center</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Min</given-names></name><role specific-use="author">Author</role><aff><institution>Shanghai Municipal Center for Disease Control and Prevention</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Jiu</surname><given-names>Yaming</given-names></name><role specific-use="author">Author</role><aff><institution>The Center for Microbes, Development and Health, National Key Laboratory of Immune Response and Immunotherapy, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, University of Chinese Academy of Sciences</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Jincun</given-names></name><role specific-use="author">Author</role><aff><institution>The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China</institution><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Meng</surname><given-names>Guangxun</given-names></name><role specific-use="author">Author</role><aff><institution>The Center for Microbes, Development and Health, National Key Laboratory of Immune Response and Immunotherapy, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, University of Chinese Academy of Sciences</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff><institution>School of life sciences, Soochow University</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public Review):</bold></p><p>Summary:</p><p>SARS-CoV-2 infection induces syncytia formation, which promotes viral transmission. In this paper, the authors aimed to understand how host-derived inflammatory cytokines IL-1α/β combat SARS-CoV-2 infection.</p><p>Strengths:</p><p>First, they used a cell-cell fusion assay developed previously to identify IL-1α/β as the cytokines that inhibit syncytia formation. They co-cultured cells expressing the spike protein and cells expressing ACE2 and found that IL-1β treatment decreased syncytia formation and S2' cleavage.</p><p>Second, they investigated the IL-1 signaling pathway in detail, using knockouts or pharmacological perturbation to understand the signaling proteins responsible for blocking cell fusion. They found that IL-1 prevents cell-cell fusion through MyD88/IRAK/TRAF6 but not TAK1/IKK/NF-κB, as only knocking out MyD88/IRAK/TRAF6 eliminates the inhibitory effect on cell-cell fusion in response to IL-1β. This revealed that the inhibition of cell fusion did not require a transcriptional response and was mediated by IL-1R proximal signaling effectors.</p><p>Third, the authors identified RhoA/ROCK activation by IL-1 as the basis for this inhibition of cell fusion. By visualizing a RhoA biosensor and actin, they found a redistribution of RhoA to the cell periphery and cell-cell junctions after IL-1 stimulation. This triggered the formation of actin bundles at cell-cell junctions, preventing fusion and syncytia formation. The authors confirmed this molecular mechanism by using constitutively active RhoA and an inhibitor of ROCK.</p><p>Diverse Cell types and in vivo models were used, and consistent results were shown across diverse models. These results were convincing and well-presented.</p><p>Weaknesses:</p><p>As the authors point out in the discussion, whether IL-1-mediated RhoA activation is specific to viral infection or regulates other RhoA-regulated processes is unclear. We would also require high-magnification images of the subcellular organization of the cytoskeleton to appreciate the effect of IL-1 stimulation.</p></disp-quote><p>Thanks for the suggestions. We tested the role of IL-1β in other RhoA-regulated processes, and found that IL-1β-mediated RhoA activation also reduced cell migration in a cell scratch assay (see Author response image 1). We also provided high-magnification images in the revised Figures 4 and 5, as well as their respective figure supplements.</p><fig id="sa3fig1" position="float"><label>Author response image 1.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98593-sa3-fig1-v1.tif"/></fig><p>(A) Cell scratch assay images of HEK293T cells treated with PBS or IL-1β. (B) Quantification of cell migration in (A).</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>In this study, Zheng et al investigated the role of inflammatory cytokines in protecting cells against SARS-CoV-2 infection. They demonstrate that soluble factors in the supernatants of TLR-stimulated THP1 cells reduce fusion events between HEK293 cells expressing SARS-CoV-2 S protein and the ACE2 receptor. Using qRT-PCR and ELISA, they demonstrate that IL-1 cytokines are (not surprisingly) upregulated by TLR treatment in THP1 cells. Further, they convincingly demonstrate that recombinant IL-1 cytokines are sufficient to reduce cell-to-cell fusion mediated by the S protein. Using chemical inhibitors and CRISPR knock-out of key IL-1 receptor signaling components in HEK293 cells, they demonstrate that components of the myddosome (MYD88, IRAK1/4, and TRAF6) are required for fusion inhibition, but that downstream canonical signaling (i.e., TAK1 and NFKB activation) is not required. Instead, they provide evidence that IL-1-dependent non-canonical activation of RhoA/Rock is important for this phenotype. Importantly, the authors demonstrate that expression of a constitutively active RhoA alone is sufficient to inhibit fusion and that chemical inhibition of Rock could reverse this inhibition. The authors followed up these in vitro experiments by examining the effects of IL-1 on SARS-COV-2 infection in vivo and they demonstrate that recombinant IL-1 can reduce viral burden and lung pathogenesis in a mouse model of infection. However, the contribution of the RhoA/Rock pathway and inhibition of fusion to IL-1-mediated control of SARS-CoV-2 infection in vivo remains unclear.</p><p>Strengths:</p><p>(1) The bioluminescence cell-cell fusion assay provides a robust quantitative method to examine cytokine effects on viral glycoprotein-mediated fusion.</p><p>(2) The study identifies a new mechanism by which IL-1 cytokines can limit virus infection.</p><p>(3) The authors tested IL-1 mediated inhibition of fusion induced by many different coronavirus S proteins and several SARS-CoV-2 strains.</p><p>Weaknesses:</p><p>(1) The qualitative assay demonstrating S2 cleavage and IL-1 mediated inhibition of this phenotype is extremely variable across the data figures. Sometimes it appears like S2 cleavage (S2') is reduced, while in other figures immunoblots show that total S2 protein is decreased. Based on the proposed model the expectation would be that S2 abundance would be rescued when cleavage is inhibited.</p></disp-quote><p>In our present manuscript, IL-1-mediated changes of the full-length spike showed some variation between authentic SARS-CoV-2 infection model and HEK293T-S + HEK293T-ACE2 coculture model, while IL-1 inhibited S2’ cleavage accompanied by a reduction of S2 subunit in both models.</p><p>In the authentic SARS-CoV-2 infection model, we observed that IL-1 inhibited S2' cleavage accompanied with a reduction in both S2 subunit and full-length spike protein. This is likely because the S2 subunit and full-length spike protein in this model are not only from infected cells, but also from intracellular viral particles. IL-1 inhibited SARS-CoV-2 induced cell-cell fusion and reduced the viral load in host cells, therefore the abundance of S2 subunit and full-length spike proteins were both reduced.</p><p>In the HEK293T-based co-culture model, IL-1 inhibited S2' cleavage accompanied with a reduction in S2 subunit, while the full-length spike protein was more or less rescued. Based on our previous study, R685A and ΔRRAR spike mutants cannot generate the S2 subunit, but still generated S2′ fragment to induce cell-cell fusion, and the S2' fragment produced from R685A and ΔRRAR spike mutants were only slightly reduced compared to wild-type spike protein, suggesting that the S2' fragment is mainly derived from the full-length spike directly, and to a minimal extent from the S2 subunit (Fig. 4B and 4G, PMID: 34930824). Thus, inhibition of S2’ cleavage by IL-1 mainly rescued the full-length spike protein.</p><disp-quote content-type="editor-comment"><p>(2) The text referencing Figure 1H suggests that TLR-stimulated THP-1 cell supernatants &quot;significantly&quot; reduce syncytia, but image quantification and statistics are not provided to support this statement.</p></disp-quote><p>Thanks for pointing out this issue. We have provided fluorescence image quantification and statistics in the revised version of our manuscript (Figure 1D, Figure 1-figure supplement 1A, Figure 1H-1I, Figure 2H-2I, Figure 1-figure supplement 1D-1E, Figure 1-figure supplement 1H-1I, Figure 2-figure supplement 1C-1D, Figure 2-figure supplement 2B-2E, Figure 2-figure supplement 2G-2H, Figure 2-figure supplement 6A-6B, Figure 2-figure supplement 7F-7G).</p><disp-quote content-type="editor-comment"><p>(3) The authors conclude that because IL-1 accumulates in TLR2-stimulated THP1 monocyte supernatants, this cytokine accounts for the ability of these supernatants to inhibit cell-cell fusion. However, they do not directly test whether IL-1 is required for the phenotype. Inhibition of the IL-1 receptor in supernatant-treated cells would help support their conclusion.</p></disp-quote><p>Thanks for the suggestion. Accordingly, we performed experiment and found that IL-1RA treatment reduced the inhibitory effect of PGN-stimulated THP-1 cell culture supernatant on cell-cell fusion, suggesting that IL-1 is required for the inhibition. This result has been added in our revised manuscript (Figure 2J and Figure2-figure supplement 4C).</p><disp-quote content-type="editor-comment"><p>(4) Immunoblot analysis of IL-1 treated HEK293 cells suggests that this cytokine does not reduce the abundance of ACE2 or total S protein in cells. However, it is possible that IL-1 signaling reduces the abundance of these proteins on the cell surface, which would result in a similar inhibition of cell-cell fusion. The authors should confirm that IL-1 treatment of their cells does not change Ace2 or S protein on the cell surface.</p></disp-quote><p>Thanks for the suggestion. Accordingly, we applied Wheat Germ Agglutinin (WGA) to stain cell surface in HEK293T cells and observed that IL-1β treatment did not change ACE2 or Spike protein on the cell surface. This result has been added in our revised manuscript (Figure 5-figure supplement 3A-D).</p><disp-quote content-type="editor-comment"><p>(5) In Figure 5A, expression of constitutively active RhoA appears to have profound effects on how ACE2 runs by SDS-PAGE, suggesting that RhoA may have additional effects on ACE2 biology that might account for the decreased cell-cell fusion. This phenotype should be addressed in the text and explored in more detail.</p></disp-quote><p>Thanks for pointing out this. We also noticed that the occurrence of cell-cell fusion reduced the amount of ACE2, whereas inhibition of cell-cell fusion restored the ACE2 abundance. Take the original Figure 5A (revised Figure 4-figure supplement 2B) as example, the increased ACE2 protein should be attributed to the decreased cell-cell fusion upon RhoA-CA transfection, as Spike binding with ACE2 leads to clathrin- and AP2-dependent endocytosis, resulting in ACE2 degradation in the lysosome (PMID: 36287912).</p><p>In addition, we have examined the potential effect of RhoA-CA on ACE2, and found that RhoA-CA did not affect ACE2 expression, nor Spike binding to ACE2 (revised Figure 5-figure supplement 2E); it did not affect ACE2 distribution on cell surface either (revised Figure 5-figure supplement 2F and G).</p><disp-quote content-type="editor-comment"><p>(6) The experiments linking IL-1 mediated restriction of SARS-COV-2 fusion to the control of virus infection in vivo are incomplete. The reported data demonstrate that recombinant IL-1 can restrict virus replication in vivo, but they fall short of confirming that the in vitro mechanism described (reduced fusion) contributes to the control of SARS-CoV2 replication in vivo. A critical piece of data that is missing is the demonstration that the ROCK inhibitor phenocopies IL-1RA treatment of SARS-COV-2 infected mice (viral infection and pathology).</p></disp-quote><p>Thanks for this suggestion. Accordingly, we applied the ROCK inhibitor in vivo to confirm its role in SARS-CoV-2-infected mice, and found similar phenotype as the IL-1RA treatment experiment. That is to say, Y-26732 treatment prevented the formation of IL-1β-induced actin bundles at cell-cell junctions, thus promoted syncytia formation and further viral transmission in vivo (revised Figure 7).</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>I suggest providing single-channel images in a supplementary figure for the live-cell images in Figures 4 and 5. Higher magnification images would also help distinguish the subcellular details of the cytoskeleton organization.</p></disp-quote><p>Thanks for the suggestion. We have provided the single channel images and higher magnification images in the revised Figures 4 and 5, as well as their respective figure supplements.</p><disp-quote content-type="editor-comment"><p>In Figure 4, the authors showed that IL-1 activates RhoA and induces the accumulation of activated RhoA at the cell-cell junctions. They also showed that IL-1 promotes the formation of actin bundles at cell-cell junctions. However, the authors have not shown any connection between RhoA and actin yet, but in lines 263-264, they claim that actin bundle formation is induced by RhoA. Evidence for this part was shown in later results, but at this moment, it is lacking. The same applies to lines 282-284; I think this conclusion that IL-1-induced actin bundle formation is through the RhoA-ROCK pathway should come after showing how RhoA affects actin bundle formation at cell-cell junctions. To this end, I suggest moving Supplementary Figures S12B and S12D to the main figure, as they provide strong evidence of the IL-1-RhoA-ROCK-actin pathway.</p></disp-quote><p>We appreciate these valuable comments. As suggested, we have moved the respective supplementary figures to the main figures to support our findings in the revised manuscript (Figure 4E and Figure 4-figure supplement 2B; Figure 5C and Figure 5-figure supplement 2A), the text has also been adjusted accordingly.</p></body></sub-article></article>